The role of cyclooxygenase-2 and prostaglandin E2 in pulmonary fibrosis. by Hodges, R.J.
THE ROLE OF CYCLOOXYGENASE-2 AND 
PROSTAGLANDIN E2 IN THE PATHOGENESIS 
OF PULMONARY FIBROSIS
Rebecca Jane Hodges
A thesis submitted to the University of London for the degree
of Ph.D.
Centre for Cardiopulmonary Biochemistry and Respiratory Medicine 
Royal Free and University College Medical School,
The Rayne Institute, 5 University Street,
London, WC1E 6JJ
1
UMI Number: U602523
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U602523
Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
Although the pathogenesis of pulmonary fibrosis is incompletely understood, an 
accepted underlying molecular mechanism is the dysregulation of soluble mediators 
which regulate fibroblast function in the lung. One such mediator is prostaglandin E2 
(PGE2), which is a potent inhibitor of fibroblast proliferation, collagen production, 
chemotaxis and myofibroblast differentiation. Levels of PGE2 have been shown to be 
decreased in bronchoalveolar lavage fluid (BALF) and lung fibroblasts from patients 
with pulmonary fibrosis. In lung fibroblasts this has been shown to be due to limited 
expression of the rate limiting enzyme in its biosynthesis, cyclooxygenase-2 (COX-2). 
However, there is currently no direct proof that limited expression of COX-2 and PGE2 
contribute to the pathogenesis of pulmonary fibrosis. This thesis has used 
pharmacological and genetic inhibition of COX-2 to address the hypothesis that limited 
expression of COX-2 and PGE2 potentiates bleomycin-induced pulmonary fibrosis. 
Through the use of the highly selective COX-2 inhibitor NS398, this thesis 
demonstrates that bleomycin-induced PGE2 production in the lung is COX-2 mediated 
for at least 14 days following injury. However, administration of NS398 had no effect 
on the development of bleomycin-induced lung fibrosis in wild type (WT) mice. 
Unexpectedly, COX-2'1' mice showed a compensatory upregulation in PGE2 
biosynthesis following bleomycin injury compared with both WT and COX-2+/' 
animals, which is evident in macrophage/monocytes but not fibroblasts derived from 
these mice. Lung homogenates showed increased expression of COX-1 in COX-2'1' 
mice compared with WT controls suggesting the compensatory synthesis is via 
increased expression of COX-1. COX-2'7' mice show an enhanced and persistent 
inflammatory response to bleomycin, however the fibrotic response to injury was 
unaltered compared with WT animals. In contrast, COX-2+/' mice showed reduced 
expression of COX-2 and subsequently limited induction of PGE2 following bleomycin 
injury. This resulted in an enhanced fibrotic response at day 28 with increased total lung 
collagen content compared with both WT and COX-2'1' mice (WT, 2.6 ±0.22; COX-2+7', 
3.77 ±0.12; COX-2'7', 2.51 ±0.26 mg collagen/lung, p<0.001).
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CHAPTER ONE:
INTRODUCTION
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1.1 Pulmonary fibrosis
The diagnosis of pulmonary fibrosis (PF) spans a range of interstitial lung diseases of 
both known and unknown aetiology. It is a chronic and progressive process leading to 
severe respiratory insufficiency and ultimately death of those affected. Treatment is 
inadequate and has not altered significantly in the last fifty years. Pulmonary fibrosis is 
characterised by inflammation, uncontrolled fibroblast proliferation and excessive 
deposition of extracellular matrix proteins, including collagens, in the lung. However, 
the mechanisms which drive this process are not fully elucidated.
This chapter will discuss the prevalence, aetiology, clinical features and pathogenesis of 
pulmonary fibrosis, specifically focusing on idiopathic pulmonary fibrosis (IPF, 
synonymously known as cryptogenic fibrosis alveolitis, CFA), before examining some 
of the features common to the fibrotic lung diseases, namely collagen deposition and 
inflammation in the lung. Following this, specific mediators known to play a role in the 
pathogenic process of pulmonary fibrosis will be discussed, focusing specifically on 
prostaglandin E2 (PGE2) and its biosynthesis via the cyclooxygenase (COX) pathway.
1.1.1 Incidence o f pulmonary fibrosis
An American study reported the incidence of pulmonary fibrosis at 80.9 per 100,000 in 
males and 67.2 per 100,000 in females (Coultas et at, 1994), and it is thought that over 
3000 people die each year from pulmonary fibrosis in the UK alone, with BPF 
accounting for 1000 of these deaths, and these figures appear to be increasing (Hubbard 
et at, 1996). IPF occurs more often amongst men than women and in both sexes there is 
a clear relationship between the development of pulmonary fibrosis and age, where two 
thirds of patients are over 60 years old (Coultas et ah, 1994).
1.1.2 Aetiology of pulmonary fibrosis
The majority of cases of pulmonary fibrosis are of unknown aetiology, for example in 
IPF, as an end point in eosinophilic granuloma, sarcoidosis, and some diseases affecting 
multiple-organ systems such as rheumatoid arthritis and systemic sclerosis there is no 
identifiable cause for the progression to lung fibrosis. However, there are a number of 
known causes which are diverse. For example, acute lung injury from an identifiable 
cause, as seen in adult respiratory distress syndrome (ARDS) may progress to 
pulmonary fibrosis; therapeutic drugs and treatments such as bleomycin or amiodarone;
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exposure to radiation during radiotherapy can also cause pulmonary fibrosis; exposure 
to both organic and inorganic particles such as avian antigens in pigeon fanciers lung; 
inorganic dusts such as silica or asbestos, and occupational exposure to metal or wood 
dusts have been shown to increase the risk of developing the disease (Hubbard et al, 
1996). A case-control study has also found cigarette smoking to be associated with a 
1.6-2.3 fold excess risk of developing the disease (Baumgartner et al, 1997). Infective 
agents such as viruses and bacteria have also been linked to an increased risk of 
developing pulmonary fibrosis. Epstein-Barr Virus (EBV), cytomegalo^ virus (CMV), 
tuberculosis^ influenza, hepatitis C, mycoplasma and legionella to name but a few, have 
been proposed to play a role (Egan et al., 1997). Recently, Tang and colleagues 
examined lung specimens from patients with IPF for the presence of herpesviruses and 
showed that one or more of four herpesviruses; EBV, CMV, human herpesvirus-7 
(HHV-7) or HHV-8, were found in 97% of the specimens from patients with IPF, 
compared with only 36% of control specimens (Tang et al., 2003).
The vast majority of IPF cases appear to be sporadic and there is no data on the 
heritability of IPF in the general population, however, genetic predisposition appears to 
play a role in the development of pulmonary fibrosis. Although rare, familial IPF 
represents about 3% of all IPF cases (Marshall et. al, 2000a), and pulmonary fibrosis is 
also associated with pleiotrop ic genetic disorders such as Hermansky-Pudlak 
syndrome which includes an IPF-like PF among other additional features that are not 
shared with sporadic IPF patients (Crystal et al, 2002). Furthermore, not all exposures 
to causal agents result in disease further suggesting a genetic component of the process, 
for example, only a small group of patients receiving similar doses of bleomycin or 
amiodarone subsequently go on to develop pulmonary fibrosis (Tisdale et al., 1995), 
and variable susceptibility is evident amongst workers exposed occupationally to similar 
concentrations of fibrogenic dusts. This is further supported in vivo where inbred strains 
of mice differ in their susceptibility to fibrogenic agents; C57B1/6 are fibrosis prone, 
where as Balb/c are fibrosis resistant after radiation (Ward et al, 1989) or over­
expression of TGF-pl (Kolb et al, 2002). To date, published studies on candidate genes 
have focused on those involved in host defence and inflammation, particularly 
polymorphisms that may regulate the functions of upstream cytokines, especially IL-ip 
and TNF-a (Whyte et al, 2000, see section 1.3.1). Most recently, Xaubet and 
colleagues examined the TGF-pi gene, the most pro-fibrotic cytokine known to date 
(see section 1.4.5) and although they found no association to susceptibility to IPF,
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polymorphisms in the TGF-pi gene were associated with a more rapid deterioration in 
lung function (Xaubet et al., 2003). Together, these data indicate a potential genetic 
predisposition which together with an appropriate trigger, may initiate the development 
of pulmonary fibrosis. Furthermore, the clinical heterogeneity of pulmonary fibrosis in 
terms of systemic involvement, rate of progression and overall prognosis may also be 
influenced by genetic factors which, if not causal, may play an important role in 
development of and/or progression of disease.
1.1.3 Clinical features of pulmonary fibrosis
Onset of symptoms is usually gradual and patients often present late, where symptoms 
such as dyspnea or cough have often been present for more than 6 months prior to 
presentation (Turner-Warwick et al, 1980; Johkoh et al, 1999). Diagnosis is confirmed 
using appearance on chest radiographs and imaging studies (HRCT), results of 
pulmonary function tests and BALF analysis, and surgical lung biopsy where 
histopathological features lead to a specific diagnosis. IPF specifically remains a 
diagnosis of exclusion as clinical features are non-specific and mimic those of a number 
of other pulmonary diseases. Collagen vascular disease, occupational or environmental 
exposure, or use of medications associated with pulmonary fibrosis must all first be 
ruled out as causes before the diagnosis of IPF.
The usual clinical course is gradual deterioration and any successful treatment of 
pulmonary fibrosis is hampered by its typically late presentation. Current treatment is 
inadequate despite aggressive therapeutic attempts. Corticosteroids have been used 
since the 1950’s, mainly due to the lack of any effective alternative, however only 
limited improvement has been reported, with or without the additional use of 
immunosuppressants (Gay et a l , 1998; Selman et al, 1998; Douglas et al, 1998 and 
Mapel et a l, 1996) and this is accompanied by a high incidence of adverse side effects. 
Despite the medical significance of fibrosis, both in the lung, and other tissues, there are 
currently no treatments which specifically target the fibrotic process itself.
Prognosis is poor with five-year survival ranging from 30 to 50% (Bjoraker et al,
1998), and average survival for this disease varies between 2.5 and 3.5 years following 
diagnosis, with or without corticosteroid therapy (Hubbard et al, 1998; King et al, 
2001). Specific pathologies on lung biopsy may provide increased survival rates. 
Recently, it has been reported that the cellular histology seen in non specific interstitial
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pneumonia (NSIP, see section 1.2) provides a clear survival advantage compared with 
usual interstitial pneumonia (UIP, Daniil et al, 1999). However, it is clear that together 
these data suggest that pulmonary fibrosis represents a significant clinical problem with 
little, if any effective treatment and a poor prognosis for affected individuals.
1.2 Pathogenesis of pulmonary fibrosis
Pulmonary fibrosis has been described as aberrant wound healing in the lung. 
Physiologically, an acute injury to the lung triggers a programme of repair comparable 
to that extensively described in skin wound healing (Clark, 1996). An initial 
inflammatory response leads to matrix production and proliferation of mesenchymal 
cells needed in the normal repair process. This is subsequently followed by degradation 
of the injured tissue and apoptosis of repair cells, both mesenchymal and inflammatory, 
usually leading to a return to normal function. This process is coordinated by the highly 
regulated expression of soluble mediators which are released by both inflammatory cells 
and resident lung cells.
However, in pathological conditions, this normal process is disrupted and, like other 
organs, the lung has a limited capacity for repair after significant injury and cell death. 
Rather than ‘wound-healing’ resulting in normal structure and function, the lung has a 
tendency to replace lost or severely damaged tissue with fibrosis or scar tissue (Kuhn, 
1991). In fibrotic tissue, following injury, damage occurs to the alveolar surface of the 
lung leading to a loss of alveolar integrity, loss of type I epithelial and endothelial cells, 
damage to the basement membrane and proliferation of type II cells. This is 
accompanied by inflammatory cell accumulation and fibroblast hyperplasia leading to 
enhanced deposition of extracellular matrix and ultimately irreversible fibrosis of the 
lung parenchyma and compromised gas exchange. The process is potentiated by the 
dysregulation of pro-fibrotic mediators such as TGF-p (see sections 1.4.4; 1.4.5) by the 
altered stromal cell population, activated epithelium and inflammatory cells. 
Pathogenesis can be affected by severity and extent of injury, aetiological agent and 
type of inflammatory response (reviewed by Gross & Hunninghake, 2001). However, 
the specific mechanisms which drive this process are not fully elucidated.
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IPF is part of a larger group of pathological diseases of unknown aetiology known as 
the idiopathic interstitial pneumonias (IIPs). The recent ATS/ERS consensus statement 
classified the DPs into seven distinct entities: IPF, non-specific interstitial pneumonia 
(NSIP), cryptogenic organising pneumonia (COP), acute interstitial pneumonia (AIP), 
respiratory bronchiolotis-associated interstitial lung disease (RB-ILD), desquamative 
interstitial pneumonia (DIP), and lymphoid interstitial pneumonia (LIP). IPF is the most 
common of the BPs and has a histological pattern of usual interstitial pneumonia (UIP) 
on lung biopsy (King et al, 2001; International consensus statement; ATS & ERS,
2000). UIP is characterised by a heterogeneous appearance with alternating areas of 
normal lung and chronic fibrosing interstitial pneumonia. Lung architecture is disrupted, 
with areas of chronic scarring with honeycomb change or marked smooth muscle 
metaplasia/hyperplasia, frequent subpleural thickening and areas of fibroblastic foci. 
Interstitial inflammation is usually mild to moderate, patchy and consists of an alveolar 
septal infiltrate of lymphocytes and plasma cells, associated with hyperplasia of Type II 
pneumocytes. Again, levels of fibrogenic cytokines such as TGF-pi, TNF-a, bFGF and 
PDGF are increased. (International consensus statement; ATS & ERS, 2000).
From what is presently known about the pathogenesis of pulmonary fibrosis, it is clear 
that two processes appear to be central in its development and progression; namely the 
initial inflammatory response to injury, followed by the deposition of extracellular 
matrix proteins, particularly collagens in the lung. The following two sections will 
discuss in greater detail the current thinking on the role of inflammation in pulmonary 
fibrosis and collagen deposition in the lung.
1.3 Inflammation in pulmonary fibrosis
Ccvuiclfi/ftML research has focused on investigating how the inflammatory response in the 
lung is triggered and which mediators are crucial to the perpetuation of the process. It is 
widely accepted that rather than resolution of the normal inflammatory response 
following injury, in pulmonary fibrosis the dysregulation of the early inflammatory 
response results in progression to chronic and persistent inflammation. This, together 
with fibroblast proliferation and differentiation into a myofibroblast phenotype, drives 
the late-stage fibrotic process in the lung leading to severe loss of function. This dogma 
is supported by a wide range of evidence in both human disease and animal models, 
however, recent reports have questioned the traditional view of inflammation driving
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the fibrotic process. This section will firstly describe the evidence for a role of 
inflammation in the development of pulmonary fibrosis before discussing the recent 
controversy and the proposed alternative hypothesis.
1.3.1 Evidence to support the role o f inflammation in the development o f pulmonary 
fibrosis
Histological evaluation of lung tissue from patients with pulmonary fibrosis showSclear 
evidence of inflammation. Patients also show increased inflammatory cell numbers in 
BAL fluid, where both neutrophils and eosinophils have been described to be present in 
increased numbers (Reynolds et al, 1997). BAL fluid neutrophilia and evidence of 
neutrophils in lung tissue have been demonstrated in patients with IPF (The BAL 
Cooperative Group Steering Committee, 1990), and an increase in the percentage of 
neutrophils or eosinophils (>5%) has generally been associated with a worse prognosis, 
with a higher likelihood of disease progression and a failure to respond to 
immunsupression (Turner-Warwick and Haslam, 1987; Hallgren et al, 1987; Schwartz 
et al, 1994). In contrast, lymphocytosis (>20%) on initial BAL occurs in <20% patients 
but appears to be associated with longer survival and a better response to therapy 
(Turner-Warwick and Haslam, 1987; Hallgren et al, 1987; Schwartz et al, 1994).
Studies have also shown inflammatory cells to be activated, releasing a variety of 
products which could cause tissue injury. Neutrophils have the capacity to release 
oxidants, proteases, complement fragments, arachidonic acid metabolites, and various 
cytokines which injure lung parenchymal cells. But the signals that recruit neutrophils 
to the lung, and perpetuate neutrophillic alveolitis are not yet fully understood. 
Leukocytes can be attracted into the lung by chemoattractants released both directly 
from alveolar macrophages and those released from lung parenchymal cells. The 
stimulus for the release of chemoattractants by lung parenchymal cells is at least in part, 
due to cytokines generated from alveolar macrophages and other cellular sources 
including alveolar epithelial cells, fibroblasts, T-helper cells and mast cells. This 
provides a self-perpetuating loop for continued inflammation.
The most commonly studied of these pro-inflammatory mediators are the early response 
cytokines TNF-a and IL-1 which have both been shown to be elevated in patients with 
pulmonary fibrosis (Zhang et al, 1993). TNF-a and IL-1 are both induced early after 
injury, and lead to pain, fever, and vasodilatation, (reviewed by Dinarello, 2000). Both
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cytokines also stimulate the production of lipid mediators, nitric oxide, chemokines, and 
stimulate fibroblast proliferation (Singh et al, 1988; Vilcek et a l, 1986; Schmidt et a l , 
1982). EL-lp has also been shown to stimulate fibroblast collagen deposition (Singh et 
al, 1988; Postlethwaite et al, 1988, see section 1.4.4).
The IL-8 family of cytokines (or chemokines) are another group which have been 
studied extensively. They represent at least 18 highly reactive peptides, whose 
biological activities include chemotactic activity for leukocytes (neutrophils, 
eosinophils, monocytes, lymphocytes), angiogenic activity, induction of collagen 
synthesis and cell proliferation. EL-8 is known to be chemotactic for neutrophils and 
increased levels of IL-8 in patients with EPF correlate with increased numbers of 
neutrophils in BALF from these patients (Carre et al, 1994; Southcott et al, 1995).
Animal models of pulmonary fibrosis have been a useful tool to study the role of pro- 
inflammatory mediators in the process. In the bleomycin model of fibrosis (see Chapter 
2) an acute inflammatory response is seen in the first 7 days which precedes matrix 
deposition and fibrosis characterised by an increase in lung collagen content 14-21 days 
following instillation of bleomycin. The intensity of inflammation has been directly 
correlated with the intensity of fibrosis in a rabbit model (Shen et al, 1988) and the list 
of pro-inflammatory mediators which increase following administration of bleomycin is 
extensive. Gene knockout and transgenic mice, along with systems which locally over­
express specific genes have helped to further understand the biology of the 
inflammatory response in this model. For example, TNF-a receptor knockout mice are 
protected from fibrosis induced by asbestos inhalation (Liu et al, 1998) and neutralising 
antibodies to TNF-a block silica-induced pulmonary fibrosis in mice (Piguet et al, 
1993b). Conversely, following over-expression of TNF-a cDNA in rat lung through 
adenoviral transfer, Sime and colleagues demonstrated severe pulmonary inflammation 
and fibrosis (Sime et al, 1998). Similarly, the transient over-expression of IL-lp using 
adenoviral gene transfer was shown to lead to extensive fibrosis following severe 
inflammation (Kolb et al, 2001), and conversely, a study using an IL-1 receptor 
antagonist was shown to prevent fibrosis in both silica- and bleomycin-induced mouse 
models (Piguet et a l, 1993b).
The role of T helper (Th) cells in the inflammatory response observed in pulmonary 
fibrosis is well studied, specifically the cytokine profiles secreted by these cells which
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can be classified as either Thl or Th2. Thl cytokines include IFN-y, IL-2, IL-12, IL-18, 
and Th2 IL-4, IL-5, IL-6, IL-10 and IL-13 (Mosmann et al, 1986; Cher and Mosmann,
1987). Studies have suggested that an imbalance in the expression of Thl:Th2 cytokines 
may be important in the pathogenesis of disorders with an inflammatory component 
such as asthma, systemic sclerosis and IPF, where Th2 responses mediate allergic 
inflammation and chronic fibroproliferation (Hoyle and Brody, 2001, Lukacs et al,
2001). Using in situ hybridisation and immunohistochemistry, sections of lung tissue 
taken from patients with IPF have been examined for the presence of a Thl vs Th2 
cytokine imbalance. This showed the predominance of Th2 over Thl (Wallace et al, 
1995) and supports the hypothesis that a persistent inbalance in the expression of 
Thl:Th2 cytokines may be a mechanism for the progression of pulmonary fibrosis.
IFN-y is the prototypic Thl cytokine and the other Thl cytokines IL-12 and IL-18 
appear to act by inducing IFN-y (Okamura et al, 1998). It has several potential 
antifibrotic actions and has been shown to inhibit fibroblast proliferation and collagen 
synthesis in vitro (Jimenez et al, 1984; Gurujeyalakshmi and Giri, 1995, see section 
1.4.4) and antagonises the functions of the pro-fibrotic mediator TGF-p 
(Gurujeyalakshmi and Giri, 1995; Eickelberg et a l, 2001). In vivo, repeated 
administration of IFN-y has been shown to reduce ECM accumulation using the 
bleomycin model of pulmonary fibrosis in mice (Giri et al, 1986; Granstein et al, 
1987; Hyde and Giri, 1990). However, in contrast, a study published in 2001 described 
reduced inflammation, weight loss and mortality in IFN-y deficient mice compared with 
wild type controls, which was accompanied by reduced levels of lung collagen 
production 21 days following administration of bleomycin (Chen et a l, 2001). Despite 
this contrasting in vivo data, an open randomised trial of 18 patients with IPF found that 
repeated administration of IFN-y together with a low dose of the steroid prednisolone 
was superior to prednisolone alone in preserving lung function in patients with mild to 
moderate IPF (Ziesche et al, 1999). Currently, the follow-up large, multicentre, 
randomised, double-blind, placebo-controlled, phase HI study of the safety and efficacy 
of IFN-y-lb is being completed. Preliminary analysis of these data suggest that although 
IFN-y produced no differences in the observed rate of progression-free survival, it did 
appear to decrease mortality, primarily in patients with mild to moderate disease (Raghu 
et a l, 2003).
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1.3.2 Evidence to suggest that inflammation is not crucial for the development of  
pulmonary fibrosis
The dogma that fibrogenesis is always preceded by, and potentially perpetuated by an 
early inflammatory response has been recently challenged in the context of DPF. This 
debate stems from the inadequacy of the current treatment for IPF where corticosteroids 
have been used for 50 years with little evidence to suggest that anti-inflammatory 
therapy is beneficial in the majority of patients with IPF (see section 1.1.3). Diseases 
involving a significant inflammatory component such as sarcoidosis and hypersensitive 
pneumonitis respond better to corticosteroid therapy and following the ERS/ATS 
reclassification of the idiopathic interstitial pneumonias (IIPs, described in section 1.2), 
so too do the inflammatory forms of IIP such as NSIP or DIP when compared with the 
more ‘fibrotic’ form of UIP (Bjoraker eta l,  1998; Daniil etal., 1999).
Several groups including Selman and Pardo (Selman and Pardo, 2002), and Gauldie 
(Gauldie, 2002a; Gauldie et al,  2002b), have developed an alternative hypothesis in 
which they suggest that rather than the traditional idea of an early inflammatory 
response leading to a late fibrotic stage, IPF is a fibroproliferative disorder preceded by 
epithelial cell activation leading to aberrant tissue remodeling, with inflammation 
appearing only after the development of fibroblastic foci. They suggest that the chronic 
and progressive nature of IPF is therefore driven by the alteration of mesenchymal and 
epithelial cell phenotypes by cytokines and matrix, rather than any inflammatory 
component. Katzenstein and Myers previously hypothesised that fibrosis can occur in 
the absence of inflammation; in a histological study, they showed IPF to be 
characterised by a pattern of UIP where the inflammatory component occurs mainly in 
areas of collagen deposition (fibroblastic foci) or honeycomb change, and rarely 
involves otherwise unaltered alveolar septa (Katzenstein and Myers, 1998).
This concept is also supported by several in vivo studies using adenovirus vectors to 
overexpress individual cytokine genes in the lung epithelium. These studies suggest that 
remodelling and fibrosis can occur in an animal model either subsequently to acute 
inflammation, as seen with over-expression of IL-lp (Kolb et al., 2001), or 
independently of inflammation, as seen with the over-expression of active TGF-P i 
(Sime et al, 1997). Furthermore, over-expression of IL-lp resulted in induction of 
TGF-p in addition to acute inflammation, and fibrosis occurred only after the transient 
expression of IL-lp has subsided, but the induced levels of TGF-p were sustained (Kolb
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et al., 2001; Sheppard, 2001), suggesting that overexpression of TGF-p, and not the 
acute inflammation, is essential for the progression of fibrogenesis.
However, these recent discussions are specifically aimed at IPF as a disease and the 
authors do not claim that these concerns over the role of inflammation in the 
development of fibrosis are applicable in all processes which lead to the end point of 
pulmonary fibrosis.
In summary, the role of inflammation in the development of fibrosis, particularly in IPF 
currently remains controversial. However, it is clear that in patients inflammation is 
present in tissue taken from diseased lung, and increased inflammatory cell numbers 
have been shown to be present in BALF. Animal models further highlight the 
importance of the inflammatory response in the development of bleomycin induced 
pulmonary fibrosis but questions remain as to how closely the animal models available 
mimic human disease. In vivo strategies which block inflammation have been shown to 
block the development of fibrosis to varying degrees although this does not translate to 
human disease in the use of corticosteroids. Current ongoing studies using the 
antiinflammatory immunomodulator IrN/-y may provide hope for the future treatment of 
the process, however further research is needed to understand the role of inflammation 
in the development of fibrosis.
Where questions may arise over the importance of the inflammatory response in the 
development of fibrosis, there is no such doubt over the role of matrix deposition in the 
process. Increased levels of extracellular matrix proteins in the lung, particularly 
collagens, are the key feature of the disease, and as a direct result gas exchange in the 
lung is severely compromised in the affected individual. The following section will 
specifically discuss collagen distribution and metabolism in both the normal and fibrotic 
lung, along with the myofibroblast, the major producer of collagen in the fibrotic lung, 
and mediators which affect its production.
1.4 Extracellular matrix in the lung
The extracellular matrix (ECM) in the lung, like other organs, is an intricate network of 
macromolecules composed of a variety of versatile proteins and polysaccharides 
including the collagens, elastic fibres, proteoglycans, fibronectin and laminin. The
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macromolecules are secreted locally and assembled into organised meshworks in close 
association with the surface of the cell which produced them. The primary role of the 
ECM is to provide a scaffolding to stabilise the physical structure of the lung, whilst 
maintaining flexibility required for respiration. However, the ECM is not inert, but 
plays an active role in regulating the behaviour of the cells in contact with it, 
influencing their development, morphology, migration, proliferation, and function, both 
physiologically and in pathological conditions.
Collagen and elastin fibres are embedded in a highly hydrated, gel-like substance 
composed of proteoglycan molecules (reviewed by Wight et al., 1991). The 
polysaccharide gel resists compressive forces on the matrix whereas collagen fibres 
strengthen and help organise the ECM, conferring tensile strength to the alveolar walls 
(reviewed by McAnulty and Laurent, 1995 and Chambers and Laurent, 1997). Rubber­
like elastin fibres (reviewed by Clearly and Gibson, 1996; Mariani et al., 1997) give the 
matrix resilience and the ability to stretch and recoil throughout respiration without 
damage to the lungs and are partially concentrated in the parenchymal regions where 
together with collagen, elastin provides the structural skeleton of the alveolar unit 
(Burri, 1985). The cell adhesive proteins such as fibronectin and laminin are also a key 
component of the ECM in the lung. Fibronectin is present throughout the interstitium 
whilst laminin is localised to the alveolar wall and basement membranes (Sethi et al.,
1999). Both proteins help in cell attachment and spreading through their interactions 
with integrins (reviewed by Juliano and Haskill, 1993); fibronectin promotes the 
attachment of fibroblasts and other cells to the matrix, whilst laminin promotes the 
attachment of epithelial cells to the basal lamina.
However, the collagen superfamily represents the most abundant group of proteins in 
the lung and excessive deposition of extracellular matrix proteins, particularly the 
collagens, is inarguably the primary characteristic of pulmonary fibrosis. Therefore the 
following section will concentrate on the collagen superfamily, discussing structure, 
metabolism and function in the normal lung, before discussing how this is altered in the 
fibrotic lung.
1.4.1 Collagen distribution and metabolism in normal lung
At least 27 members of the collagen superfamily have been described to date (Pace et 
al, 2003), each with specific mechanical and biochemical properties. However, they all
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share a basic structure of three alpha (a)-polypeptide chains coiled into a triple helix. 
Over 40 distinct a-chains have been described which combine in various ways to form 
the 11 collagens identified in the lung (Pace et al., 2003; Boot-Handford et al., 2003). 
For example, collagen HI is a homodimer consisting of three al(III)-chains, whereas 
collagen I is a heterodimer consisting of an a2(I)-chain combined with two al(I)- 
chains. Individual a-chains contain a large proportion of the smallest amino acid, 
glycine which allows close packing and hydrogen bonding between the chains. The 
generalised structure of an a-chain is (Gly-X-Y) n, where the X and Y positions are 
frequently held by the imino acids proline and hydroxyproline. Hydroxyproline is not 
incorporated directly into proteins, but is produced post-translationally via the 
hydroxylation of proline. This creates extra hydrogen bonds, which further stabilise the 
triple helix. Although the incorporation of amino acids other than proline and 
hydroxyproline decrease stability of the triple helix, they are essential for the assembly 
of the triple helical molecules into fibrils.
The fibrillar collagens (I, n, III, V and XI) contain approximately 1000 amino acids in 
the (Gly-X-Y) formation with 2 short terminal domains. Approximately 90% of 
collagen in the lung is fibrillar types I and IE in a ratio of 2:1 (Kirk et a l, 1984). These 
are distributed throughout the interstitium, large bronchi and blood vessels and provide 
strength, rigidity (collagen I) and compliance (collagen III) to tissues (Mays et al.,
1988). Fibroblasts are the major producer of these collagens (Hance et al., 1976), but 
they may be synthesised by other cells, such as endothelial cells, epithelial cells, 
alveolar type II cells and smooth muscle cells. Non-fibrillar collagens (including IV, VI 
and VII) contain other residues interspersed within their a-chains. Type IV collagen is 
the major component of the alveolar and capillary basement membranes (Crouch et al., 
1990) and the most common non-fibrillar collagen in the lung. The short-non-triple- 
helical sequences interspersed within the a-chains provide increased flexibility to 
collagen IV.
The collagens exist in a dynamic equilibrium involving constant degradation and 
synthesis of new molecules. Synthesis of collagen fibrils comprises firstly of 
intracellular steps to assemble and secrete procollagen, a longer molecule containing 
additional propeptides at both the N- and C-terminal ends. Secondly, the procollagen is 
converted into collagen close to the cell membrane, and is then incorporated into stable,
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cross-linked collagen fibrils. Briefly, procollagen DNA is transcribed to pre-mRNA in 
the nucleus (k/\ci is subsequently spliced to form functional mRNA. Translation 
occurs in ribosomes of the rough endoplasmic reticulum (RER) to make pre-procollagen 
a-chain. The pre-procollagen a-chain contains an N-terminal signal peptide that 
facilitates movement across the RER and is cleaved either during translation or shortly 
after peptide synthesis to form the procollagen a-chain. Whilst the a-chains are 
growing on ribosomes, co- and post-translational modifications occur including 
hydroxylation of specific proline and lysine residues in the Y position to form 
hydroxyproline and hydroxylysine. Mannose-rich oligosaccharides are transferred onto 
aspargine-linked carbohydrate units in the C-propeptides of fibrillar collagens and some 
domains in non-fibrillar collagens.
In fibrillar collagens, triple helix formation occurs from the C-terminus to the N- 
terminus following alignment of 3 procollagen a-chains which form both intra- and 
interchain disulphide bonds between lysine and hydroxylysine residues. The helical 
procollagen molecules are then transported to the Golgi where they are packaged in 
secretory vesicles for transport into the extracellular space. During or immediately after 
secretion, the N- and C-terminal propeptides are enzymatically cleaved by procollagen 
N- and C-proteinase respectively. In fibrillar collagens, cleavage of propeptides leads to 
spontaneous assembly into fibrils at the cell plasma membrane. The fibrils are initially 
held together by electrostatic interaction, however following cross-linking by lysyl 
oxidase forming strong covalent bonds, collagen fibrils possess the tensile strength of 
steel. Most non-fibrillar collagens usually undergo proteolytic processing but covalently 
cross-link with other molecules to form open-meshed networks.
Collagen synthesis and degradation continues in the lung throughout life and turnover 
rates for newly synthesised collagen are extremely rapid. In vivo it has been estimated 
that an amount of collagen equivalent to one tenth of the total collagen content is 
synthesised and degraded each day (Laurent 1982; McAnulty and Laurent, 1987). In 
vitro, lung fibroblasts have been shown to degrade between 10-40% of the procollagen 
they synthesise depending on the culture conditions (reviewed by Rennard et al., 1982). 
This process has been shown to occur within 15 mins in vivo (McAnulty and Laurent, 
1987) and is likely to occur intracellularly as 15 minutes is considerably less than that 
required by cells to secrete collagen molecules (Dehm and Prockop, 1972, 1973; Grant 
et al., 1972). In the lung, the proportion of newly synthesised procollagen degraded
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ranges between 30% in young animals to 80% in aged animals (Mays et al, 1989). 
Degradation of defective procollagen molecules occurs in lysosomes with enzymes such 
as cathepsins B, D, and L being capable of degrading nonhelical procollagen molecules. 
Triple helical protein molecules are degraded through an alternative pathway termed the 
‘basal degradation’ pathway and it has been proposed that this occurs in the trans-Golgi 
apparatus (Barile et al, 1990). Extracellular degradation much slower as the collagen
A
fibril is extremely stable. Degradation occurs by proteases released by a number of cell 
types including inflammatory and mesenchymal cells. These include the matrix 
metalloproteases (MMPs); the collagenases, stromelysins and gelatinases, and the serine 
proteases.
1.4.2 Collagen distribution and metabolism in fibrotic lung
In the normal lung alveolar walls are thin to allow maximal gaseous exchange, and 
contain small amounts of collagen for structural support. However, in pulmonary 
fibrosis excess collagen deposition leads to thickening of the interstitium and loss of 
lung architecture resulting in impaired lung function. Excess collagen deposition in the 
lungs of patients with pulmonary fibrosis results in small, stiff lungs which show 
radiographic honeycombing. Many studies have aimed to establish the cause of excess 
deposition of collagen in pulmonary fibrosis. There is evidence to suggest that the 
balance between synthesis and degradation of collagen is altered in pulmonary fibrosis 
leading to increased deposition of collagen in the lung (Laurent, 1987). This may be 
caused by direct dysregulation of collagen synthesis and/or degradation i.e., collagen 
gene expression, or indirectly through enhanced proliferation of fibroblasts, or changes 
in levels of both pro- and anti-fibrotic soluble mediators which affect collagen synthesis 
and/or degradation. Mediators which affect fibroblast function will be discussed further 
in section 1.4.4.
In human disease, BALF procollagen peptide levels have been shown to be increased in 
CFA (Low et al, 1983; Cantin et al, 1988; Bjermer et al, 1989), systemic sclerosis 
(Harrison et al, 1990) and sarcoidosis (Low et al, 1983; Bjermer et al, 1986). Using in 
situ hybridisation, type I procollagen mRNA expression has also been shown to be 
increased in human lung (Broekelmann et al, 1991). Furthermore, an increase in C- 
terminal procollagen peptide has also been demonstrated by immunohistochemistry 
(McDonald et al, 1986) and levels of procollagen C- proteinase, the enzyme which
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cleaves the C-terminal procollagen peptide, has been shown to be enhanced in patients 
with ARDS (Entzian et al, 1990).
Using the bleomycin model in vivo, rates of collagen synthesis have also been shown to 
be increased (Phan et al., 1981; Laurent and McAnulty, 1983) in association with 
increased levels of type I and HI collagen mRNAs (Kelly et a l, 1985; Raghow et al, 
1985; Hoyt and Lazo, 1988; Shahzeidi et al, 1993) Furthermore, lung fibroblasts 
obtained from rats treated with bleomycin show enhanced collagen synthesis compared 
with control fibroblasts (Phan et al, 1985). Microarray technology has recently 
demonstrated increased expression of the genes encoding for collagens I and III in 
human fibrotic tissue samples compared with normal lung and expression of genes 
encoding collagen VI, tenascin C, osteopontin and fibronectin were also increased (Zuo 
et al, 2 0 0 2 ).
Collagen degradation is less well studied in human pulmonary fibrosis but increased 
levels of collagenases have been reported in BALF of patients with CFA (Gadek et al,
1979). However, other studies have suggested that the increase in collagen content in 
CFA is related to a decrease in collagenase activity (Selman et al, 1986). MMPs 
degrade components of the ECM, and Selman and co-workers (Selman, et. al., 2000) 
recently evaluated the expression of the collagenase subfamily (MMP-1, -9 and -13), 
the gelatinase subfamily (MMP-2, 9), membrane type-1 MMP and all 4 of the tissue 
inhibitors of metalloproteases (TIMPS) in biopsies taken from patients with CFA. This 
study showed that there was a higher expression of TIMPS compared with MMPs in the 
fibrotic lung. Overall, the study concluded that there is a prevailing non-degradative 
microenvironment in the lungs of patients with CFA.
1.4.3 The myofibroblast
The major producers of extracellular matrix macromolecules in the active fibrotic 
lesion, the fibroblastic foci, are the fibroblasts, and any change in their numbers or 
function will undoubtedly effect the function of the lung as an organ. Fibroblastic foci 
include a heterogeneous population of fibroblasts with an intermediate phenotype of a 
fibroblast and a smooth muscle cell, termed the myofibroblast. These cells express a- 
smooth muscle actin (a-SMA), suggesting the fibroblasts have acquired morphological 
and biochemical features of contractile cells (Adler et al. 1989; Mitchell et al., 1989; 
Zhang et al., 1997; Zhang et al, 1996; Desmouliere and Gabbiani, 1995). The presence
32
of myofibroblasts in both patients with, and animal models of, pulmonary fibrosis is 
well documented (Adler et a l, 1989; Mitchell et al, 1989; Kuhn and McDonald, 1991; 
Pache et al, 1998), and the failure of the disease to resolve in patients with progressive 
disease, correlates with the persistence of myofibroblasts (Kuhn and McDonald, 1991).
Myofibroblasts have been identified as the predominant source of increased collagen 
gene expression in the fibrotic lung (Zhang et al, 1994), and their contractile phenotype 
has been shown to correlate with the development of decreased lung compliance (Alder 
et al, 1989; Mitchell et al, 1989; Zhang et al, 1994). These cells have also been shown 
to be a significant source of pro-inflammatory and pro-fibrotic mediators such as TGF- 
Pi (Zhang et al, 1995). These mediators themselves recruit inflammatory cells, creating 
a positive feedback loop intensifying, or prolonging the inflammation associated with 
the fibrotic foci (Phan, 2002).
Fibroblasts transition into myofibroblasts occurs though a process regulated by 
cytokines and ECM components (Desmouliere and Gabbiani, 1995), of which TGF-p is 
thought to be the most efficient (Desmouliere, 1995). TGF-p i has been shown to 
stimulate a-SMA mRNA and protein production in myofibroblasts (Mitchell et al, 
1989; Zhang et al, 1996; Desmouliere e ta l ,  1993) and this process has been shown to 
be inhibited by both IFN-y and PGE2 (Yokozeki et al, 1999; Kolodsick et al, 2003), 
however the mechanisms by which myofibroblast transition is regulated are still not 
fully elucidated.
1.4.4 Mediators offibroblast function
In addition to regulating fibroblast-myofibroblast transition, soluble mediators such as 
cytokines are important in regulating the other key features of pulmonary fibrosis such 
as fibroblast proliferation and collagen production. It is generally accepted that an 
important underlying molecular mechanism in the pathogenesis of pulmonary fibrosis is 
the over- and/or under-production and dysregulation of certain cytokines and 
polypeptide growth factors (reviewed by Coker et al, 1998; Zhang and Phan, 1996; 
Smith et a l, 1995; Khalil and Greenberg, 1991) which regulate fibroblast function at 
various levels.
For example, collagen production is regulated at the level of synthesis, deposition and 
turnover by altering the levels of gene transcription, mRNA processing and degradation
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(reviewed by Ramirez and DiLiberto, 1990; McAnulty and Laurent, 1995). The list of 
potentially important mediators is extensive and whilst this thesis can not discuss each 
important mediator in turn, Table 1.1 summarises those mediators known to have 
stimulatory effects on fibroblast collagen production and proliferation, whereas Table 
1.2 summarises those mediators known to have negative regulatory effects.
Mediators which increase Mediators which increase
fibroblast collagen production____________ fibroblast proliferation
Angiotensin II Brilla etal.,  1994 Angiotensin II Marshall et a l ,  2000
CTGF Frazier etal., 1996 CTGF Frazier et al., 1996
ET-1 Dawes et al ,  1996 ET-1 Peacock et al., 1992
Insulin Goldstein et al., 1989 EGF Kurata and Hata, 1991
Insulin-like-growth Goldstein et al ,  1989 Fibroblast Wahl and Gately, 1983
factor (IGF) activating factor
IL-1 Postlethwaite et al., 
1988
Fibronectin Bitterman etal.,  1983
IL-4 Postlethwaite et al ,  
1992
IGF Phillips e ta l ,  1987
IL- 6 Duncan and Berman, 
1991
IL-1 Singh etal., 1988
TGF-P Varga and Jimenez, IL-4 Trautmann et a l ,  1998
1986
Thrombin Chambers et a l ,  1998 IL-13
PDGF
Thrombin
TNF-a
Kraft et a l ,  2001 
Oliver e ta l ,  1989 
Gray e t a l ,  1990 
V ilceketa/., 1986
Table 1.1 Mediators known to promote fibroblast collagen production and
proliferation
Mediators which decrease Mediators which decrease
fibroblast collagen production_________ fibroblast proliferation
EGF Kurata and Hata 1991 IFN-a Elias e ta l ,  1987
IFN-a Jimenez e ta l ,  1984 IFN-P Tominaga and Lengyel 
1985
IFN-y Heckmann etal,  1989 IFN-y Elias et al., 1987
p g e 2 Saltzman etal., 1982 p g e 2 Oliver etal., 1989
Retinoic acid Oikarinen etal., 1985
Table 1.2 Mediators known to inhibit fibroblast collagen production and
proliferation
In addition to its role in fibroblast-myofibroblast transition, one of the most important 
pro-fibrotic mediators listed in Table 1.1 is transforming growth factor-beta (TGF-p). 
This thesis is primarily concerned with the role of the negative regulatory mediator 
prostaglandin E2 (PGE2, Table 1.2) which is an important negative regulator of the
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actions of TGF-p. The following sections will first further discuss the role of TGF-p in 
the development of the fibrotic response before introducing PGE2 .
1.4.5 Transforming growth factor-beta (TGF-p)
In mammals there are three isoforms of TGF-p (TGF-pi.3) all of which signal through 
the same receptors and have similar biological functions. However, it is TGF-p 1 which 
has been the most widely studied in the context of fibrogenesis and the continued 
overproduction of TGF-p 1 appears to be a central factor in the molecular mechanisms 
which lead to pulmonary fibrosis.
TGF-pi is a fibroblast chemoattractant and is able to exert a bimodal effect on fibroblast 
proliferation via an autocrine PDGF-dependent pathway (Battergay et al, 1990). 
Furthermore it has been shown to stimulate biosynthesis of type I collagen (Roberts et 
al., 1986; Ignotz and Massague, 1986; Varga and Jimenez, 1986) and is the most potent 
stimulator of fibroblast collagen production described to date. The stimulatory effect of 
TGF-pi on fibroblast collagen production is mediated both transcriptionally and 
translationally; TGF-p 1 is known to increase collagen mRNA transcription and stability 
(Ignotz et al., 1987; Raghow et al, 1987; Varga et al, 1987). Furthermore, TGF-pi has 
also been shown to reduce the proportion of newly synthesised procollagen degraded 
before secretion (McAnulty et al., 1991), and to limit extracellular degradation of 
collagen through inhibiting the expression of collagenases, whilst promoting expression 
of their respective inhibitors (Overall et al., 1989; Shi et al., 1990; Edwards et al., 
1987). In addition to collagen, TGF-P 1 is a potent modulator of a number of genes 
known to be involved in tissue remodelling and fibrosis. For example, TGF-p 1 increases 
the production and/or activity of connective tissue growth factor (CTGF, Lasky et al, 
1998), and other genes of the ECM: fibronectin (Ignotz and Massague, 1986) and 
proteoglycans (Bassols and Massague, 1988), which together result in an excess 
accumulation of ECM proteins. Beside the lungs, the role of TGF-p has also been 
demonstrated in other organs undergoing fibrotic changes (Khalil et al, 1991).
In patients with IPF, immunohistochemical studies have shown enhanced expression of 
TGF-pi in a number of cell types including alveolar macrophages bronchiolar epithelial 
cells, fibroblasts and myofibroblasts (Khalil et al, 1991, Zhang et al., 1995). 
Furthermore, a large number of studies using animal models of pulmonary fibrosis have
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confirmed both the fibrogenic nature of TGF-P \ over-expression and have demonstrated 
the anti-fibrotic effects of TGF-pi inhibition, such as with anti-TGF-pi antibodies 
(reviewed by Lasky and Brody, 2000).
The pleiotrop ic actions of TGF-pi, its important influence on ECM metabolism, and its 
ability to regulate the production of other cytokines in an a paracrine fashion (Lyons and 
Moses 1990), makes it arguably the most important pro-fibrotic mediator. However, the 
other side of the balance must be considered; not only is over-production of pro-fibrotic 
mediators important in the development of the disease, but so too is the under­
production of potentially important anti-fibrotic mediators. One such mediator is 
prostaglandin E2 , or PGE2 . TGF-P 1 is one of the mediators known to induce the 
synthesis of PGE2 which is a potent inhibitor of both fibroblast collagen production, 
proliferation and myofibroblast differentiation in the lung. It is this autocrine synthesis 
of PGE2 that is responsible for the anti-proliferative effects of TGF-P 1 (McAnulty et al,
1997) and limits the stimulation of collagen synthesis by TGF-p 1 (McAnulty et al, 
1995). This thesis will specifically focus on the role of PGE2 as a mediator of 
pulmonary fibrosis and the next sections will describe the physiological and 
pathological roles of PGE2 in the lung and its biosynthesis via the cyclooxygenase 
pathway.
1.5 Prostaglandin E2
PGE2 is an eicosanoid, a class of lipid mediators derived from phospholipase-released 
arachidonic acid. The eicosanoids are involved in numerous biological functions and 
include both prostanoids and leukotrienes, generated via the cyclooxygenase and 
lipoxygenase pathways respectively. There are currently two cyclooxygenase (COX) 
isoforms generated from separate genes, namely COX-1 and COX-2. Physiologically, 
prostaglandins are implicated in ovulation, fertilisation, platelet aggregation and 
maintenance of renal function, in addition to being regulators of fever, pain and 
inflammation. Briefly, those generated via the actions of COX-1 are seen to have a 
homeostatic function, whereas those generated via COX-2 are generally considered 
inflammatory and pathogenic, although this is definition not clear-cut. The COX 
isoforms will be discussed in greater detail in sections 1.8-1.10. Prostanoids generated 
by COX-1 and COX- 2  include the prostaglandins (PGE2 , PGD2, PGF20C, PGI2) and 
thromboxane (TXA2) and their biosynthetic pathway is shown in Figure 1.1.
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Leukotrienes (LTB4 , LTC4 , LTD4 and LTE4) will not be discussed in significant detail 
in this thesis, however there is also substantial evidence for a role for leukotrienes in 
pulmonary fibrosis. They have been reported to directly stimulate fibroblast 
proliferation and collagen synthesis (Baud et al, 1987) and this is consistent with the 
finding of a constitutive activation of 5-liopxygenase (5-LO) in the lungs of patients 
with IPF (Wilbom et al, 1996). Lung homogenates from these patients contained 15- 
fold more LTB4 than homogenates from non-fibrotic lungs (Wilbom et a l, 1996). 
Furthermore, mice deficient in 5-LO are protected from bleomycin-induced lung 
fibrosis (Peters-Golden e ta l, 2001).
There is substantial evidence to suggest that PGE2 may play an important role in the 
pathogenesis of pulmonary fibrosis, both directly via £ffects on fibroblast number and 
function, and indirectly by modulating production of pro-fibrotic mediators in the lung. 
The following sections will firstly discuss its biosynthesis via the cyclooxygenase 
pathway, followed by the effects of prostaglandins, specifically PGE2, in the lung, and 
the cellular mechanisms by which it may modulate fibroblast function and the 
inflammatory response. Finally, evidence will be presented to suggest that levels of 
PGE2, and cyclooxygenase-2 (COX-2), the rate-limiting enzyme in its biosynthesis, are 
altered in patients with pulmonary fibrosis.
1.6 Biosynthesis of PGE2
The key enzyme in PGE2 biosynthesis is cyclooxygenase (COX, also known as 
prostaglandin H2 synthase, PGHS), which initially converts phospholipase-released 
arachidonic acid to prostaglandin G2 (PGG2) by a cyclooxygenase reaction. COX also 
then catalyses the reduction of the 15-hydroperoxyl group of PGG2 to prostaglandin H2 
(PGH2) by a peroxidase reaction. PGH2 is then converted by a hydroperoxidase reaction 
to the various prostaglandins; PGE2 PGD2 PGF2a PGI2 and thromboxane (TX), by tissue 
specific synthases. This pathway is shown in Figure 1.1. Two COX isoforms which are 
products of separate genes have been described to date; COX-1 and COX-2, and in 
2002 a sequence for a proposed COX-3 was described. The COX isoforms are very 
similar in length; COX-1 has 576 amino acids and COX-2 604, of which 60-65% are in 
an identical sequence (O’Banion et al, 1992; Ryseck et al., 1992; Fletcher et al, 1992; 
Hsi e ta l,  1994).
37
Membrane phospholipids n n n n
)<yDOO<X)00<yDoooooooo6
Phospholipase A2 
Arachidonic acid
COX
Prostaglandin G2 
COX -------- ►
Prostaglandin H:
Tissue specific isomerases
Prostacyclin Prostaglandin E2
E P „  EP2) EP3, EP,Prostaglandin D
DPi, DPo
Thromboxane A2 Prostaglandin F2a
TPa, TPp FPa. FPp
Figure 1.1 Prostanoid biosynthetic pathway
Schematic to show intermediate steps in biosynthesis of specific 
prostanoids formed by cyclooxygenase reaction and their specific 
receptors
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The isoforms are similar in enzymatic function but their cell-specific expression and 
regulation, subcellular localisation, and their physiologic functions are thought to be 
quite different (Smith et al, 1994). For example, whilst both COX-1 and COX-2 are 
present on the lumenal surfaces of the endoplasmic reticulum and of the inner and outer 
membranes of the nuclear envelope (Morita et al, 1995, Spencer et al, 1999), COX-2 is 
more highly concentrated in the nuclear envelope (Morita et a l , 1995). Generally the 
constitutive COX-1 is used in the immediate PG synthesis which occurs within several 
minutes of stimulation of Ca mobilisers, whereas the inducible COX-2 is an absolute 
requirement for delayed PG synthesis, which lasts for several hours after pro- 
inflammatory stimuli. COX-2 also has a primary immediate response after Ca2+ 
mobilisation.
The following sections will discuss the biosynthesis of PGE2 in chronological order, 
beginning with substrate release, then discussing the COX isoforms, describing gene 
structure, function, activity, and roles, both physiological and pathological. PG 
synthases and receptors will then be discussed followed by the degradation pathway and 
pharmacological inhibitors of COX activity.
1.7 Substrate availability
The first step in the production of prostanoids is the release of free arachidonic acid 
(20:4«-6), the main constituent of phospholipid membranes. Arachidonic acid is the 
principal substrate for prostanoid biosynthesis in mammalian cells, although both COX 
isoforms are capable of utilising additional substrates, but to differing abilities. COX-2 
will accept a wider range of fatty acids as substrates than COX-1 (Otto and Smith,
1995).
AA exists esterified in cell membrane phospholipids, however, non-esterified AA is 
required as the substrate for eicosanoid biosynthesis. Following an appropriate trigger, 
one or more of the phospholipase systems is activated at the endoplasmic reticulum and 
nuclear envelope to cleave AA from the glycerol backbone of the lipid bilayer 
(Holtzman et al, 1991). AA can be mobilised by several different phospholipase A2s. 
Amongst them cPLA2 and type DA and type V secreted PLA2 (sPLA2) predominately 
contribute to prostaglandin production.
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Specific coupling between COXs and particular PLA2S subtypes have been proposed, 
i.e., coupling of CPLA2 and COX-2 and SPLA2 with COX-1 (Reddy and Herschman, 
1997; Bingham et al, 1996). However, co-expression studies have clearly demonstrated 
that both CPLA2 and several SPLA2 isozymes are capable of supplying AA to both 
COX-1 and COX-2 in the immediate responses and mainly to COX-2 in the delayed 
responses (Murakami et al, 1999a; Murakami et al, 1999b; Murakami et al, 1999c; 
Murakami et al, 2001). Additionally, studies using CPLA2 null mice have shown CPLA2 
to be essential for both immediate and delayed phases of PG generation. (Uozumi et al, 
1997; Bonventre et al, 1997). The actions of SPLA2S in either phase appear to be cell 
type-specific and depend on their temporal expression, secretion process, and sorting 
into particular membrane microdomains (Murakami et a l , 1999b; Murakami et al, 
2001).
1.8 COX-1
Both COX-1 and the proposed COX-3 are encoded from a single gene on chromosome 
9 (Funk et a l, 1991; Kraemer et al, 1992; Chandrasekharan et al, 2002). COX-1 was 
originally purified from sheep vesicular gland (Van der Ouderaa et al, 1977) and the 
primary structure was identified by cDNA cloning (Merlie et a l, 1988; Yokoyama et 
al., 1988; DeWitt and Smith, 1988). The COX-1 gene is 22kb in length, contains 11 
exons (Yokoyama and Tanabe, 1989) and is expressed in lung fibroblasts as two mRNA 
transcripts of 5.5kb and 2.7kb (Diaz et al, 1992). The complete amino acid sequence 
was determined by cloning and sequence analysis of human genomic DNA encoding for 
the enzyme, and in its processed form, the glycoprotein has 576 amino acids and exists 
as a 72kDa homodimer (Yokoyama and Tanabe; 1989; DeWitt et al, 1990; Picot et a l,
1994).
The COX-1 gene is constitutively expressed in nearly all tissues and prostanoids 
synthesised via COX-1 are generally thought to be responsible for homeostatic 
functions such as gastric cytoprotection, regulation of renal blood flow, and platelet 
aggregation. There are several putative transcriptional regulatory elements in the 
promoter region, including two Spl motifs, two AP-2 sites, an NF-IL6  motif, and a 
GATA but like many ‘housekeeping genes’, COX-1 lacks a TATA box, a CAAT box, 
and is GC-rich (Kraemer et al, 1992). However, preferential expression at high levels 
occurs in certain tissues and expression increases in cell lines undergoing differentiation
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(reviewed by Morita, 2002). Induction of COX-1 without differentiation has also been 
reported in guinea pig gallbladder inflammation where enhanced bradykinin-stimulated 
prostaglandin release has been shown to be due to de novo synthesis of COX-1 protein 
(Bogar et al., 1999).
The physiological roles of COX-1 have been deduced from the deleterious 
gastrointestinal side effects of NSAIDs which are thought to be associated with 
inhibition of basal COX-1 levels. This has lead to the subsequent development of COX- 
2 selective NSAIDs by the pharmaceutical industry. Surprisingly, mice deficient in 
COX-1 do not exhibit evidence of spontaneous gastric injury in the absence of an 
inflammatory stimulus despite a 99% reduction in gastric PGE2 levels (Langenbach et 
al, 1995). However, it has been shown that COX-1 deficient mice are more susceptible 
to acute dextran-sodium sulphate (DSS)-induced colitis (Morteau et al., 2000). 
Additionally COX-1 null mice also show reduced indomethacin-induced gastric 
ulceration, reduced platelet aggregation and a decreased inflammatory response to AA 
(Langenbach et ah, 1995).
1.9 COX-2
In the early 1990’s COX was demonstrated to exist as two distinct isoforms (Xie et al, 
1991; Hla et a l, 1992). The COX-2 gene is found on chromosome 1 (Tay et a l, 1994) 
and is significantly smaller than the COX-1 gene at 8.3kb (Hla et a l, 1992; Appleby et 
al., 1994; Kosaka et al, 1994). It contains 10 exons and is expressed as a single 4.4kb 
mRNA transcript in fibroblasts (Diaz et al., 1998).The cDNA for COX-2 encodes a 
polypeptide that before cleavage of the signal sequence contains 604 amino acids that is 
60-65% identical to that of the human COX-1 polypeptide. The main differences 
between the genes are firstly that the first intron in COX-1 is lost in COX-2 and 
secondly, that the introns in the COX-2 gene are shorter than those in the COX-1 gene.
As a primary response gene, levels of COX-2 mRNA and protein are normally 
undetectable in most tissues, but are readily induced by a variety of mediators including 
pro-inflammatory and pro-fibrotic cytokines such as IL-1, TNF-a, or LPS, and 
hormones or oncogenes (Smith and Dewitt, 1996; Smith et al., 1996; Herschman,
1996). Products of the COX-2 pathway themselves may also alter the expression of the 
enzyme; PGE2 has been shown to upregulate COX-2 expression via upregulation of
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cAMP levels in a variety of cell types including murine macrophages (Hinz et a l, 
2000b) and human blood monocytes (Hinz et al., 2000a). Expression of COX-2 also 
occurs in specialised tissues where it plays specific roles in individual processes such as 
reproduction (Lim et al, 1999; Lim et al, 1997), immunity (Rocca et al, 1999) renal 
physiology (Cheng et al, 1999) or pancreatic secretion (Robertson et al, 1998). Factors 
which regulate COX-2 expression in these cells are often specific to the process, for 
example in the kidney, expression of COX-2 in the macula densa depends on lumenal 
salt concentrations (Harris et al, 1994). The lung is the second highest source of COX-2 
mRNA (O’Neill and Ford Hutchinson, 1993), and high levels of expression are 
associated with epithelial cells (O’Neill and Ford Hutchinson, 1993; Asano et al, 1996) 
and macrophages (O’Neill and Ford Hutchinson, 1993).
COX-2 expression is controlled both at the level of gene transcription and post- 
transcriptional events. COX-2 is an inducible immediate-early gene and sequence 
analysis of the 5’-flanking region of the mouse (Fletcher et a l, 1992), rat (Sirois et al 
1993) and human (Appleby et al, 1994; Tazawa et al, 1994; Kosaka at al, 1994) genes 
have shown several potential transcriptional regulatory elements, including a TATA 
box, a cyclic AMP response element (CRE), two NF-IL6  (C/EBP) motifs, two AP-2 
sites, three Spl sites, two NF-kB sites and an E-box, allowing transcriptional regulation 
of COX-2 by a broad spectrum of mediators (Appleby et al, 1994, reviewed by Tanabe 
and Tohnai, 2002). Since many activators, under different conditions, lead to regulation 
of COX-2 gene expression it is therefore difficult to identify a common signalling 
pathway in all cases. However, pathways common to the inflammatory response have 
been linked to the increased expression of COX-2 including the NFkB and NF-IL6  
(C/EBP) pathways, as well as one or all of the three mitogen-activated protein kinase 
(MAPK) signalling pathways: ERK1/2, JNK/SAPK and p38RK/Mpk2 (Su et al, 1996).
Post-transcriptionally COX-2 may also be regulated by affecting mRNA stability as it is 
highly unstable due to the presence of AU rich elements in the 3’UTR of the COX-2 
gene (Appleby et al, 1994; Dixon et al, 2000). It has been reported that the MAPK 
signalling pathway is involved in regulating gene expression at the post-transcriptional 
level (Chen et al, 1998; Winzen et al, 1999) as activation of one or more MAPKs 
results in stabilisation of the target mRNA. Mediators which induce COX-2 gene 
expression such as TGF-p and IL-1 a  also stabilise COX-2 mRNA via induction of 
MAPK p38 (Diaz et al, 1998; Gou et al, 1998).
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Anti-inflammatory cytokines such as IL-4, IL-10 and IL-13 have been reported to 
inhibit the expression of COX-2 (Lee, et al, 1992; Onoe et al, 1996; Niiro et al, 1997), 
and despite the absence of a glucocorticoid response element (GRE) on the 5’-flanking 
region of the human COX-2 gene glucocorticoids, such as dexamethasone, strongly 
suppressed COX-2 expression induced by inflammatory stimuli. The mechanism of 
glucocorticoid-mediated repression of COX-2 gene expression involves suppression of 
AP-1 and NF-icP-dependent transcription (Yang Yen et al, 1990; Auphan et a l, 1995), 
although at 6  hours following treatment with dexamethasone, COX-2 transcription is 
only inhibited by 40% but COX-2 protein and mRNA are completely repressed, 
indicating the presence of other post-translational methods of repression (Newton et al,
1998). Indeed, dexamethasone shortens the poly-A tail which confers stability to mRNA 
transcripts, resulting in the premature degradation of COX-2 mRNA (Ristimaki et al, 
1994; Newton e ta l,  1998).
In summary, COX-2 has been shown to play a role in physiological processes such as 
renin secretion in the kidney, wound/ulcer healing, female reproductive functions, bone 
metabolism and vascular protection. The co-ordination of COX-2 gene expression 
occurs through a combination of regulating gene expression and post-translational 
events and this high level of complexity is needed to tightly control the expression of 
COX-2 which can have pathogenic effects when expression is dysregulated. Increased 
COX-2 induction has been primarily associated with a number of pathological processes 
such as acute and chronic inflammatory states, pain, fever, Alzheimer’s disease and 
cancer (Hinz and Brune, 2002; Dubois et al, 1998), and the use of COX-2 deficient 
animals to investigate these events will be discussed later in this chapter (see section 
1.19).
1.10 COX-3
In 2002 a so-called third COX isoform was described (Chandrasekharan et a l, 2002) 
and controversially named COX-3 despite not being a product of a separate gene. COX- 
3, along with two new smaller forms of COX-1 also described in this paper, are formed 
from the COX-1 gene by ‘alternative splicing’ of COX-1 mRNA. This results in a 
protein which is similar to COX-1 with the addition of an N-terminal extension due to 
the retention of intron-1 and the retained signal peptide. It was suggested that the
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retention of intron 1 may change the way the enzyme molecule is folded, may affect 
dimerisation, or the conformation of the active site (Chandrasekharan et a l, 2002).
COX-3 was shown to be preferentially inhibited by acetaminophen (paracetamol) and 
may help to explain some of the unanswered questions as to the mode of action of 
acetaminophen. Often classified as an NSAID (see section 1.18), acetaminophen 
relieves pain and reduces fever, yet is not an effective anti-inflammatory medicine and 
does not markedly inhibit either COX-1 or COX-2. Chandrasekharan et a l 
demonstrated that COX-3 is strongly expressed in the canine brain and may be involved 
in mediating pain, however this still leaves unanswered questions as the pyretic 
response has been associated with rapid induction of COX-2, not COX-1 (and therefore 
not COX-3, as a COX-1 gene product). Pyresis has been shown to be inhibited in mice 
deficient in COX-2, but not COX-1/3, (Li et al, 1999) and COX-2 selective inhibitors 
are as good as traditional NSAIDs at reducing fever but these only react weakly with the 
COX-1/3 enzymatic site (Luong et al, 1996; Kurumbail et al, 1996; Riendeau et al,
1997). Previous data has also indicated a COX-2 variant involved in pain. The same 
group to describe COX-3 have also previously suggested an existence of an isoform of 
COX-2 that is particularly sensitive to acetaminophen (Simmons et al, 1999; Botting et 
al, 2000), and Willoughby et a l suggested the existence of an inducible COX-3 
involved in the resolution of inflammation which unlike COX-1 and COX-2 does not 
produce pro-inflammatory prostanoids but anti-inflammatory members of the prostanoid 
family (Willoughby et al., 2000). Both Willoughby and Botting hypothesised that this 
new enzyme included the COX-2 specific carboxyl terminus which allowed it to be 
detected by COX-2 specific antibodies. Whether or not COX-3 and the COX-2 derived 
variants are true isoforms, or splice variants, it is interesting that multiple COX 
isoenzymes could be derived from just two distinct genes.
However, in a recent letter to the editor published in Immunology Letters, the true 
existence of COX-3 has been questioned by Dinchuk and colleagues. Chandrasekharan 
described that the length of intron 1 in human COX-3 differed by one nucleotide from 
the sequence observed in the dog and suggested that this may have been a sequencing 
error. However, Dinchuk raises the issue that if not a sequencing error, this would shift 
the remainder of the protein out of frame with respect to the open reading frame of 
COX-1. After cloning COX-1 cDNAs and human genomic fragments spanning the 
region, Dinchuk found these clones to agree with the published human COX-1 intron 1
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sequence of 94, not 93 nucleotides as seen in the dog, and therefore suggest that none of 
the downstream alternative splices are able to rescue the reading frame of the proposed 
COX-3 in humans (Dinchuk et al., 2003). This suggests that a full-length, catalytically 
active form of COX-3 does not appear in humans, however further research is required.
1.11 PGE synthases
The final stage in generation of specific prostaglandins from PGH2 involves the terminal 
PG synthases. Specific synthases have different structures and exhibit cell- and tissue- 
specific distributions. Two synthases have been described for PGE2 synthesis, namely 
cytosolic PGE2 synthase (cPGES) and perinuclear membrane-bound PGES (mPGES, 
Beuckmann et al., 2000). cPGES is constitutively expressed in a wide variety of cells 
and tissues and is associated with heat shock protein 90 (HSP90) whereas mPGES is a 
perinuclear protein belonging to the microsomal glutathione-S-transferase (GST) 
family. Its expression is strongly induced by pro-inflammatory stimuli and is also down 
regulated by anti-inflammatory glucocorticoids (Murakami et al., 2000; Thoren and 
Jakobsson, 2000).
It has been hypothesised that there is selective functional linkage between COX 
isoforms and the PGES. This idea is supported by studies using co-expression and 
antisense which have shown that the constitutive cPGES and the inducible mPGES 
favour COX-1 and COX-2 respectively (Tanioka et al., 2000; Murakami et al., 2000). 
Similarly to the expression of the COX isoforms to which they are coupled, this linkage 
may aid in controlling the spatial and temporal production of PGE2 in a tissue and 
stimulus-dependent fashion.
Recently, it has been shown that mice lacking inducible mPGES show impaired 
inflammatory and pain responses (Trebino et al, 2003). These animals are viable and 
fertile and develop normally compared with wild type controls, however homozygote 
deficient animals display a marked reduction in inflammatory responses compared with 
wild type mice in multiple assays.
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1.12 PGE receptors
There are at least 9 known prostaglandin receptors, and PGE2 signals via four separate 
G-coupled rhodopsin-type receptors, each with seven transmembrane domains encoded 
for by a different gene, namely EP1-4 (Coleman et al., 1994). Most EP receptors are 
localised at the plasma membrane although some are situated at the nuclear envelope 
(Bhattacharya et al., 1998). The receptors also differ both in the cell type in which they 
are expressed, and the intracellular pathways which they signal through. Thus the 
existence of subtype receptors allows PGE2 to have diverse and opposing actions in 
different cell types. EP2 and EP4 are considered ‘relaxant’ receptors and signal through 
Gs-mediated increases in intracellular cAMP. The ‘contractile’ receptor EP1 signal 
though Gq-mediated increases in intracellular calcium. And EP3 is regarded as an 
‘inhibitory’ receptor that couples to G* and decreases cAMP formation. In fibroblasts, 
PGE2 has been shown to reduce a i (I) collagen expression via the EP2 receptor and 
consequent rise in cAMP (Choung et al, 1998) and PGE2 inhibits the fibroblast to 
myofibroblast transition via EP2 signalling and cAMP elevation (Kolodsick et al., 
2003). Knockout mice for each receptor subtype have been generated (Ushikubi et al.,
1998) and these animals may help establish a role for the receptors in pulmonary disease 
in the future. A recent publication has also described the first use in vivo of an EP2 
receptor-selective PGE2 agonist. This agonist was administered locally into bones, and 
successfully induced bone repair in a fracture model in rats without the side effects of 
administering PGE2 (Paralkar et al., 2003, Grant et al., 1991).
1.13 Inactivation of PGE2
In addition to synthesis, degradation is a rapid mechanism by which physiological levels 
of prostaglandins can be altered. The liver and lungs are responsible for their 
inactivation (Piper et al., 1970; Samuelsson., 1964) and over 90% of PGE2 is 
inactivated during a single passage through the pulmonary vascular bed (Ferreira and 
Vane, 1967).
Inactivation of PGE2 occurs intracellularly and first requires carrier-mediated transport 
across the cell membrane as prostaglandins diffuse poorly (Bito and Baroody, 1975; 
Schuster et al., 1998). This is followed by intracellular catabolism (Ensor and Tai, 1995; 
Schuster et al., 1998) of which the first reaction, enzymatic oxidation of the 15-
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hydroxyl group, is crucial because it leads to the loss of biological activities (Ensor and 
Tai, 1995). This reaction is catalysed by 15-hydroxy-PG dehydrogenase (15-PGDH or 
PGDH) and less importantly, carbonyl reductase (CR). PGDH is found in many 
mammalian tissues and is known to be inducible and responsive to steroid hormones 
(Greenland et al, 2000). NSAIDs also inhibit PGDH (Cho and Tai, 2002), and genetic 
deletion of PGDH leads to an increase in circulating blood/tissue levels of PGE2 
(Coggins et al, 2002).
1.14 PGE2 in the lung
Prostaglandins are formed by most cells in our bodies and act as both autocrine and 
paracrine lipid mediators. PGE2 is the major prostanoid in the lung and has been 
reported to be present in bronchoalveolar lavage fluid at 2 0 ng/ml, 80-fold higher than in 
plasma (0.25ng/ml, Ozaki et al., 1987). However, this value may not represent a truly 
basal level as bronchoalveolar lavage itself may induce PGE2 synthesis. It is synthesised 
by fibroblasts, epithelial cells, smooth muscle cells, endothelial cells and macrophages 
and is thought to have bronchoprotective effects. These include bronchodilation, 
inhibition of eosinophil chemotaxis and inhibiting release of mediators from mast cells 
in the lung (Pavord and Tattersfield, 1995).
Synthesis of PGE2 by fibroblasts in the lung can be induced by a range of pro-fibrotic
and pro-inflammatory mediators known to be increased in the pathogenesis of
pulmonary fibrosis, such as TGF-p, IL-lp, TNF-a and PDGF (McAnulty et al, 1995;
1997; Diaz et al, 1989; Keerthisingam et al, 2001; Wilbom et al, 1995; Mauviel et al,
1988; Habenicht et al, 1985). TNF-a and IL-lp are also known to increase PGE2
production via increasing the steady-state levels of COX-2 mRNA (Diaz et a l, 1992).
PGE2 is thought to have a negative feedback effect on PDGF production which
counteracts its effect on fibroblasts proliferation (Boyle et al., 1999) and is a potent
inhibitor of TGF-p 1-induced fibroblast proliferation and collagen synthesis (McAnulty
et a l, 1995; 1997, see section 1.4.4). Inflammation also induces production of PGE2 in
fib/vvs
the lung (see section 1.16). Using the bleomycin model of pulmonary, increased levels 
of PGE2 in plasma (Chandler and Giri, 1983) and lung homogenate (Giri and Witt, 
1985) have been shown following injury in hamsters, and in bronchoalveolar lavage 
fluid in mice (Moore et al, 2000). Furthermore, vanadium pentoxide (V2 O5 , Bonner et
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al, 2001) and ovalbumin (Gavett et al., 1999) have also been shown to increase levels 
of PGE2 in the lungs of mice.
In pulmonary fibrosis there may be failure in this tightly regulated mechanism, and 
defective suppression of pro-inflammatory and pro-fibrotic cytokines may lead to 
unrestrained fibroblast proliferation and collagen production in the fibroblastic foci. 
Mechanisms for a failure to upregulate PGE2 synthesis in pulmonary fibrosis will be 
discussed in detail in section 1.17
1.15 Cellular effects of PGE2
PGE2 is known to inhibit an array of fibroblast functions known to be important in the 
pathogenesis of pulmonary fibrosis such as fibroblast proliferation (Elias et al. ,1988; 
Bitterman et al, 1986), collagen synthesis (Korn et al, 1980; Goldstein and Polgar, 
1982; Saltzman et al., 1982), fibroblast to myofibroblast differentiation (Kolodsick et 
al, 2003), fibroblast chemotaxis (Kohyama et al., 2001) and contraction of ECM 
matrices (Skold et al., 1999; Zhu et al., 2001). In addition it has also been shown to 
promote degradation of newly synthesised collagen (Baum et al., 1980; Brilla et al, 
1995). The following section will discuss how PGE2 is responsible for these cellular 
effects and discuss potential mechanisms for its action.
Addition of exogenous PGE2 has been shown to down regulate cxi (I) collagen gene 
expression in lung fibroblasts induced by TGF-pi (Fine et al., 1989) and TNF-a (Diaz et 
al., 1989), and attenuate collagen type I and III production induced by IL-1 (Goldring 
and Krane, 1987). It is known that PGE2  raises intracellular cAMP levels, suggesting a 
potential causal relationship between levels of cAMP and modulation of collagen 
metabolism and fibroblast proliferation via the EP2 and/or EP4 receptors which act via 
stimulation of cAMP. Indeed, it has been shown that PGE2 can reduce a i (I) collagen 
RNA expression via the EP2 receptor and consequent rise in cAMP (Choung et 
al, 1998) and previous work has suggested that elevating cAMP levels directly in IMR- 
90 cells suppresses collagen production (Polgar et al, 1979; Clark et al, 1982)
A simultaneous increase in levels of cAMP has also been demonstrated following the 
inhibition of collagen production and increased intracellular degradation of newly 
synthesised collagen by PGEi (Baum et a l, 1980; Barile et al, 1988, Brilla et a l,
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1995). Furthermore, this can be duplicated with cAMP agonists and inhibited with 
antagonists (Baum et al, 1980). A role for cAMP in PGE2-mediated inhibition of 
proliferation has been demonstrated in arterial smooth muscle cells and hepatic stellate 
cells (Bomfeldt et al, 1997; Mallat et al, 1998) and the cAMP analogue dibutryl cAMP 
has been shown to block the proliferation of human lung fibroblasts in response to 
serum (Fine and Goldstein, 1987). PGE2-mediated inhibition of fibroblast chemotaxis 
has also been shown to act via a cAMP dependent mechanism where the inhibitory 
effect of PGE2 was itself inhibited by a cAMP-dependent protein kinase (PKA) inhibitor 
suggesting that the cAMP dependent effect is mediated by PKA (Kohyama et al, 2001). 
PGE2 has also been shown to inhibit the expression of lysyl oxygenase, the enzyme 
which catalyses the first step in the cross-linking of collagen fibrils required for the 
deposition of collagen into the ECM. Again, this has been shown to be mediated via 
cAMP and EP2 receptors (Choung et al, 1998).
The ability of PGE2 to inhibit fibroblast to myofibroblast transition has also been shown 
to be mediated by EP2 signalling and subsequent increases in cAMP production. In a 
recent study, Kolodsick and colleagues showed that the inhibitory effects of PGE2 on 
TGF-p-induced a-SMA expression in IMR-90 fibroblasts are mimicked by an EP2 
selective agonist, butaprost, and forskolin-induced direct activation of adenyl cyclase. 
Conversely, an EP2 antagonist was shown to block the inhibitory effects of PGE2 
(Kolodsick et al, 2003).
However, cAMP-independent mechanisms have also been shown to downregulate oti 
(I) collagen gene transcription, possibly acting via a PGE2 inducible protein (Fine et al,
1992). More recently PGE2 has been shown to inhibit transcription of the CTGF gene 
which is itself induced by TGF-p and directly activates 0 Ci (I) collagen mRNA 
transcription (Leof et al, 1986). The anti fibrotic effects of PGE2 may therefore involve 
inhibition of CTGF transcription (Ricupero et a l , 1999). PGE2 has also been shown to 
downregulate signalling TGF-p receptors which could limit collagen gene expression 
(Fine e ta l,  1995).
1.16 PGE2 and inflammation
Aspirin and other non-steroidal antiinflammatory drugs (NSAIDs) are the most widely 
used class of drug world-wide (see section 1.18). Amongst other indications, they are
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commonly used in the treatment of chronic inflammatory diseases and inhibit the 
production of prostanoids, including PGE2, via inactivation of COX. As previously 
mentioned, prostaglandins (PGs) derived from COX-1 are often described as 
performing homeostatic functions such as gastric cytoprotection, whereas those derived 
from COX-2 are seen as pathogenic and associated with inflammation. For this reason 
COX-2 selective NSAIDs have been developed over the last 15 years with the aim of 
inhibiting COX-2-derived PGs whilst maintaining the production of ‘housekeeping’ 
levels of COX-1-derived PGs and therefore avoiding the side effects associated with 
NSAIDs. The use of COX-2 selective NSAIDs for rheumatoid arthritis is now 
widespread (Simon et al., 1998). Pro-inflammatory mediators such as IL-1 or TNF-a 
increase production of PGE2 via the induction of COX-2 (Endo et al, 1995) and one 
mechanism of action of the powerful anti-inflammatory steroid dexamethasone is as an 
inhibitor of IL-lp-induced COX-2 at both the transcriptional and post-transcriptional 
level. Therefore, there is considerable evidence for the role of PGE2 in both promoting 
and modulating inflammation.
In vivo, administration of PGE2 appears to promote inflammation by increasing vascular 
permeability and potentiating the effects of pro-inflammatory mediators (Williams et 
al., 1979; Agro et al., 1996; Serhan et al., 2000). In vivo administration of PGE2 
neutralising antibodies have also been shown to reduce paw oedema, hyper-analgesia 
and IL- 6  production following carrageenan and adjuvant-induced inflammation 
(Portanova et al, 1996). In the lung, administration of NSAIDs have been used to 
examine the role of the inflammatory response in the bleomycin model of pulmonary 
fibrosis. The first such study was that of Thrall and co-workers who showed that 
treatment with indomethacin ameliorates bleomycin-induced fibrosis in rats. After 60 
days, treatment with indomethacin resulted in reduced lung collagen accumulation 
compared with bleomycin alone, although this was not seen at day 14 and no mention is 
made of intermediate timepoints. Histopathologic evidence of pulmonary fibrosis was 
reduced following indomethacin treatment, as was the reported bleomycin-induced 
eosinophilia (Thrall et al., 1979). Following this, diclofenac acid (Voltaren) was used in 
a hamster model where pre-treatment before intratracheal bleomycin administration 
followed by daily injections of the NSAID reduced lung collagen accumulation at both 
14 and 21 days compared with bleomycin alone. However, no assessment of PGE2 
levels were made in this study (Chandler and Young, 1989). Indomethacin was again 
used by Mall and co workers following systemic administration of bleomycin in rats.
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Histological analysis revealed reduced fibrosing alveolitis in the bleomycin-treated 
animals and quantitative morphometric analysis indicated that treatment with 
indomethacin reduced alveolar wall thickening, fibrosis and inflammatory cell 
accumulation. However, animals treated with indomethacin lost over 50% of their body 
weight throughout the experiment and had reduced lung volumes which was not seen in 
control animals which received bleomycin alone (Mall et al, 1991).
However, these three studies all used continuous administration of the NSAID from the 
time of bleomycin instillation. The bleomycin model is characterised by an acute 
inflammatory response in the first 7 days prior to the increase in total lung collagen 
accumulation typically seen by day 14. In a slightly different approach, Moore and co­
workers delayed administration of indomethacin until 1 0  days after bleomycin 
instillation when the acute inflammatory response has decreased. In this experiment 
contrasting results were observed; animals which received indomethacin showed an 
enhanced fibrotic response compared with control mice suggesting that PGE2 is 
protective against bleomycin-induced lung injury (Moore et al., 2000).
The cellular effects of PGE2 have also been shown to be anti-inflammatory. Stimulated 
macrophages and neutrophils both produce PGE2 via COX-2 (Brook et al., 1999; 
Maloney et al., 1998) and its effects on these cells are inhibitory as PGE2 promotes 
macrophage deactivation (Strassman et al., 1994), and reduces macrophage (Zeidler et 
al., 2000) and neutrophil chemotaxis and aggregation (Armstrong et al., 1995; Wise et 
al., 1996). In fibroblasts, although PGE2 is induced by the pro-inflammatory cytokines 
TGF-pi, IL-ip, TNF-cx and PDGF (Diaz et al., 1989; McAnulty et al., 1995; 1997; 
Yucel-Lindberg et a l, 1995; Mauviel et al., 1988; Habenicht et al, 1985) it has also 
been shown to form a negative feedback loop on these cytokines. This is demonstrated 
for TGF-pi and PDGF on fibroblast proliferation (McAnulty et al., 1997; Boyle et al,
1995) and TGF-pi on collagen production (McAnulty et al., 1995). PGE2 has also been 
shown to stimulate the production of anti-inflammatory cytokines such as IL-10 
(Strassman et al., 1994) and inhibits the production of pro-inflammatory cytokines from 
macrophages (Fadok et al., 1998; Standiford et al., 1992) as well as reducing respiratory 
burst and degranulation in neutrophils (Fantone et al, 1984; Weksler and Goldstein,
1980). Synthesis of pro-inflammatory leukotrienes (Christman et al., 1993) and IgE 
(Pene et al, 1988) are also inhibited by PGE2 and products of COX-2 also produce anti­
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inflammatory mediators such as PPAR-y (Gilroy et al, 1999) and lipoxins (Levy et al., 
2001).
When given alone in vivo, PGE2 does not produce significant levels of pain, swelling or 
neutrophil infiltration (Portanova et al, 1996; Serhan et al., 2000). Specifically in the 
lung, PGE2 is bronchodilatory (Mathe and Hedqvist, 1975) and administration of PGE2 
blocks both the early and late response to antigen challenge in asthmatics (Pavord et al,
1993). PGE2 administration also prevents airway hyper-reactivity in aspirin-intolerant 
asthmatics (Sladek et al, 1994, Sestini et al, 1996). A study by Grant and co-workers 
showed that continuous intravenous infusion of PGEi for 22 hours in a hamster model 
of bleomycin-induced pulmonary fibrosis lead to decreased neutrophil influx and 
plasma leak in the lungs of treated animals (Grant et al, 1991). This suggests a 
protective role for PGE2 in the inflammatory response and both COX-1 and COX-2 
deficient mice showed increased inflammatory response following antigen challenge 
(see section 1.19, Gavett et al, 1999), and COX-2 deficient mice show an increased 
inflammatory response to vanadium pentoxide challenge in the lung compared to both 
wild type and COX-1 deficient mice (Bonner et al, 2002). However, as shown in 
section 1.19, not all studies using COX-2 deficient mice conclude that the inflammatory 
response is enhanced in these animals. Together these data suggest that the role for 
PGE2 and other products of the COX pathway in the inflammatory response is complex.
1.17 Reduced expression of PGE2 and COX-2 in pulmonary fibrosis
Despite the increased expression of TGF-p and other pro-fibrotic mediators which 
induce its synthesis, levels of PGE2 in BALF from patients with IPF have been shown to 
be 50% lower than in normal individuals (Borok et a l , 1991). Macrophages obtained 
from patients with IPF also show a reduced capacity to produce PGE2 (Ozaki et 
a/., 1987). Furthermore, fibroblasts derived from the lungs of patients with IPF show 
both decreased basal levels of synthesis of PGE2 compared with normal cells (Wilbom 
et al, 1995; Keerthisingam et al, 2001, Marchand-Adam et al, 2003), and fail to 
induce PGE2 synthesis on stimulation with IL-lp, TNF-a, LPS or TGF-pi (Wilbom et 
al, 1995; Keerthisingam et al, 2001; Vancheri et al, 2000). However, this is 
contradicted by Cruz-Gervais and colleagues who have shown PGE2 levels to be 
unaltered in fibrotic fibroblasts compared with control cells. Despite this report, the
52
majority of data suggest that PGE2 deficiency is associated with several cell types in 
fibrotic lung disease.
Using fibroblasts derived from patients with IPF it has been shown that the failure to 
induce synthesis of PGE2 in response to an array of pro-fibrotic mediators is associated 
with a decreased capacity to upregulate COX-2 (Wilbom et al, 1995; Keerthisingam et 
al, 2001). Wilbom demonstrated that fibroblasts derived from the lungs of patients with 
pulmonary fibrosis express normal levels of COX-1 protein and radiolabelling studies 
showed these fibroblasts to be able to release endogenous A A, excluding a defect in the 
cPLA2-mediated release of AA in these cells. Furthermore PGE2 was also synthesised 
when the endoperoxidase intermediate PGH2 was added to the fibrotic cells, bypassing 
the COX pathway, excluding a defect in PGES. However, COX-2 protein expression 
was significantly decreased in fibrotic lung fibroblasts (Wilbom et al, 1995), and this 
laboratory has also shown this to be true at the mRNA level (Keerthisingam et al,
2001). This failure to upregulate COX-2 leads to a more fibrogenic phenotype in these 
cells characterised by a loss in the antiproliferative response to TGF-Pi and an increase 
in procollagen production following stimulation with TGF-pi (Keerthisingam et al, 
2001).
Reasons for the failure to upregulate COX-2, and subsequently synthesis of PGE2 in 
pulmonary fibrosis are currently unknown. However, there may be several potential 
explanations. Functional variants in the COX-2 gene may affect gene expression or 
mRNA stability leading to a loss in inducibility. Recent work from this laboratory has 
described a novel functional change in the 5’ transcriptional regulatory promoter region 
of the COX-2 gene (-765G>C). This polymorphism has been shown to affect the 
transcription rate of a reporter gene in transient transfection studies (Papafili et al,
2002). Future work may determine the role of this polymorphism in fibrotic lung 
disease. Alternatively, since there is no evidence to suggest that fibroblasts derived from 
patients with pulmonary fibrosis show a general defect in their response to pro-fibrotic 
mediators, other than a failure to induce COX-2, there may be dysregulation of the 
transcription factors or signalling molecules upstream of the COX-2 gene. Finally, the 
inability to induce COX-2 could reflect an acquired defect that is specific to the lung. 
For example, viral infection could alter a cells ability to induce COX-2. EBV, a 
herpesvirus previously associated with the development of pulmonary fibrosis (Egan et 
al, 1997; Tang et al, 2003), has been shown to inhibit COX-2 expression both at the
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transcriptional and translational levels, resulting in suppression of PGE2 biosynthesis in 
monocytes (Savard et al., 2000).
Together, these data suggest that a decreased capacity to upregulate synthesis of PGE2 
via dysregulation of COX-2 expression may play a key role in the pathogenesis of 
pulmonary fibrosis. This thesis aims to address this hypothesis in vivo by inhibiting the 
function of COX-2, and therefore presumably PGE2 synthesis, both pharmacologically 
and using COX-2 deficient mice, in the bleomycin model of lung fibrosis. The final 
sections in this chapter discuss pharmacological inhibition of COX-2 and COX-2 gene 
disrupted animals.
1.18 Pharmacological inhibition of COX
Non-steroidal anti-inflammatory drugs (NSAIDs) have anti-inflammatory, analgesic, 
and anti-pyretic effects. In 1971, Vane showed the action of NSAIDs to be due to the 
inhibition of cyclooxygenase and production of pro-inflammatory prostaglandins (Vane, 
1971). All classical NSAIDs compete with arachidonate for binding to the 
cyclooxygenase active site and therefore inhibit both COX-1 and COX-2, but in general 
preferentially inhibit COX-1 (Munroe and Lau 1995; DeWitt, 1999). NSAIDs are 
competitive inhibitors which interfere with fatty acid substrate binding in one of three 
general modes of inhibition (Munroe and Lau, 1995; DeWitt, 1999): either rapid, 
reversible binding (e.g. ibuprofen); or rapid, lower affinity reversible binding followed 
by time-dependent, higher affinity slowly reversible binding (e.g. flurbiprofen); or 
finally, rapid, reversible binding followed by covalent modification, as in the acetylation 
of Ser530 by aspirin.
The use of NSAIDs is associated with problematic side effects including gastrointestinal 
toxicity where they have been shown to induce ulceration and promote bleeding of 
existing ulcers. Renal toxicity has also been associated with the use of NSAIDs, and the 
use of COX inhibitors in aspirin-intolerant asthmatics causes adverse respiratory 
reactions (reviewed by Szczeklik and Stevenson, 1999). With the identification of 
COX-2, and its induction by inflammatory agents, it has been proposed that the anti­
inflammatory effects of NSAIDs are due to inhibition of COX-2, whereas the side 
effects including gastrointestinal and renal toxicity are due to inhibition of the 
‘housekeeping’ actions of COX-1. The structural differences between the COX sites of
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the two isoforms have permitted the development of a new generation of isoform 
selective inhibitors (Luong et al., 1996) designed to exhibit many-fold higher selectivity 
towards COX-2 (Munroe and Lau, 1995; DeWitt, 1999) such as celecoxib, rofecoxib 
and NS398. Celecoxib has been licensed in the treatment of patients with osteoarthritis 
and rheumatoid arthritis, and rofecoxib for the treatment of patients with osteoarthritis 
and acute musculoskeletal pain and are largely free of gastrointestinal side effects. 
However, in other reports, both ulceration and GI toxicity have been linked to the use of 
selective COX-2 inhibitors (Reuter et al., 1996) suggesting that COX-2 derived 
metabolites play a role in maintaining the integrity of the gastric mucosa. This data is 
also supported by in vivo work by Morteau who showed that COX-2'7' mice show 
enhanced experimentally-induced colitis compared with WT animals (Morteau et al., 
2000).
NS398 is one of the most selective COX-2 inhibitors (Futaki et al., 1993; Futaki et 
al., 1994; Warner et al., 1999), and although not used clinically, has been studied 
extensively in vivo. NS398 has previously been shown to be highly selective for COX-2 
and to significantly inhibit inflammation-induced PGE2 production in vivo at doses as 
low as l-1.5mg/kg (Masferrer et al., 1994; Paya et al., 1997; Futaki et al., 1997) without 
affecting constitutive PG synthesis in the stomach (Masferrer et al., 1994). At 1 and 
lOmg/kg NS398 has previously been shown not to inhibit COX-1 activity in mouse 
granuloma tissue (Gilroy et al., 1998), and at doses of up to 30mg/kg body weight it has 
been shown not to inhibit COX-1 activity either systemically or in the stomach of mice 
(Wallace et al., 1998). This thesis has used NS398 to investigate the relative 
contribution of COX-1 and COX-2 in PGE2 synthesis following bleomycin-induced 
lung injury and a dose of 3mg/kg administered orally twice daily was used to maximise 
inhibitory effect on COX-2, whilst maintaining selectivity by not inhibiting COX-1 
activity.
1.19 COX-2 deficient mice
Transgenic mice have proved useful tools in identifying the role of specific mediators in 
disease and therefore COX-2 deficient (COX-27  ) mice appear to be an ideal model to 
investigate the effect of COX-2 deficiency on the development of experimentally 
induced pulmonary fibrosis. To date, COX-27' mice have provided valuable information 
concerning some of the functions of COX-2 both in physiological processes and
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disease. Two strains of COX-2 deficient mice have been generated; Morham and 
colleagues disrupted exon 8  (termed COX-2ex8/ex8) of the COX-2 gene whilst Dinchuk et 
al disrupted exon 1 (termed COX-2exl/exl, Morham et al, 1995; Dinchuk et al, 1995). 
Phenotypic characteristics of COX-27' mice are summarised in Table 1.3.
Organ/process Effect of COX-27' phenotype References
Viability Not lethal in utero 
Reduced neonatal viability
Dinchuk et al., 1995; 
Morham etal., 1995
Fertility Reduced fertility and null females infertile.
Effects on ovulation, fertilisation, implantation 
and decidualisation
Dinchuk et al., 1995; 
Morham et al., 1995; 
lAm etal., 1997;
Davis etal., 1999
Prostaglandin synthesis Normal constitutive synthesis 
Decreased inducible synthesis
Dinchuk et al., 1995; 
Morham etal., 1995; 
Morteau et al., 2000; Bonner 
et al., 2002
GI tract No spontaneous gastric ulceration or 
inflammation
Increased DSS-induced colitis
Dinchuk e ta l ,  1995; 
Morham etal., 1995; 
Morteau et al., 2000
Kidney Renal dysplasia, impaired postnatal renal 
development
Dinchuk et al., 1995; 
Morham etal., 1995
Lung Increased allergic responses and inflammation to 
ovalbumin sensitisation and challenge 
No difference in LPS-induced inflammation 
Enhanced inflammatory and fibrotic response to
v 2o 5
Decreased severity of cerulein-induced 
pancreatitis-associated lung injury
Gavett etal., 1999;
Zeldin et al., 2001
Bonner et al., 2002
Song et al., 2002; 
Etheridge et al., 2002;
Carcinogenesis Decreased tumour development Oshima etal., 1996; 
Chulada et al., 2000; 
Zhang et al., 2000; 
Tiano et al, 2002
Pancreas Decreased severity of cerulein-induced 
pancreatitis
Song et a l, 2002; Etheridge 
etal., 2002
Heart Cardiac fibrosis
Increased cardiac ischemia/reperfusion injury
Dinchuk at al., 1995; 
Camittaetal., 2001
Peritoneum Peritonitis and multiple adhesions Dinchuk et a l, 1995
Bone
Brain
Normal skeletal development 
Decreased bone resorption 
Decreased fracture healing 
Decreased autoimmune arthritis 
Decreased febrile response 
Decreased ischemic brain injury
Okada et al., 2000; 
Zhang et al., 2001; 
Zhang et al., 2002; 
Myers et al.,,2000
Li et a l, 1999;
Li et a l, 2001; 
Iadecola et al., 2001
Table 1.3 Phenotypic characteristics of COX-2'7' mice. Modified from Loftin et al., 2002
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Female COX-2 homozygote mice are infertile and both sexes show reduced viability. 
This increased mortality has been shown to be due to chronic renal failure secondary to 
renal developmental abnormalities, including fibrosis. Fibrotic abnormalities of the 
heart and ovaries have also been described and an increased incidence of peritoneal 
adhesions (Dinchuk et al., 1995; Morham etal., 1995).
These mice have been used to investigate the role of COX-2 pathological conditions, 
including cancer, where COX-2 deficiency has been shown to protect against 
tumourgenesis (Chulada et al., 2000; Zhang et al., 2000 Oshima et al., 1996; Tiano et 
al, 2002). Neither Morham or Dinchuk described alterations in inflammatory responses 
to either tetradecanoyl phorbol acetate (TPA) or arachidonic acid (Dinchuk et al, 1995; 
Morham et al., 1995; reviewed by Langenbach et al., 1999). However COX-2 deficient 
mice do show an enhanced colonic inflammation following DSS-induced colitis 
(Morteau et al.,2000). In the lung, it has been shown that COX-2 deficient mice show 
an enhanced allergic response following ovalbumin challenge with enhanced pulmonary 
eosinophilia and lymphocytosis (Gavett et al., 1999) although following administration 
of LPS there is no enhanced inflammatory response. Recently Bonner and colleagues 
described an enhanced inflammatory response to the transition metal V2O5 . This was 
accompanied by an increase in lavage TNF-a levels and an increase in lung collagen 
production suggesting that COX-2 may be protective in fibrotic disease (Bonner et al.,
2002). This agrees with previous histological data from our laboratory showing that 
COX-2 deficient mice exhibit an enhanced fibroproliferative response to bleomycin 
(Keerthisingam et al., 2001). Despite our preliminary work, and that of Bonner, the 
response of COX-2 7' mice to fibrotic stimuli such as bleomycin remains to be fully 
evaluated and the data presented in this thesis provides additional insight into the role of 
COX-2 in both the inflammatory and fibrotic processes.
1.20 Summary and aims of study
Pulmonary fibrosis is a chronic and progressive process leading to severe respiratory 
insufficiency and ultimately death of those affected individuals. Prognosis is poor and 
current treatment is inadequate. The pathogenesis of pulmonary fibrosis is incompletely 
understood, but from what is known it is clear that two processes appear to be central in 
its development and progression; namely the inflammatory response to injury, followed 
by the deposition of extracellular matrix proteins, particularly collagens in the lung.
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Many of the cellular and molecular pathways involved in mediating these two processes 
are tightly regulated by soluble mediators such as cytokines, growth factors and lipid- 
mediators and it is widely accepted that the dysregulation of these mediators is an 
important underlying molecular mechanism in the pathogenesis of pulmonary fibrosis.
Once such mediator is prostaglandin E2 (PGE2) which is a potent inhibitor of fibroblast 
proliferation, collagen production, chemotaxis and myofibroblast differentiation in the 
lung. Despite the increased expressioi^pro-fibrotic mediators such as TGF-p known to 
induce its synthesis, levels of PGE2 in both BALF and lung fibroblasts from patients 
with pulmonary fibrosis have been shown to be reduced compared with controls. In 
vitro, this failure to upregulate PGE2 biosynthesis has been associated with a decreased 
capacity to upregulate the inducible isOform of the key enzyme in its biosynthesis, 
cyclooxygenase-2 (COX-2). This results in a more fibrotic phenotype in these cells, 
characterised by a loss in the anti-proliferative response to TGF-P and increased 
procollagen production. Preliminary results have also shown that COX-27' mice show 
an enhanced fibroproliferative response to bleomycin-induced lung injury compared 
with WT animals.
Despite large amounts of indirect evidence that limited expression of COX-2 and PGE2 
contributes to the pathogenesis of pulmonary fibrosis there is no direct proof. Therefore 
this thesis will address the hypothesis that;
A failure to upregulate COX-2 and therefore PGE2 biosynthesis will potentiate 
bleomycin-induced pulmonary fibrosis.
The specific aims of this thesis are:
• To investigate the production of COX-1, COX-2 and PGE2 in the lungs of wild 
type mice following bleomycin-induced injury. The specific COX isoform(s) 
upregulated following bleomycin injury is(are) not known. This will be examined 
using western analysis. The in vivo pharmacological inhibition of COX-2 using 
NS398 will be used to investigate the production of PGE2 in the lungs of wild type 
mice.
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• To investigate the fibrotic and inflammatory responses to bleomycin-induced 
lung injury in wild type mice following pharmacological inhibition of COX-2.
NS398 will be orally administered and the fibrotic response will be evaluated 
histologically, and biochemically by measuring total lung collagen production. The 
inflammatory response will be evaluated by counting total cell number in 
bronchoalveolar lavage fluid and differential cell counts.
• To investigate PGE2 production following bleomycin-induced lung injury in the 
absence of COX-2 using COX-2 deficient (COX-2'7' and COX-2+/') mice . The
response of these animals will be compared to those of wild type control mice.
• To investigate the fibrotic and inflammatory responses to bleomycin-induced 
lung injury in COX-2 deficient mice. The response of these animals will be 
compared to those of wild type control mice.
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CHAPTER TWO:
MATERIALS AND METHODS
1
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Section 1 In vivo inhibition of COX-2 function
possiktte
^protective role for COX- 2  and PGE2 in the 
bleomycin model of lung injury. This will be done by inhibiting COX-2 function in vivo 
in two ways; firstly, pharmacologically using the highly selective COX-2 inhibitor N-[- 
2-cyclohexyloxy]-4-nitrophenyl methanesulphonamide (NS398), and secondly, 
genetically, using COX-2 gene deficient mice (COX-2"7', COX-2+/). Sections 2.1 and
2.2 describe animals used in this study, including COX-2 deficient mice, and section
2.3 describes the pharmacological inhibition of COX-2 function.
2.1 Animals
COX-2 deficient (COX-2'7') and strain matched C57BL6/SV129 wild type (COX-2+/+ 
Jackson Laboratory, Maine, USA) mice (stock numbers 101045 and 002476) were bred 
at University College London (UCL). F3 generation mice were mated and F4 generation 
mice were used as experimental subjects. Due to the infertility of female COX-27' mice 
(Dinchuk et al., 1995; Morham et al., 1995), COX-2 heterozygous (COX-2+/*) females 
were bred with both COX-2'7' and COX-2+/' males to maximise the breeding colony. 
Litters were weaned at four weeks of age and subsequently genotyped using genomic 
DNA. The animals were housed at UCL Central Biological Services facility on a 12 
hour light/12 hour dark cycle at 25°C. Food and water were available ad libitum.
2.1.1 Wild type mice
The breeding strategy also produced COX-2+7+ littermate animals. The two strains of 
wild type mice each represent valid controls and have both been used in previously 
published work with COX-2 deficient mice (Keerthisingham et al., 2001; Zeldin et al., 
2001). The majority of the work discussed in this thesis used wildtype littermate 
animals (coded B196), however the study using the COX-2 pharmacological inhibitor 
NS398 used only strain-mated control animals (coded B197). The strain of wild type 
mice used in particular experiments will be indicated on each figure.
2.2 Genotyping COX-2 deficient mice
COX-2'7' and COX-2+7' mice show no phenotypic differences in their appearances 
compared with each other, or littermate wild type animals and therefore each individual 
animal must be genotyped. This was done using polymerase chain reaction (PCR)
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The aim of this thesis is to
amplification of genomic DNA isolated from the tail, which involves amplifying a 
region of the COX-2 gene altered in transgenic mice. This method was previously 
established in our laboratory (Keerthisingam, 2000).
2.2.1 Extraction of genomic DNA
Ear punches were used to identify individual mice. Approximately 0.5cm of the tip of 
the mouse tail was removed using clean scissors and placed in a centrifuge tube together 
with a drop of blood from the cut surface of the tail. This was immediately snap frozen 
in liquid nitrogen and silver nitrate was applied to the tail wound to stop further 
bleeding. Frozen tail samples were thawed on a glass microscope slide kept on ice. The 
tissue was cut into approximately 1 mm pieces using a clean scalpel and then sheared 
further. The pieces were transferred into a clean, autoclaved 1.5ml tube and the blood 
washed out of the original tube using 500jxl of lysis buffer (0.1M EDTA, 0.9% w/v 
NaCl, 0.05M Tris, 1% w/v SDS) and transferred into the clean tube. After each sample 
the forceps and scalpel were washed with 70% ethanol to avoid contamination between 
samples. Proteinase K (BDH/Merck) was added to give a final concentration of l|ig/ml 
and the lid of the tube was wrapped in parafilm and inverted several times. Two tubes 
were placed in a 50ml centrifuge tube containing 25ml H2O and placed in a shaking 
waterbath overnight at 37°C.
Following digestion the tubes were centrifuged (12000 x g, 5 min, RT) to pellet the 
remaining tissue. The supernatant was transferred to a clean, autoclaved 1.5ml 
centrifuge tube and the tissue pellet washed with 500|il lysis buffer, inverted several 
times and recentrifuged. The supernatant from this step was then added to the original 
supernatant. An equal volume of isopropanol was added and the tube inverted several 
times until a white precipitate of DNA was seen. The precipitate was pelleted by 
centrifugation (12000 x g, 5 mins, RT) and the supernatant decanted and discarded. 
Finally the pellet was washed with 1ml 70% (v/v) ethanol and inverted several times 
before being recentrifuged. The ethanol was decanted and the DNA pellet air dried 
before being dissolved in 1 0 0 (il double-deionised water (ddH2 0 ) overnight at room 
temperature.
2.2.2 DNA concentration
A 5jil aliquot of genomic DNA was diluted with 995)0.1 distilled water in a 1.5ml 
centrifuge tube giving a dilution factor of 200. The purity and concentration of the DNA
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was determined by spectrophotometry measuring the optical density (OD) at both 260 
and 280nm. The purity was assessed by the OD26o-OD28o ratio, and a ratio of 1.7:1 
indicated relatively pure DNA. DNA was quantified by measuring the OD260 and 
calculated using the formula:
DNA (pg/ml) = OD260 x 50 x dilution factor (200)
The samples of genomic DNA were diluted in ddH20 to give working concentrations of 
lOOjitg/ml. If problems with protein contamination were encountered with the PCR, 
these stocks were further diluted to 10|ig/ml. Both working stocks and genomic DNA 
were stored at 4°C.
2.2.3 PCR protocol
The COX-2 deficient mice were generated by replacing a 1.8Kb fragment of the gene 
containing exon 1 with a 1.6Kb neomycin cassette (Dinchuk et al., 1995). The PCR 
amplifies a 922bp product from the endogenous COX-2 gene and a 1.4Kb product from 
the disrupted allele (Figure 2.1). This protocol was adapted from conditions suggested 
by the Jackson Laboratory and further modified within our laboratory (Keerthisingham, 
2000).
Three primers (Gibco Life Sciences) were used to amplify the specific region; a 
common downstream primer (547), a specific upstream primer for the wild type allele 
(546) and a specific primer for COX-2 deficient alleles (013). The nucleotide sequences 
are shown in Table 2.1 below:
Primer Nucleotide sequence
546 5-ATC TCA GCA CTG CAT CCT GC-3’
547 5-CAC CAT AGA ATC CAG TCC GG-3’
013 5 -CTT GGG TGG AGA GGC TAT TC-3’
Table 2.1 Prim er nucleotide sequences used in PCR to genotype COX-2'7' mice 
2.2.4 PCR Conditions
Each well of the PCR microtitre plate (Hybaid, Middlesex, UK) contained 200ng DNA 
(2pl of a 100ng/|xl solution) and 3jll1 distilled water overlayed with a drop of mineral oil.
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1 .8 k b
546 0.922kb
547
3’
Exon 1
wildtype allele
013
neomycin cassette
3’ disrupted allele
Figure 2.1 Disruption of exon 1 of the COX-2 gene in COX-2'7' mice 
A 1.8Kb fragment of the gene containing exon 1 was replaced in the 
transgenic mice with a 1.6Kb neomycin cassette. The PCR primers 546 
and 547 amplifies a 922bp product from the endogenous COX-2 gene 
and primers 013 and 547 amplified a 1.4Kb product from the disrupted 
allele.
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Controls were used in each PCR using mouse DNA from confirmed genotypes and 5|il 
distilled water as a negative control. Sufficient reaction mixture to give a 10pl reaction 
volume (final concentrations 50mM KCL, lOmM dNTPs, 1.5mM MgCh, 0.2pM primer 
546, 0.2pM primer 547 , 0.04pM primer 013) was prepared in a 1.5ml centrifuge tube. 
Taq DNA polymerase (5U/pl, Amersham Biosciences, Amersham, UK) was then added 
to the reaction mixture to give a final concentration of 2U/pl. After mixing, 5|il reaction 
mixture was added to each well under the mineral oil. The plate was then pulse 
centrifuged for 30secs (300 x g) to remove air bubbles and ensure total mixing of the 
components before being placed in a pre-programmed thermocycler (Peitler 
Thermocycler, MJ Research). The PCR conditions used were one cycle of initial 
denaturing (94°C, 3 mins), followed by 34 cycles of denaturing, annealing and 
extension (94°C, 1 min; 62°C, 2 mins; 72°C, 2 mins), with one cycle of final extension 
(72°C, 5 mins).
After the reaction was complete the products were separated by electrophoresis. A 2% 
(w/v) agarose (Ameresco, Ohio, USA) gel was prepared dissolved in lx TBE buffer 
(0.09M Tris-borate, 0.002M EDTA, pH8 ). The gel solution was heated in a microwave 
for approximately 2  minutes at full power and then cooled under running water. 
Ethidium bromide was added to the gel at a final concentration of 0.5pg/ml. The gel 
was poured into a cast, 20 well combs placed in position and allowed to solidify at RT. 
Once solidified, the gel was transferred to the gel tank filled with lx TBE running 
buffer and the combs removed. 5pl of 5x loading buffer was added to each well of the 
microtitre plate and lOpl of each product was run per well. A DNA molecular weight 
marker (Marker VIII, 0.25|ig/ml, Boehringer Mannheim,) was run on each gel and the 
gel run for 25 minutes at 150 volts. The DNA bands were visualised using a 
phosphorimager (Fuji, FLA-3000) and the animal genotype determined by the band 
pattern. Figure 2.2 shows an example of a PCR gel.
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1.44kb
0.922kb
1.114kb 
0.9kb 
0.62kb 
0.501/ 
0.489kb
Molecular weight marker 
Negative control
C COX-2'7' control
D COX-2+/'control
E COX-2+/+ animal
Figure 2.2 Representative PCR gel
2.3 Pharmacological inhibition of COX-2
The highly selective COX-2 inhibitor NS398 (Cayman Chemicals/Alexis Corporation, 
Nottingham, UK) was dissolved in dimethyl sulfoxide (DMSO, Sigma, UK) at 25mg/ml 
and stored as aliquots, at -40°C. Immediately prior to administration NS398 was thawed 
to room temperature, diluted in 1% Tween80 (Sigma, UK) phosphate buffered saline 
(PBS) to a concentration of 750|ig/ml and administered to mice within one hour of 
preparation. Each animal received 3|ig NS398/kg body weight in a final volume of 
30p,l, a dose known to selectively inhibit COX-2 without affecting COX-1 activity (see 
sections 1.18, 4.3.1). The inhibitor was administered by oral gavage every twelve hours 
as previously described (Gilroy et al., 1998). Control animals received 30pl of vehicle 
alone. The first dose of NS398 was administered one hour prior to intratracheal 
instillation of bleomycin. To determine the effectiveness of NS398, PGE2 was measured 
in bronchoalveolar lavage fluid (BALF) from both treated and control animals as 
described in sections 2.5 and 2.7.
Section 2 The bleomycin model of lung fibrosis
Animal models of pulmonary fibrosis have been useful tools for studying the 
pathogenesis of lung fibrosis. Bleomycin is an anti-neoplastic agent isolated from a 
strain of Streptomyces verticillus which exhibits dose-dependent pulmonary toxicity 
leading to progressive pulmonary fibrosis in 3-40% of patients treated with the drug. 
However, the toxic effects have been utilised advantageously in animal models where 
bleomycin-induced lung injury resembles biochemical and functional changes
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associated with human pulmonary fibrosis with the exception that it is non-progressive 
(Schrier et al., 1983; Clark et al., 1983; Thrall and Barton, 1984; Aso et al., 1976; 
Borzoneetal., 2001).
Bleomycin has been administered intravenously, intramuscularly, intraperitoneally, and 
intratracheally (IT) and all lead to an acute inflammatory response in the first 7 days 
which precedes matrix deposition and fibrosis characterised by an increase in lung 
collagen content 14-21 days following instillation of bleomycin. The inflammatory 
response to bleomycin instillation varies dependent on route of administration and dose, 
and the intensity of inflammation has been directly correlated with the intensity of 
fibrosis in a rabbit model (Shen et al., 1988). IT instillation has the advantages of using 
less bleomycin than other methods, has a quicker kinetic development of lung injury 
and a clear time of initiation of injury. But the distribution of fibrosis is patchy with 
more peribronchial damage compared with administration via other routes.
Bleomycin induces lung injury by generating reactive oxygen radicals under aerobic 
conditions on binding to intracellular DNA and iron which in turn leads to DNA 
damage (Sugiura and Kikuchi 1978; Thrall and Scalise, 1995). This can then reduce 
molecular oxygen leading to generation of various types of reactive oxygen species that 
can cause marked DNA strand scission (Moseley, 1989).
2.4 Administration of bleomycin
Both male and female mice aged 6-10 weeks of age were used in all experiments. 
Animals were anaesthetised in a chamber using halothane gas (3%) in 2L/min O2 . On a 
heated mat (37°C), the necks were shaved and dampened with ethanol. A 1cm incision 
was made over the trachea and the tissue blunt dissected to reveal the trachea which was 
then cannulated. Animals were instilled with bleomycin sulphate (l-3mg/kg body 
weight; Kyowa Hakko, Slough, UK) dissolved in 50pi 0.9% saline or 0.9% saline alone 
as a control. The bleomycin was injected directly into the anterior trachea using a 1ml 
syringe with a 23 gauge needle. Three stitches were used to close the wound and the 
animal allowed to regain consciousness. At least 6  animals per group were analysed for 
biochemical and cytological assessment and at least 3 for histological assessment.
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2.5 Bronchoalveolar lavage and collection of lung tissue
Each animal was terminally anaesthetised using an intraperitoneal injection of 
pentobarbitone sodium (200mg/ml; Sanofi Animal Health, Watford, UK) 3, 7,14, 28 or 
84 days following bleomycin instillation. Following laparotomy and exanguination by 
severing the ii^erior vena cava the trachea was cannulated with a 2 2  gauge venflon 
(Ohmeda BOC, Sweden). The lungs were lavaged with a total of 5ml PBS in ten 0 .5 ml.<xh<j,ut£s 
This maximised the total number of cells retrieved whilst avoiding over-inflation of the 
lung. Each aliquot was instilled slowly over 15 seconds, left in situ for 30 seconds and 
then removed over a further 15 seconds. The bronchoalveolar lavage fluid (BALF) was 
kept on ice throughout the procedure and over 90% of the instilled volume was 
consistently recovered. After lavage the trachea was cut and the lungs were 
subsequently removed, blotted dry on tissue and snap frozen in liquid nitrogen prior to 
analysis of lung hydroxyproline. The lavage samples were centrifuged (300 x g) at 4°C 
for 5 minutes to pellet the cells and the fluid removed and stored as 1ml aliquots at -  
80°C prior to analysis of PGE2 .
2.6 Cytological analysis of bronchoalveolar lavage
Following the removal of the BALF, the cell pellet was resuspended in 500pl 
Dulbecco’s Modified Eagles Medium (DMEM, Gibco-BRL, Paisley, UK) containing 
10% foetal bovine serum (FBS, Imperial Laboratories, Andover, UK) to a single-cell 
suspension. Total lavage cell numbers were determined using a haemocytometer on an 
inverted light microscope (Axioscope 20, Carl Zeiss, Germany). Cell preparations were 
generated from lOOpl of single-cell suspension containing between 0.5-1.0 x 106 
cells/ml and were spun in a cytometer (Cytospin 3, Shandon, UK) at lOOOrpm for 3 
minutes. The slides were left overnight to dry and then fixed in methanol and stained. 
Differential cell numbers were assessed by counting DiffQuik (DADE AG, 
Switzerland) stained cytospin preparations. At least 500 cells per sample were 
differentiated, using conventional morphological criteria for macrophages/monocytes, 
lymphocytes, and polymorphonuclear leukocytes (PMNs). Total cell numbers were 
expressed xlO ' 3 and differential cell counts as either total number of
<3
macrophage/monocyte, lymphocytes or PMNs xlO' , or as a percentage of the total cell 
number.
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2.7 Measurement of prostaglandin E2 (PGE2)
PGE2 was measured in BALF, lung tissue and cell-conditioned medium using a specific 
enzyme immunoassay (Amersham Biosciences, Amersham, UK). The assay is based on 
competition between unlabelled PGE2 and a fixed quantity of specific antibody. Once 
bound, the antibody complex is immobilized on pre-coated microtitre wells and the 
amount of labelled PGE2 determined by adding a horseradish peroxidase enzyme 
substrate. The concentration of PGE2 in unknown samples of both BALF and cell- 
conditioned media was determined by interpolation from a standard curve.
2.7.1 Assay protocol
The protocol used permitted the detection of PGE2 in the range of 40 to 640pg/ml. 
Samples containing higher concentrations of PGE2 were diluted accordingly in PBS 
(BALF) or serum-free DMEM (cell-conditioned media and lung tissue). The coated 96 
well microtitre plate and reagents were thawed and equilibrated to room temperature 
before use. Assay buffer (0.1M phosphate buffer) was prepared by diluting 1M 
phosphate buffer in H20 . This buffer was then used to reconstitute the lyophilized PGE2 
antibody and conjugate. The conjugate was stored on ice for the duration of the assay 
while the antibody remained at room temperature. Wash buffer (0.01 M phosphate 
buffer) was prepared by diluting 0.4M phosphate buffer in ddH20 . A standard curve for 
PGE2 was prepared by diluting a stock solution of PGE2 in assay buffer with 
concentrations ranging from 1 to 32 pg/well.
All blanks and standards were run in duplicate. To determine non-specific binding 
(NSB) of the conjugate, lOOp.1 assay buffer was added to the first two wells, followed 
by 50(0.1 assay buffer into the zero standard wells. After vortexing, 50|il of each standard 
was pipetted into the appropriate well, starting with the most dilute. 50|il of the neat and . 
diluted unknown samples were aliquoted into the remaining wells. Finally 50|l l 1 of PGE2 
antibody was added to all wells except the blanks and NSB wells and the plates covered 
and incubated on ice at 4°C for 3h. At the end of the incubation period, 50|il of 
conjugate was added to all wells except the blank. The plate remained on ice and was 
incubated for a further lh. At the end of the incubation period, the contents of the plate 
were flicked out and the wells were filled with wash buffer using a wash bottle. This 
was repeated a further 3 times. After the plate was dried on blotting paper to remove 
residual buffer, 150(xl of enzyme substrate, 3,3’,5,5’-tetramethylbenzidine (TMB) was
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added to each well and the colour reaction allowed to proceed at RT on a plate shaker 
for 30min. The reaction was terminated with the addition of lOOpi 1M H2SO4 and the 
optical density (OD) immediately measured at 450nm, using a microtitre plate 
spectrophotometer (Titertek Multiscan).
2.7.2 Calculations
The average OD for each set of replicate wells was calculated. The NSB value was 
subtracted from the standards and unknown samples and the percentage bound substrate 
(% B /B o) determined using the following formula: v
% B /B o = (standard or sample OD -  N S B  OD) xlOO 
(zero standard OD -  N S B  OD)
The standard curve was generated by plotting % B/Bo (y axis) as a function of the log 
PGE2 concentration (x axis). A representative standard curve is shown in Figure 2.3. 
The concentration of PGE2 in 50|il of unknown samples was read directly from the 
linear region of the sigmoid curve. Results were expressed as pg PGE2 per ml BALF, or 
pg per 1 0 5 cells for in vitro experiments.
2.8 M easurement of 15-epi-Lipoxin A4 (15-epi-LXA4)
Similarly to PGE2, 15-epi-LXA4 was measured in BALF using a specific enzyme 
immunoassay (Neogen Corporation, supplied by Quidel, UK). The assay operates on a 
similar basis of competition between the enzyme conjugate and 15-epi-LXA4 in the 
sample for a limited number of binding sites. The bound enzyme conjugate is detected 
by the addition of a coloured substrate and the extent of colour development is inversely 
proportional to the amount of 15-epi-LXA4 in the sample, which is determined by 
interpolation from a standard curve. However, unlike PGE2, 15-epi-LXA4 can not be 
directly assayed in BALF and requires purification using solid-phase extraction prior to 
the assay.
2.8.1 Sample preparation
A 500|il aliquot of BALF was acidified to pH 3.5 with the addition of approximately 
20pl IN HC1. Ci8 Sep-Pak light cartridges (Waters Corporation) were used for 
extraction and preconditioned by washing with 2ml ethanol followed by 2ml ddH20.
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Figure 2.3 Representative prostaglandin E 2 standard curve
A stock solution of PGE2 was serially diluted to known 
concentrations ranging from l-32pg/well. A standard curve was 
generated by plotting %B/B0 as a function of the log PGE2 
concentration. Replicate data points are shown at each 
concentration. The concentration of PGE2 in unknown samples 
was determined by interpolation from the linear region of the 
curve.
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The acidified sample was applied to the column at a rate of 1ml per minute. Following 
this the column was washed with 1 ml of ddH2 0  followed by 1 ml of petroleum ether. 
The 15-epi-LXA4 was eluted with 2ml of methyl formate and the methyl formate was 
evaporated with a stream of nitrogen gas. The residue was dissolved in 250|il of diluted 
extraction buffer provided in the kit (diluted 1:5 in ddtbO) and assayed for 15-epi-LXA4 
content.
2.8.2 Assay procedure
The protocol permits the detection of 15-epi-LXA4 in the range of 0.02-2ng/ml. 
Samples containing higher concentrations of 15-epi-LXA4 were diluted accordingly in 
extraction buffer. Two vials of lyophilized horseradish peroxidase conjugate were 
provided and were each reconstituted using 75|il of ddf^O. This was further diluted 
1:50 using EIA buffer. If the contents of both vials of conjugate were required, the 
concentrated conjugates were pooled before dilution to the working concentration. 
Wash buffer provided was diluted 10-fold with ddH2 0 . A 96 well microtitre plate was 
provided pre-coated with anti-15-epi-LXA4 rabbit antibody. A standard curve for 15- 
epi-LXA4  was prepared by diluting a stock solution of 15-epi-LXA4 in EIA buffer with 
concentrations ranging from 0.02 to 2 ng/ml. Blanks and standards were run in 
duplicate. 50pl of EIA buffer was added to the zero standard wells and after vortexing, 
50|ll1 of each standard was pipetted into the appropriate wells, starting with the most 
dilute. 50|il of the diluted unknown samples were aliquoted into the remaining wells. 
Finally 50pl of dilute enzyme conjugate was added to each well except the blank, the 
plate was mixed on a microplate shaker and then covered and incubated at room 
temperature for one hour. At the end of the incubation period, the contents of the plate 
were flicked out and the wells were filled with wash buffer from a wash bottle. This was 
repeated a further two times as instructed. After the plate was dried on blotting paper to 
remove residual buffer, 150}il of enzyme substrate, stabilized 3,3’, 5,5’
Tetramethylbenzidine (TMB) plus hydrogen peroxide, was added to each well and the 
colour reaction allowed to proceed at RT on a plate shaker for 30mins. The plate was 
either read in a microtitre plate spectrophotometer (Titertek Multiscan) at 650nm or the 
reaction was stopped with 50|iil of Neogen’s Red Stop Solution and then read at 650nm.
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2.8.3 Calculations
After the substrate background was subtracted from all absorbance values, the average 
OD for each set of replicate wells was calculated. The zero standard became the Bo 
value and the percentage bound substrate (% B /B o) was determined using the following 
formula:
% B/Bo = (standard or sample OD / Bo) x 100
The standard curve was generated by plotting % B /B 0 (y axis) as a function of the log 
15-epi-LXA4 concentration (x axis). A representative standard curve is shown in Figure 
2.4. The concentration of 15-epi-LXA4 in unknown samples was read directly from the 
linear region of the sigmoid curve. Results were expressed as ng 15-epi-LXA4 per ml 
BALF.
2.9 Measurement of Leukotriene C4 (LTC4)
LTC4 was measured in BALF using a specific enzyme immunoassay (Cayman 
Chemical Company, supplied by Alexis Corporation, UK) and required solid-phase 
extraction prior to assay. Ci8 Sep-Pak light cartridges were used following a similar 
method to that described in section 2 .8 , substituting methanol for ethanol to increase 
solubility of LTC4 . Following evaporation of methyl formate, the residue was dissolved 
in 350j l l 1 of serum-free DMEM.
Again, the assay operates on the basis of competition between unlabelled LTC4 and an 
LTC4-acetylcholinesterase conjugate (LTC4 tracer) for a limited amount of LTC4 
antiserum. The amount of LTC4 tracer is determined by adding Ellman’s Reagent, 
which contains acetylthiocholine and 5,5’-dithio-&/s-(2-nitrobenzoic acid), the 
substrates for acetylcholinesterase. The concentration of LTC4 in unknown samples was 
determined by interpolation from a standard curve. The protocol permitted the detection 
of LTC4 in the range 7.8-1000pg/ml. EIA buffer was prepared by diluting the 
concentrate provided 1:10 using ddfUO. This buffer was then used to reconstitute the 
lyophilized LTCVacetylcholinesterase tracer and LTC4 antiserum. Wash buffer was 
prepared by diluting the concentrate provided (5ml) to a total volume of 2L with ddH20 
with the addition of 1ml of Tween 20 provided.
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Figure 2.4 Representative 15-epi-lipoxin A4 standard curve
A stock solution of 15-epi-LXA4 was serially diluted to known 
concentrations ranging from 0.02-2ng/ml. A standard curve was 
generated by plotting %B/B0 as a function of the log 15-epi-LXA4 
concentration. Replicate data points are shown at each 
concentration. The concentration of 15-epi-LXA4 in unknown 
samples was determined by interpolation from the linear region of 
the curve.
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A standard curve for LTC4 was prepared by diluting the LTC4 standard using ddH20 to 
give a stock solution of lOng/ml. A standard curve for LTC4 was prepared by further 
diluting the stock solution in EIA buffer to give concentrations ranging from 7.8- 
lOOOpg/ml. All blanks and standards were run in duplicate. To determine non-specific 
binding (NSB) of the tracer, lOOpl assay buffer was added to the first two wells, 
followed by 50|il EIA buffer into Maximum Binding (Bo) wells. After vortexing, 50pl 
of each standard was pipetted into the appropriate well, starting with the most dilute. 
50j l l 1 of the unknown samples were aliquoted into the remaining wells and 50p<l of LTC4 
tracer was added to each well except the NSB and the blank wells. The plate was 
covered and incubated for 18h at room temperature. To develop the plate a vial of 
Ellman’s reagent provided was reconstituted with 20ml of ddt^C). This is light sensitive 
and was wrapped in aluminum foil. The contents of the plate were flicked out and the 
wells were filled with wash buffer using a wash bottle. This was repeated a further 4 
times. After the plate was dried on blotting paper to remove residual buffer, 200|xl of 
Ellman’s Reagent was added to each well. The plate was covered in aluminum foil and 
the colour reaction allowed to proceed at RT on a plate shaker for 60-90 minutes. The 
plate was read at 405nm using a microtitre plate spectrophotometer.
2.9.1 Calculations
The average OD for each set of replicate wells was calculated. The NSB value was 
subtracted from the standards and unknown samples and the percentage bound substrate 
(% B /B o) determined using the following formula:
% B/Bo = (standard or sample O D  -  N S B  O D ) xlOO
( B o O D - N S B  O D )
The standard curve was generated by plotting % B/Bo (y axis) as a function of the log 
LTC4 concentration (x axis). A representative standard curve is shown in Figure 2.5. 
The concentration of LTC4 in unknown samples was read directly from the linear region 
of the sigmoid curve. Results were expressed as pg LTC4 per ml B  ALF.
2.10 Histological assessment of lung fibrosis
Animals were terminally anaesthetized 28 days following bleomycin instillation as 
described (section 2.5). Following laparotomy and exanguination by severing the
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Figure 2.5 Representative leukotriene C4 standard curve
A stock solution of LTC4  was serially diluted to known 
concentrations ranging from 7.8-100pg/ml. A standard curve was 
generated by plotting %B/B0 as a function of the log LTC4 
concentration. Replicate data points are shown at each 
concentration. The concentration of LTC4 in unknown samples was 
determined by interpolation from the linear region of the curve.
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inferior vena cav , the pulmonary vasculature was perfused using approximately 2 ml 
heparinised PBS by direct injection into the right atrium using a butterfly cannula until 
the lungs turned white. This was followed by 2ml of ice cold 4% paraformaldehyde to 
fix the lungs. The then cannulated using a 22 gauge venflon (Ohmeda BOC,
Sweden) and inflated and fixed by intratracheal instillation of ice cold 4% 
paraformaldehyde fixative in PBS at a pressure of 20cm H2O for 5 mins. The trachea 
was ligated and the heart and lungs removed en bloc and stored in 4% 
paraformaldehyde overnight at 4°C.
Tissue processing and slide staining was performed by Mr. Steve Bottoms.
The lungs were processed to paraffin wax and 3(xm sections were cut and stained with a 
specific stain for matrix proteins, modified Martius Scarlet Blue. This is a trichrome 
stain in which there is serial application of Orange G, Red mix (Ponceau de Xylidine 
and acid fuchsin) and Chicago sky blue dyes in order to differentiate tissues. Staining 
was performed in an automated Stainer (Sakura DRS-601, Bayer pic, Newbury, UK). 
Sections were firstly dewaxed and rehydrated through a series of solutions containing 
decreasing concentrations of alcohol. They were then treated with Lugol’s Iodine to 
improve the differentiation of subsequent staining. Iodine was removed using sodium 
thiosulphate and sections were immersed in Celestine Blue to improve retention of 
haematoxylin. Sections were then treated with the first two trichromes, Orange G 
followed by Red Mix. Phosphotungstic acid was used to stabilise red staining before the 
third trichrome was applied, Chicago Blue. This was differentiated with acetic acid 
before the sections were dehydrated, cleared in xylene and coverslips were applied 
using an automated machine (Sakura Coveraid, Bayer pic, Newbury, UK). The full 
staining protocol is given in Table 2.2:
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Step Time Treatment Notes
1 3 min Xylene
2 3 min Xylene
3 2 min 100% alcohol
4 2 min 90% alcohol
5 2 min 70% alcohol
6 5 min Lugol’s reagent
7 3 min Sodium thiosulphate 3% in distilled water
8 1 min Tap water
9 10 min Celestine Blue
10 1 min Tap water
11 30 sec Distilled water
12 5 min Haematoxylin
13 3 sec Tap water
14 20 sec Acid alcohol
15 2.5 min Tap water
16 30 sec 90% alcohol
17 8 min Orange G 0.2% in Picric alcohol
18 5 min Distilled water
19 7 min Red mix 0.5% Ponceaux de Xylidine and 0.5% 
Acid Fuchsin in 1% Glacial acetic acid
20 20 sec Distilled water
21 30 sec Phosphotungstic acid
22 20 sec Distilled water
23 5 min Chicago sky blue
24 20 sec 1 % acetic acid
25 20 sec 70% alcohol
26 20 sec 90% alcohol
27 20 sec 100% alcohol
28 4 min Xylene
Table 2.2 Modified Martius Scarlet Blue staining protocol
2.11 Measurement of hydroxyproline by reverse phase high pressure liquid 
chromatography (HPLC)
Hydroxyproline was measured as an index of total lung collagen, samples were 
processed according to previously published methods from our laboratory (Mutsaers et 
al.f 1998) Hydroxyproline was quantified by reverse-phase HPLC of 7-chloro-4- 
nitrobenzo-oxaol,3-diazole (NBD-Cl)-derivatized lung protein hydrosylates. The 
secondary amino acids hydroxyproline and proline react with NBD-C1 to generate a 
chromophore with maximum light absorbance at 495nm. Total lung collagen was 
calculated assuming that the lung contains 12.2% w/w hydroxyproline (Laurent et al., 
1981).
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2.11.1 Tissue preparation
Lungs were removed 14, 28 or 84 days following instillation of either saline or 
bleomycin and snap frozen in liquid nitrogen as described in section 2.5. Lungs were 
stored at -80°C before being crushed to a fine powder under liquid nitrogen using a 
pestle and mortar. Aliquots of 10-20mg lung powder were accurately weighed and 
hydrolysed for 16 hours in 2mls 6 M HC1 at 110°C. Samples were then decolourised by 
the addition of approximately 20mg of charcoal (BDH, Merck, UK) and filtered 
(0.65pm pore, Millipore, Watford, UK). Samples were stored at room temperature prior 
to chromatography.
2.11.2 Amino acid derivatization
The samples were derivatised following methods previously published from our 
laboratory (Campa et al., 1990). Briefly, the clear filtered hydrolysates were diluted 
1:100 using ddH2 0  and 200pl aliquots transferred to 1.5ml centrifuge tubes, three holes 
pierced in the lid, and evaporated under vacuum using a centrifugal sample concentrator 
(Savant, SpeedVac Plus SCI 10, Life Science International). The dried hydrolysate was 
re-dissolved in lOOp.1 ddfLO, buffered with lOOpl 0.4M potassium tetraborate, pH 9.5 
and mixed with lOOpl of 36mM NBD-C1 in methanol. Whilst minimising exposure to 
light, samples were vortexed and incubated in a water-bath at 37°C for 20 minutes. The 
reaction was stopped by adding 50jil of 1.5M HC1 followed by 150pi of a concentrated 
solution of buffer A (167mM sodium acetate, pH 6.4, in 26% acetonitrile v/v). After 
vortexing and filtering through a HPLC 0.22pm pore size filter (Sartorius), lOOpl 
aliquots were injected into the HPLC column and eluted with an acetonitrile gradient.
2.11.3 Chromatographic conditions
Derivatised samples were separated using a single pump HPLC system (HPLC system 
523, Biotek Instruments, Bucks, UK) with a reverse-phase cartridge column 
(LiChroCART LiChrospher 250mm length x 4mm diameter, 5pm particle size, 100 RP- 
18, BDH/Merck) following previously published methods from our laboratory (Campa 
et al., 1990). Running buffers A (8 % v/v acetonitrile and 50mM sodium acetate, pH 6.4) 
and B (75% v/v acetonitrile) were freshly prepared and degassed (Gastorr 153, Biotek 
Instruments) prior to use. The HPLC system was equilibrated in buffer A for 40 minutes 
and then three derivatized standard solutions containing 50pmol hydroxyproline were 
analysed. Derivatized standards and samples were eluted at lml/min though an
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acetonitrile gradient, generated by changing the relative proportions of buffer A and B
over time as shown below:
Time % Buffer B
0 0
5 5
6 80
1 2 80
12.5 0
25 0
Table 2.3 Elution gradient for separation of hydroxyproline by 
reverse-phase HPLC
The running time per sample was 25 minutes and hydroxyproline produced a peak at 
approximately 5-6 minutes. Figure 2.6 shows a representative chromatograph of a 
standard and a sample of lung tissue.
2.11.4 Quantification o f lung collagen content
Amounts of hydroxyproline (hyp) were quantified by comparing peak areas with those 
generated from a standard solution prepared under identical conditions to produce an 
‘HPLC number’. This number was used to calculate total lung collagen (mg/lung) using 
the following calculation:
HPLC x Volume of HC1 (2000|j.l) x Dilution factor (100) x Dilution factor of sample (5)a 
number Volume of dried hydrolysate (200fil) of hydrolysate injected onto column
= pmol of hyp x 131
1000000000
= mg hyp x lung wt x 8.1967c = mg collagen per lung 
aliquot wt
Note,
a.
b.
c.
Dilution factor is 5 since the redissolved sample is diluted 1:5 by the addition o f 0AM  potassium  
tetroborate, NBD-Cl, HCl and concentrated solution o f buffer A.
131 represents the molecular weight o f hydroxyproline
8.1967 converts mg hyp per lung to mg collagenAung by assuming the lung contains 12.2% w/w hyp, 
where 8.1967 = 100% /12 .2%  (Laurent et a l, 1981)
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Figure 2.6 Representative HPLC chromatographs
Figures 2.6A and 2.6B show a reprentative chromatograph o f a 
hydroxyproline standard of known concentration eluted at 
5.29mins. The area under the hydroxyproline curve shown in Figure 
2.6B is used to calculate the amount o f hydroxyprlone present in an 
unknown sample of lung hydroslyate shown in Figure 2.6C
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2.12 Western Analysis of COX-1, COX-2 and CPLA2 protein expression
COX-1, COX-2 and CPLA2 protein expression was examined using western analysis of 
lung tissue taken 7 and 14 days following instillation of bleomycin.
2.12.1 COX-2 protein expression
Approximately 10-20|ig lung tissue removed either 7 or 14 days following instillation of 
bleomycin or saline was homogenised in 500|il of buffer (50mMTrisHCl, 0.1% 
Tween20) containing protease inhibitors (Complete, Roche, Germany) using a glass 
Ultraturis homogeniser. The homogenate was centrifuged (12000 x g) at 4°C for 30mins 
to pellet tissue fragments and the supernatant analysed. Protein was measured in a 5pl 
aliquot of each sample using a bicinchoninic acid (BCA) colourmetric assay (Pierce, 
UK) to ensure equal quantities were applied to each lane. Working reagent was prepared 
by combining 50 parts reagent A (NaCC>3 , NaHCC>3 BCA detection reagent and 
C6H4 C>6Na2 in 0.2N NaOH) with 1 part reagent B (4% w/v CUSO4 solution). 200|il of 
the working reagent was added to 5pl of either sample or known protein standards, and 
5|il of homogenising diluent and incubated for 30 minutes at 37°C. The absorbance was 
read at 550nm using a microtitre plate spectrophotometer (Titertek Multiscan).
7.5% SDS-PAGE gels were constructed and electrophoresed using the XCell II Sure 
Lock™ Mini Cell system (Novex, San Diego, USA). Each gel contained one lane of 5jil 
molecular weight marker (Rainbow™, Amersham Pharmacia Biotech, UK) and one 
lane of lOOng of purified COX-2 (ovine) electrophoresis standard (Cayman 
Chemicals/Alexis Corporation, Nottingham, UK). Sample lysate containing 25-30|ig 
protein was added to 8 x Laemlli sample buffer and heated at 95°C for 5mins. The 
lysates were pulse centrifuged for 30 seconds at 10000 x g before equal amounts of 
protein (25-30pg) were loaded onto the remaining lanes and the gel run for 2-3 hours at 
150V in SDS-PAGE tank buffer (25mM Tris, 192mM glycine and 0.1% w/v SDS). Two 
gels were run, one gel was used for western analysis and the companion gel stained with 
0.1% v/w Coomassie brilliant blue R-250, 10% v/v methanol and 4% acetic acid for 2 
hours and then destained using a solution of 10% v/v methanol and 7.5% v/v acetic 
acid. The remaining gel was submerged in transfer buffer (SDS-PAGE tank buffer, 10% 
methanol) and proteins electro-transferred onto a nitrocellulose membrane (Hybond- 
ECL, Amersham Pharmacia Biotech, UK) for 2hrs at a constant current of 0.8mA/cm2 
using semi-dry blotting apparatus (BioRad, UK). Following transfer, non-specific
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binding was blocked by incubating the membrane for 1-2 hours in 5% skimmed milk 
(Marvel, UK) in TBST (50mM Tris, 150mM NaCl, 0.02% Tween-20®, pH 7.4) at RT. 
The membrane was incubated overnight at 4°C with a COX-2 polyclonal rabbit anti­
mouse primary antibody (Cayman Chemicals/Alexis Corporation, Nottingham, UK) at a 
1:1000 dilution in 2% skimmed milk TBST. Following 3 x 5  mins washing in TBST, 
the membrane was incubated in a horseradish peroxidase conjugated goat anti-rabbit 
secondary antibody at a dilution of 1:2000 in 2% skimmed milk TBST for 1 hour at 
room temperature. The membrane was washed again for 3 x 15 mins in TBST, and then 
immunoreactive bands visualised using enhanced chemiluminescence (ECL) western 
blotting detection agents (Amersham Pharmacia Biotech, UK). Band intensities were 
calculated by scanning the films (Sharp JX-300 colour scanner) and quantifying band 
densities using Image Master™ software (Amersham Pharmacia Biotech, UK).
2.12.2 COX-1 and CPLA2  protein expression
Dr Caroline Wheeler-Jones at the Royal Veterinary College, London, performed the 
majority of western blots for CPLA2 and COX-1 in lungs removed 14 days following 
instillation of either saline or bleomycin.
Protein was extracted from lung tissue using a technique of repeated freeze-thaws. 
Approximately 20pg of powdered lung tissue was added to 200pl RIPA buffer (1% 
Triton X-100 (w/v), 0.1% SDS (w/v), 158mM NaCl, ImM EDTA, lOmM Tris-HCl, 
ImM NaV0 3 , ImM AEBSF, 50|ig/ml leupeptin, pH 7.2) and immersed in liquid 
nitrogen for several seconds. This was followed by immersion in a 37°C water:bath for 
several seconds. Samples were vortexed every second freeze-thaw cycle. This cycle was 
repeated 5 times per sample. Samples were then centrifuged (5min, 10000 x g, 4°C) and 
the supernatants transferred to clean microcentrifuge tubes. Protein was measured as 
described above and lysate containing 100-150|ig protein was added to 2x Laemlli 
sample buffer and heated at 95°C for 5mins. The lysate was pulse centrifuged for 30 
seconds at 10000 x g before being loaded into lanes of a 10% SDS-PAGE gel. Gels 
were constructed and electrophoresed using the PROTEAN II xi electrophoresis 
equipment (BioRad, Hemel Hemstead, UK). Each gel also contained one lane of a 
molecular weight marker (New England BioLab, USA). Purified COX-1 and CPLA2 
protein standards' were not used, however initial experiments contained thrombin- 
stimulated human umbilical vein endothelial cell (HUVEC) lysates prepared by Dr
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Wheeler-Jones. These samples had previously been validated to produce 
immunoreactive bands consistent with both CPLA2 and COX-1.
Gels were electrophoresed at a constant current of 25mA per gel as samples moved 
through the stacking gel, followed by 15mA per gel overnight for 20 hours in SDS- 
PAGE tank buffer (25mM Tris, 192mM glycine and 0.1% w/v SDS). Following 
electrophoresis, gels were submerged in transfer buffer and proteins electro-transferred 
onto PVDF membrane for 3hrs at a constant current of 0.8mA/cm2 using semi-dry 
blotting apparatus (BioRad, UK). To examine protein loading, the gel was subsequently 
stained with a solution of 0.1% v/w Coomassie brilliant blue R-250, 10% v/v methanol 
and 4% acetic acid for 2 hours and then destained using a solution of 10% v/v methanol 
and 7.5% v/v acetic acid.
The membrane was carefully cut into two at approximately 80kDa, as visualised by the 
molecular weight markers (New England BioLab, USA). This allowed the top section of 
the gel to be probed for CPLA2 at 110 kDa and the lower part COX-1 at 70kDa. Non­
specific antibody binding was blocked by incubating the membrane for 3 hrs in 0.2% 
w/v I-Block® dissolved in TBS (20mM Tris, 137mM NaCl, pH 7.6) for CPLA2 , and 3% 
BSA in TBST for COX-1. Membranes were incubated overnight at room temperature 
with the appropriate primary antibody (COX-1 -  goat anti-rabbit polyclonal, and CPLA2 
-  rabbit anti-mouse monoclonal antibodies, both used 1:1000 (both Santa Cruz, Caine, 
Wiltshire UK)) diluted in TBST. Blots were then washed with TBST (6 x lOmin) and 
incubated for 1 hr with horseradish-peroxidase (HRP) conjugated anti-goat IgG (COX- 
1) or anti-rabbit IgG (CPLA2) both 1:10000 dilution in TBST. Following further 
washing (8 x lOmin) in TBST, immunoreactive bands were visualised by ECL 
according to manufacturers instructions, and band densities quantified as previously 
described.
Section 3 In vitro studies
2.13 Wild type and COX-2'7' fibroblast PGE2 production
2.13.1 Isolation of murine lung fibroblasts
Lungs were removed from untreated WT and COX-2'7* mice aged 6-8 weeks and 
transferred to the laboratory in a 50ml centrifuge tube containing serum-free DMEM
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containing 4mM L-glutamine, lOOU/ml penicillin, 100|ig/ml streptomycin and 2.5|ig/ml 
amphoteracin B. The lungs were cut into small pieces with a sterile scalpel in a petri 
dish and transferred into a 50ml centrifuge tube containing 20ml DMEM and 1 mg/ml 
Type 2 bacterial collagenase (Worthington Biochemical Corporation, New Jersey, 
USA). The tissue was incubated at 37°C for 2 hours in a shaking water-bath. After this 
time the suspension was filtered through a 100pm nylon filter (Falcon, Becton 
Dickinson, USA) to remove debris and diluted at a ratio of 1:1 with FBS to reduce the 
collagenase activity. The suspension was then centrifuged at 300 x g for 5 minutes to 
pellet the cells and resuspended in 20% FBS DMEM. The cell suspension was then re­
centrifuged to remove any remaining bacterial collagenase and then suspended in 5ml 
DMEM containing 20% FBS, 4mM L-glutamine, lOOU/ml penicillin, lOOpg/ml 
streptomycin and 2.5pg/ml amphoteracin. The cell suspension was transferred to a 
25cm tissue culture flask (TRP, Switzerland) and incubated in a humidified atmosphere 
of air containing 10%CC>2 at 37°C. Cell culture media was replaced every 3-4 days. 
Cells were routinely cultured in 75cm3 tissue culture flasks. Amphotericin B was 
included for the initial three passes only and cultures of COX-2 deficient fibroblasts 
were also supplemented with 1 pg/ml indomethacin (Sigma) for the first three passages
2.13.2 Cell passage
Cells were passaged when confluent. Media was removed and the cell monolayer 
washed with 10ml PBS to remove traces of serum. 5mls of trypsin/EDTA (trypsin 
0.05% w/v; EDTA 0.02% w/v) was added to the monolayer and the cells were 
incubated for 2 minutes at 37°C. When visualised using an inverted light microscope 
(Axioscope 20, Carl Zeiss, Germany) the cells became rounded and detached from the 
culture flask. An equal volume of DMEM containing 10% FBS was added to the flask 
to neutralise the trypsin. This lOmls was removed and centrifuged at 300 x g for 5 
minutes to pellet the cells. The media was removed and the cell pellet resuspended in 
lOmls DMEM containing 20% FBS, glutamine and antibiotics with a 1:4 split ratio.
2.13.3 Measurement o f PGE2  in cell-conditioned media
Wild type and COX-2 7' fibroblasts were used for measurement of PGE2 at passage 
numbers 2-4. Once confluent, cells were trypsinized as previously described (section 
2.13.2). Cells were resuspended in 20% FBS DMEM and seeded at 105 cells/well in 12 
well plates and grown to confluence. Once confluent, cells were incubated for a further 
24 hours. The media was removed and replaced with 1ml preincubation media
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containing 0.4% (v/v) FBS, 4mM glutamine, 50|ig/ml ascorbic acid and 0.2mM proline 
for 24 hours. After this time the preincubation media was replaced with 1ml fresh media 
containing either 0.2% FBS (control media), or control media with TGF-pi (lng/ml), 
NS398 (5|ig/ml), or both TGF-pi and NS398 and incubated for a further 24 hours. The 
media was then removed and frozen at -80°C before being analyzed for PGE2 as 
previously described (section 2.7). The cell layer was then trypsinized using 500pl 
trypsin and 500j l l 1 of DMEM containing 10% FBS to give a 1ml single-cell suspension 
and the cell number counted using an Improved Neubauer Haemacytometer 
(BDH/Merck) under phase-contrast using an inverted light microscope. The number of 
cells /ml was then calculated using the formula:
Cells/ml = number of cells counted x 10"4 
Fibroblast PGE2 production was expressed as pg/105 cells.
2.14 Wild type and COX-2'7' macrophage/monocyte PGE2 production
Due to the difficulty in isolating sufficient pulmonary macrophages, an established 
model routinely used in the laboratory was used to isolate peritoneal 
macrophages/monocytes (Kruisbeek & Vogel, 1995; Bellingan et al., 2002). WT and 
COX-2'7' mice aged 6-8 weeks were injected intraperitoneally (I.P) with 2ml (4%w/v) 
thioglycolate. Bellingan and co-workers have previously shown macrophage/monocyte 
numbers to be maximal 5 days following I.P injection of thioglycolate, with minimal 
numbers of PMNs at this time (Bellingan et al., 2002). Therefore, at day 5 the animals 
were ;ICiXUrt by cervical dislocation and the peritoneum lavaged using 5ml. sterile 
PBS. Lavage fluid was kept on ice at all times. The inflammatory cells were isolated by 
centrifuging the lavage fluid (300 x g) for 5 minutes at 4°C. The cells were resuspended 
in serum free DMEM and counted using a haemacytometer as described above. Cells 
were seeded at 1000 cells/well in 96 well plates and left overnight to adhere in a 
humidified atmosphere of air containing 10%CC>2 at 37°C. The cell layer was washed 3 
times with DMEM to remove red blood cells and non-adherent inflammatory cells. 
150jil fresh media was then added to each well and the plate incubated for a further 24 
hours in a humidified atmosphere of air containing 10%CC>2 at 37°C. After 24 hours the 
media was removed and assayed for PGE2 as previously described in section 2.7.
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2.15 Statistical analysis
All in vivo data are presented as mean ± standard error of the mean (SEM) for at least 6 
animals unless stated. In vitro data is presented as mean ± SEM for 6 replicate cultures 
and is representative of 3 separate experiments. Statistical analysis was performed using 
an unpaired Students t-test for single, or ANOVA for multiple group comparison. A p 
value of less than 0.05 was considered significant.
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CHAPTER THREE:
RESULTS
88
Section 1. Preliminary studies to determine optimum bleomycin dose and 
timepoints for studies of inhibition of COX-2 function
3.1 Effect of sex on body and lung weight following intratracheal instillation of 
saline and bleomycin
Due to limited numbers of mice available, performing all animal experiments using only 
one sex of mouse was not feasible. As expected, the mean body weight of male animals 
(WT, COX-2+/' and COX-2’7' in equal proportions) was significantly greater than female 
mice 14 days following administration of either saline or bleomycin (Figure 3.1 A, 
p<0.001). To overcome the variation in body weight between male and female animals, 
the sexes were equally distributed throughout all experiments described. Furthermore, 
sex did not affect lung weight 14 days following administration of either saline or 
bleomycin (Figure 3.1B), and therefore differences in body weight between male and 
female animals are unlikely to have a discernible affect on BALF PGE2 levels or total 
lung collagen production.
3.2 Wild type mice
Due to the breeding strategy of mating COX-2+/' males with COX-2+/' females, COX- 
2+/+ (wild type, WT) littermate animals were produced in addition to the strain-matched 
WT mice originally provided by the suppliers, and used by this laboratory in a previous 
publication (Keerthisingham et al., 2001). Both strains of wild type mice are on a 
C57BL6/SV129 background and represent equally valid controls since littermate mice 
have also been used in previously published work with COX-2 deficient mice (Zeldin et 
al, 2001). Both control groups are represented in this thesis due to the availability of the 
mice; strain matched animals were used in the majority of studies undertaken at earlier 
periods, whereas the work progressed to using wild type littermate animals once these 
became freely available. The first section will discuss phenotypic differences between 
the wild type strains in respect to body weight and their response to bleomycin injury. 
This will be characterised by parameters fundamental to this thesis, i.e., levels of PGE2 
in bronchoalveolar lavage (BALF) and total lung collagen content.
89
§
%
•&OCQ
30
25
20
15
10
I ] Female 
I I Male * * **
*§>
0.3
0.25
0.2
% 0.15
oo
0.1
0.05
0
B
J ' T
Saline Bleomycin
Figure 3.1 Effect of sex on body and lung weight 14 days following 
instillation of either saline or bleomycin
Figure 3.1 A shows female and male body weight (equal distribution of 
all strains and COX-2 genotype animals) in grams 14 days following 
instillation of either 0.9% saline or bleomycin (1 mg/kg). Figure 3. IB 
shows male and female lung weight in grams at this time. 10-16 B 196 
mice (WT, COX-2+/' and COX-27' mice in equal proportions) at 6-8 
weeks of age were used in each group. ** indicates p<0.001 compared 
with female mice.
90
3.2.1 Body weight and weight loss following intratracheal instillation of bleomycin 
in wild type mice
Figure 3.2A shows the average body weight of both littermate (B196) and strain- 
matched (B197) control mice at 6-8 weeks of age prior to use. No difference was 
observed between the initial starting weight of either strain of wild type animals. Figure 
3.2B represents changes in body weight over 28 days following IT administration of 
either saline or bleomycin (1 mg/kg). At all timepoints examined, neither strain showed 
a significant difference in body weight following administration of bleomycin compared 
with saline alone. However, there were differences in the pattern of weight changes 
between the strains.
Littermate controls (B196) initially lost weight 3 days following instillation of saline 
alone however by day 7 body weight was greater than day 0 and continued to increase 
over the timecourse. By 28 days B196 body weight following saline alone was 
significantly greater than 3 days, p<0.05. Following bleomycin, B196 mice lost on 
average over 2g in weight by day 3 (approximately 10% of initial start weight), however 
again by day 7 this had been regained and body weight was significantly greater than 
day 3, p<0.001. B196 mice continued to gain weight over the timecourse and by day 28 
had gained 5.45g compared with day 3, p<0.005.
Following administration of either saline or bleomycin, strain-matched wild type mice 
(B197) had lost weight at day 7 compared with day 0, however, since data is 
unavailable for B197 mice at day 3, it is unclear as to whether a greater loss in weight 
was observed at an earlier time. After day 7, body weight increased over the remaining 
timecourse, but at a lower rate than B196 mice and at day 28 body weight was not 
significantly different compared with the initial start weight. At days 7, 14 and 28 the 
weight change observed in B 196 mice following instillation of saline was significantly 
greater than B197s, p<0.01 and at days 14 and 28 the weight change in B 196s following 
bleomycin was significantly greater than B 197s, p<0.001.
3.2.2 PGE2  production in wild type mice
Day 14 was chosen as a representative timepoint to examine both BALF PGE2 
production and total lung collagen following injury, as significant increases in total lung 
collagen following bleomycin would not be expected prior to this time. Lungs were 
lavaged using PBS and PGE2 measured in lavage fluid from both littermates and strain-
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Figure 3.2. Comparison of body weight and weight change between 
strains of wild type animals following intratracheal instillation of saline or 
bleomycin
Figure 3.2A shows average starting body weight in grams in B 196 and B197 
at 6-8 weeks old. N= 20 mice per group. Figure 3.2B shows weight change 
following IT instillation of either 0.9% saline or bleomycin (1 mg/kg). 6-8 
animals were used in each group. * indicates p<0.01 compared with B197 
Sal, t  indicates p<0.001 compared with B197 Blm.
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matched wild type mice. Figure 3.3 shows that whilst both strains of WT mice showed 
a significant increase in BALF PGE2 following injury, littermate animals (B196) 
produced significantly higher levels of BALF PGE2 , both basally, and following 
instillation of bleomycin compared with strain-matched controls (B197, p<0.05 in both 
cases). However the fold increase in BALF PGE2 production fQllowing instillation of 
bleomycin was similar between strains (B196 6.6-fold, B197 7-fold).
3.2.3 Collagen production in wild type mice
At day 14 following instillation of either saline or bleomycin lungs were removed and 
collagen content was assessed by the measurement of hydroxyproline using HPLC as 
described (section 2.11). Figure 3.4 shows that following instillation of saline alone 
collagen levels are similar in both strains of WT mice (B196: 1.58mg ±0.11 vs B 197: 
1.64mg ±0.09). Following the administration of bleomycin, total lung collagen 
increased significantly in both strains, as is typical of the bleomycin model (B196: 
2.10mg ±0.14 vs B197: 2.34mg ±0.12, p<0.05 in both cases) although levels were not 
significantly different between the two strains.
In summary, both strains of wild type mice represent valid controls although some 
differences do exist in their phenotypes and their production of PGE2 in the lung. For 
these reasons the results of the two strains were kept separate throughout all 
experiments, and not combined. All following data using COX-2 deficient mice will be 
compared to only one strain, which will be clearly identified.
3.3 Bleomycin dose response
Increasing doses of bleomycin were used to investigate the effect on PGE2 and collagen 
production in the model.
3.3.1 Effect of bleomycin dose and PGE2  production
Previous studies in mice have shown that levels of PGE2 in lung homogenates (Giri et 
al., 1985) and in serum (Chandler et a l, 1983) are increased following intratracheal 
instillation of bleomycin. Additionally, Figure 3.3 shows a significant increase in 
BALF PGE2 following IT administration of bleomycin (1 mg/kg) in both wild type 
control groups. Figure 3.5 shows PGE2 levels following increasing doses (0-3mg/kg) of 
bleomycin in strain-matched wild type mice (B197), 14 days following injury. There
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Figure 3.3. Comparison of BALF PGE2 levels in strain-matched 
(B197) and littermate (B196) controls
Lungs were lavaged with PBS 14 days following IT administration of 
either saline or bleomycin (1 mg/kg). BALF PGE2 was measured by EIA. 
7-10 animals were used per group.* indicates p< 0.05 compared with 
B197 equivalent treatment.
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Figure 3.4. Comparison of total lung collagen accumulation in 
strain-matched (B197) and littermate (B196) controls
Lungs were removed 14 days following IT administration of either 
saline or bleomycin (1 mg/kg) and total lung collagen measured by 
HPLC. 7-10 animals were used per group. * indicates p< 0.05 
compared with strain-matched saline-treated mice.
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Figure 3.5. BALF PGE2 levels following instillation of increasing 
doses of bleomycin
Animals were lavaged with PBS 14 days following instillation of 
bleomycin (0-3mg/kg). BALF PGE2 was measured using a 
commercially available EIA. * p<0.05 compared with instillation of 
saline alone. 7-9 animals were used per group.
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was an eight-fold and thirteen-fold increase in BALF PGE2 levels following instillation 
of 1 mg/kg and 3mg/kg bleomycin respectively, however the difference in PGE2 
produced between 1 and 3 mg/kg bleomycin was not statistically significant.
3.3.2 Effect o f bleomycin dose on total lung collagen production 
Figure 3.6 shows the significant increase in total lung collagen content in B197 wild 
type mice 14 days following IT administration of Img/kg bleomycin, as previously 
described (Figure 3.4, p<0.05). However, when the dose of bleomycin was increased to 
3 mg/kg no further increase lung collagen content was observed .
Together, Figures 3.5 and 3.6 show no significant differences in either BALF PGE2 
levels or lung collagen content using bleomycin at either 1 or 3 mg/kg. From the 
hypothesis, it is proposed that inhibition of COX-2 activity, either by pharmacological 
inhibition, or by using COX-2 deficient mice, will result in an enhanced fibrotic 
response to bleomycin compared with control animals. Although PGE2 and collagen 
production do not alter significantly with the high dose of bleomycin, the low dose of 
1 mg/kg was chosen for all future experiments to maximise any potential increase in the 
fibrotic response seen in mice in the absence of COX-2 activity.
3.4 Effect of bleomycin on COX expression
Figures 3.3 and 3.5 show that bleomycin induces production of PGE2 in the lung. To 
investigate which COX isoform(s) is (are) responsible for PGE2 synthesis following 
bleomycin-induced lung injury, COX isoform protein expression was examined using 
western blotting. Strain-matched wild type mice were used at 14 days following 
instillation of bleomycin. Figure 3.7 shows that protein expression of COX-1 increased 
approximately 1.5-fold following instillation of bleomycin compared with saline alone, 
although this increase is non-significant. In contrast, COX-2 protein expression is 
significantly upregulated following the instillation of bleomycin compared with saline 
alone, p<0.05.
Thus, it has been shown that in wild type mice bleomycin injury upregulates COX-2, 
but not COX-1 protein, which suggests COX-2 to be responsible for the significant 
increase in PGE2 synthesis observed. As is typical of the model, the dose of bleomycin 
chosen for all future studies causes a significant increase in total lung collagen at 14
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Figure 3.6 Effect of increasing doses of bleomycin on total lung 
collagen
Lungs were removed 14 days following IT administration of bleomycin 
(0-3mg/kg) and total lung collagen measured by HPLC. 7-9 animals 
were used in each group. ** indicates p<0.01 compared with saline 
alone.
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Figure 3.7. COX expression following IT administration of saline 
and bleomycin
Lungs were removed 14 days following injury. Protein was extracted 
and electrophoresed on SDS-PAGE gels. Levels of COX-1 and COX-2 
were detected using western blotting with goat polyclonal COX-1 
(Figure 3.7A) and rabbit polyclonal COX-2 antibodies (Figure 3.7B). 
Band densities were quantified as described and represent the mean 
± SEM for 5 (COX-2) or 6 (COX-1) animals. * indicates p<0.05 
compared with saline. MWM denotes molecular weight marker.
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days following injury. These data suggest this model to be ideal for investigating the 
effects of inhibiting COX-2 activity in vivo.
Section 2. Pharmacological inhibition of COX-2
To further investigate if the induction of PGE2 synthesis in the bleomycin model of 
pulmonary fibrosis is COX-2 specific, and the role of COX-2 in the development of the 
fibrotic response, mice were treated with the selective COX-2 inhibitor NS398 twice 
daily via oral gavage. B197 animals were used in all experiments throughout Section 2.
One hour prior to IT administration of either bleomycin (1 mg/kg) or saline, animals 
were dosed with either NS398 (3mg/kg, see sections 1.18, 2.3 and 4.3.1) or vehicle 
(0.1%DMSO, l%Tween80 in PBS). Subsequent doses of NS398 or vehicle were given 
every 12 hours thereafter.
3.5 Effect of instillation of NS398 on body weight
Figure 3.8 shows that administration of NS398 did not affect body weight at any time 
over the 28 day timecourse. Similarly to Figure 3.2, there is also no significant 
difference in weight loss in mice who received bleomycin compared with those who 
received saline.
3.6 Effect of NS398 on PGE2 synthesis
Following treatment with either 3mg/kg NS398 or vehicle for up to 28 days, BALF 
PGE2 levels were measured as previously described. Figure 3.9 shows that following 
instillation of saline alone, BALF PGE2 levels are low but measurable in all groups, and 
do not change with either time or treatment with NS398. This suggests that basal levels 
of BALF PGE2 are COX-1-mediated.
Following IT administration of bleomycin and vehicle alone, BALF PGE2 production 
significantly increased for at least 28 days following injury compared with saline 
control, p<0.05 in all cases (Figure 3.9). The highest levels were observed at the 
earliest timepoint examined, day 7 (744.3pg/ml BALF), and decreased in a time
100
Vehicle/ Sal 
Vehicle/Blm
NS398/ Sal 
NS398/ Blm
0.5
-1.5
Days following IT instillation
Figure 3.8. Changes in body weight following intratracheal 
instillation of saline or bleomycin and treatment with NS398
Following intratracheal instillation of either 0.9% saline or 
bleomycin (1 mg/kg) animals were instilled twice daily via oral 
gavage with either NS398 (3mg/kg body weight) or vehicle 
(0.1%DMSO in PBS, 1% Tween80). 6-8 animals were used in each 
group.
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Figure 3.9. Effect of selective inhibition of COX-2 on PGE2 
production in the lung
Following treatment with either the selective COX-2 inhibitor, NS398, 
or vehicle, animals were lavaged using PBS at 7, 14 and 28 days 
following IT administration of either saline or bleomycin (1 mg/kg). 
BALF PGE2 was measured by EIA. 6-8 animals were used per group. 
* indicates p<0.05 compared with saline control, t  p<0.05 compared 
with vehicle treated bleomycin.
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dependent manner at days 14 (517.3pg/ml) and 28 (350pg/ml). However, at day 28 
BALF PGE2 was still significantly increased following instillation of bleomycin 
compared with saline alone, p<0.05.
At days 7 and 14 following instillation of bleomycin, treatment with the COX-2 
selective inhibitor NS398 almost completely inhibited bleomycin-induced BALF PGE2 
production. At 7 days PGE2 production was reduced by 86% and at 14 days by 77% 
compared with treatment with vehicle alone, and at both timepoints, values were not 
significantly different from animals treated with saline/NS398.
However, at 28 days bleomycin-induced PGE2 production was no longer inhibited 
following administration of NS398. Levels of BALF PGE2 in bleomycin/NS398-treated 
mice were similar to those in bleomycin/vehicle-treated animals (313.6 vs 350pg/ml 
BALF).
3.7 Effect of pharmacological inhibition of COX-2 on the development of 
bleomycin induced pulmonary fibrosis
NS398 has been shown to successfully inhibit PGE2 production for at least 14 days 
following bleomycin instillation. PGE2 is known to inhibit lung fibroblast collagen 
production (McAnulty et al, 1995), and promote breakdown of newly synthesised 
collagen (Baum et al, 1980; Brilla et al., 1995), therefore it was hypothesised that 
pharmacological inhibition of COX-2 activity, and the subsequent inhibition of PGE2 
biosynthesis would lead to an enhanced fibrotic response to bleomycin.
Figures 3.10 shows that following treatment with vehicle alone, total lung collagen 
production significantly increases following instillation of bleomycin, p< 0.05. 
However total lung collagen content following bleomycin injury is not further enhanced 
following pharmacological inhibition of COX-2 using NS398. Indeed, there is no 
significant increase in the mean total lung collagen content in animals instilled with 
bleomycin compared with instillation of saline alone. At 28 days following instillation 
of bleomycin total lung collagen content is significantly increased compared with saline 
alone in both NS398 and vehicle-treated animals, p<0.05 in both cases, Figure 3.11. By 
28 days lung collagen content had not increased further in vehicle-treated mice
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Figure 3.10. Effect of pharmacological inhibition of COX-2 on the 
fibrotic response to bleomycin 14 days following injury
Lungs were removed and total lung collagen measured using HPLC. 
Each point represents total lung collagen for an individual mouse. Mean 
lung weight per group is indicated by a horizontal bar. 6-8 animals were 
used per group. * indicates p<0.05 compared with respective saline 
control.
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Figure 3.11. Effect of pharmacological inhibition of COX-2 on 
the fibrotic response to bleomycin 28 days following injury
Lungs were removed and total lung collagen measured using 
HPLC. Each point represents total lung collagen for an individual 
mouse. Mean lung weight per group is indicated by a horizontal 
bar. 7-9 animals were used per group. * indicates p<0.05 
compared with respective saline control.
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following administration of bleomycin compared with the equivalent group at day 14 
(see Figure 3.10) following injury. Similarly, there was no further increase in lung 
collagen content between NS398-treated mice 28 days following bleomycin compared 
with those at day 14, and selective inhibition of COX-2 did not lead to an enhanced 
fibrotic response to bleomycin injury at this time compared with vehicle treated 
animals.
3.8 Effect of NS398 on inflammatory response to bleomycin-induced lung 
injury
At 7, 14 or 28 days following instillation of bleomycin, lungs were lavaged with PBS 
and inflammatory cells isolated. Total cell number was determined using a 
haemocytometer and cytospin preparations were made to obtain differential cell counts.
At days 7, 14 and 28 there was no difference in total cell numbers following bleomycin 
injury, compared with administration of saline alone. Furthermore, this was unaffected 
by treatment with NS398 at any timepoint examined (Table 3.1).
Following instillation of saline, BALF contained greater than 97% 
macrophages/monocytes at all timepoints examined, and was unaffected by treatment 
with NS398 (Table 3.1). In comparison, day 7 following instillation of bleomycin 
BALF contained a decreased proportion of macrophage/monocytes due to increased 
numbers of polymorphonuclear leukocytes (PMNs) and lymphocytes compared with 
saline alone, p<0.001 in all cases. However treatment with NS398 had no significant 
effect on the cellular profiles at day 7. Numbers of PMNs and lymphocytes present in 
BALF following instillation of bleomycin declined with time in both NS398- and 
vehicle-treated animals and by day 14 there was no longer a significant increase 
following bleomycin instillation compared with saline alone. In summary, treatment 
with NS398 did not affect the inflammatory response to bleomycin.
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Day I.T.
instillation
Treatment Total cell count 
(xl0'3)
Macrophage,
%
Neutrophil,
%
Lymphocyte,
%
7 Saline Vehicle 383.5 +51.4 98.2 ± 0 .5 0.1 ±0.1 0.9 ±0.4
Bleomycin Vehicle 353.2 ±40.8 76.7 ±  5.9 * 10.8 ± 2 .9  * 12.8 ±3.0*
Saline NS398 318.2 ±43.1 97.9 ±  0.8 0.7 ± 0 .3 1.5 ±0.5
Bleomycin NS398 406.2 ±30 .7 79.1 ±  1.7 * 7.1 ± 0 .9  * 13.7 ±1.0*
14 Saline Vehicle 342.7 ±60.1 98.4 ±  11.6 0.3 ± 0 .9 1.2 ± 1 .2
Bleomycin Vehicle 356.4 ±  34.5 95.8 ± 2 .0 3.0 ±  1.8 1.0 ± 0 .3
Saline NS398 281.4 ±25.7 99.4 ± 0.2 0.2 ±0.1 0.4 ± 0 .2
Bleomycin NS398 386.5 ±40.5 94.6 ±2.1 3.4 ±  1.7 1.6 ± 0 .5
28 Saline Vehicle 292.3 ±34.1 99.1 ± 0 .5 0.3 ±0.1 0.6 ± 0 .4
Bleomycin Vehicle 306.1 ±36.4 98.0 ± 0.6 1.6 ± 0 .5 0.4 ±0.1
Saline NS398 237.3 ±26.7 99.9 ±0.1 0.1 ± 0 .0 0.1 ± 0 .0
Bleomycin NS398 331.4 ±37.2 98.2 ± 0 .7 1.4 ± 0 .4 0.4 ± 0 .3
Table 3.1 Effect of NS398 on inflammatory response to bleomycin-induced lung 
injury
Following treatment with either the selective COX-2 inhibitor NS398 or vehicle alone, 
animals were lavaged using PBS at 7, 14 and 28 days following IT administration of 
either 0.9% saline or bleomycin (1 mg/kg). Total cell number was determined using a 
haemocytometer and expressed as total cell count (xl0‘3). Cytospin preparations were 
made to obtain differential cell counts which are expressed as a percentage of total cells. 
6-8 animals were used per group. * indicates p<0.001 compared with relative treatment 
saline at day 7.
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3.9 Histological assessment of bleomycin-induced lung injury following 
treatment with NS398
Lung injury was assessed at 14 and 28 days following instillation of bleomycin or saline 
in mice treated with either NS398 or vehicle control. Histological sections were stained 
using modified MSB where matrix proteins such as collagen are stained blue, and 
inflammatory cells stained red. Representative areas are shown in Figures 3.12 and 
3.13. Figure 3.12A and B show animals treated with either vehicle or NS398 14 days 
following instillation of saline alone. In both groups, normal lung architecture is 
retained, with thin alveolar walls and matrix staining limited to the interstitium, airways 
and blood vessels. A small number of inflammatory cells are present in the interstitium, 
but administration of NS398 does not appear to greatly affect normal lung architecture. 
This does not alter after 28 days administration of NS398, where lung histology remains 
normal, and comparable to vehicle treated animals following saline instillation (3.13A 
and B).
In contrast, all mice instilled with bleomycin showed characteristic lesions (Figures 
3.12 and 3.13 C, D, E and F) with patchy loss of alveolar architecture and thickening of 
the interstitium. This was accompanied by increased numbers of fibroblast 
/myofibroblast-like cells within the lesion (Figures 3.12 and 3.13 E and F). The 
increased matrix staining correlated with increased production of collagen in the lungs 
as assessed by the measurement of hydroxyproline (Figure 3.10 and 3.11). BALF 
inflammatory cell numbers were not increased following bleomycin injury at either 14 
or 28 days (Table 3.1), however at a higher power, both Figures 3.12E, F and 3.13E, F 
show significant numbers of inflammatory cells localised to lesions, irrespective of 
treatment with NS398.
3.10 Pharmacological inhibition of COX-2: Summary
Through western analysis and the use of the selective COX-2 inhibitor NS398, it has 
been shown that following bleomycin-induced lung injury, wild type mice synthesise 
PGE2 predominantly through upregulation of COX-2. PGE2 is capable of inhibiting 
several processes thought to be important in the fibrotic response, namely 
fibroproliferation, collagen production and myofibroblast differentiation. Therefore it 
was hypothesised that reduced levels of PGE2, via inhibition of its biosynthesis, would
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Figure 3.12. Effect of pharmacological inhibition of COX-2 using 
NS398 (3mg/kg) 14 days following IT instillation of either 0.9% 
saline or bleomycin (1 mg/kg)
Micrographs of lung sections stained using modified MSB. A) vehicle 
treated and B) NS398-treated mice following instillation of saline 
alone. C) & E) vehicle-treated, D) & F) NS398-treated mice following 
instillation of bleomycin. Original magnification xlOO (A-D) and 
x200 (E & F).
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Figure 3.13. Effect of pharmacological inhibition of COX-2 using 
NS398 (3mg/kg) 28 days following IT instillation of either 0.9% 
saline or bleomycin (1 mg/kg)
Micrographs of lung sections stained using modified MSB. A) 
vehicle treated and B) NS398-treated mice following instillation of 
saline alone. C) & E) vehicle-treated, D) & F) NS398-treated mice 
following instillation of bleomycin. Original magnification xlOO (A- 
D) and x200 (E & F).
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lead to an enhanced fibrotic response to bleomycin. However, despite almost total 
inhibition of PGE2 production by NS398 for at least 14 days following injury, collagen 
production in the lungs of these mice was not further enhanced at either timepoint 
examined. The inflammatory response to bleomycin assessed by lavage cell profiles was 
also unaltered in mice treated with NS398 compared with vehicle alone.
The incomplete inhibition of PGE2 production by day 28 following injury may 
confound the approach of pharmacological inhibition of COX-2 in this model. 
Therefore, an alternative strategy to inhibit COX-2 production, and therefore 
presumably induced PGE2 synthesis following lung injury, would be to use gene 
disrupted animals. The use of COX-2 deficient mice in the bleomycin model of 
pulmonary fibrosis will be discussed in the following section.
Section 3 COX-2 deficient mice
Previous reports have shown COX-2 homozygous deficient (COX-2'7') mice to be 
unable to upregulate PGE2 synthesis following a variety of injurious stimuli in a range 
of organs (Morteau et al., 2000; Zeldin et al., 2001; Bonner et al., 2002). Therefore, it 
was hypothesised that following bleomycin injury COX-2'7' mice would show limited 
induction of PGE2 synthesis, which in turn may result in a more severe fibrotic response 
to bleomycin-induced lung injury for reasons previously described.
COX-2 heterozygous deficient (COX-2+7') mice were also used. These animals have 
previously been shown to produce intermediate amounts of COX-2 at the RNA level 
(Dinchuk et al., 1995). In addition, Figure 3.14 shows intermediate production of COX- 
2 protein in the lung, both basally and following instillation of bleomycin compared 
with WT mice. As expected, COX-2'7' mice produce no COX-2 protein. Production of 
PGE2 following lung injury has not previously been investigated in COX-2 
heterozygous deficient mice.
3.11 Effect of COX-2 deficiency on body weight and weight changes following 
bleomycin instillation
All experiments in Section 3 use littermate wild type mice as control animals. Figure 
3.15A shows the mean body weights of WT, COX-2+7' and COX-2'7' mice aged 6-10
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Figure 3.14 COX-2 expression in the lungs of WT, COX-2+/" and 
COX-2"7" mice following instillation of either saline or bleomcyin
Protein extracted from WT, COX-2+/" and COX-2"7' lungs was 
electrophoresed on SDS-PAGE gel and detected immunologically 
using a rabbit anti-mousenpolyclonal COX-2 antibody. Figure 3.14 is 
representative of a further 3 blots.
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weeks before the start of all subsequent experiments. COX-2 deficiency has no effect on 
mean body weight compared with WT animals.
Following instillation of saline alone, all three genotypes showed little change in body 
weight for the first 7 days, Figure 3.15B. By day 14 there was a l-2g increase in body 
weight in all three genotypes and at day 28 both WT and COX-2'7' mice gained 2.5-3g, 
significantly increased compared with day 7, p<0.01. Following instillation of 
bleomycin all three genotypes lost weight by day 3 but this was regained, and 
subsequently increased by day 14 Figure 3.15C. By day 28 all three genotypes gained 
2-3.5g in weight although this was not significantly different to that observed following 
administration of saline alone in any genotype.
3.12 Measurement of BALF PGE2 in COX-2'7' and COX-2+7' mice following 
intratracheal instillation of bleomycin
As previously shown in Figures 3.3, 3.5 and 3.9, lavage PGE2 levels were significantly 
increased in WT mice for at least 28 days following intratracheal instillation of 
bleomycin. It was hypothesised that COX-2'7' mice would be unable to upregulate 
synthesis of PGE2 , however unexpectedly, Figure 3.16 shows that this was not the case.
Control levels of BALF PGE2 following administration of saline alone were low but 
measurable at each timepoint examined. Generally, BALF PGE2 levels following 
instillation of saline were unaffected by either COX-2 genotype or time following 
instillation, however at day 14 BALF PGE2 was significantly greater in WT mice 
compared with COX-2+/‘ animals, and this value is increased compared with WT BALF 
PGE2 at day 7, p<0.05 in both cases. However BALF PGE2 levels in COX-2+7' and 
COX-2'7' mice are not significantly different, either throughout the timecourse, or 
compared with WT or COX-2'7‘/COX-2+7' mice at any time.
Three days following administration of bleomycin all three genotypes showed an 
increase in BALF PGE2 compared with instillation of saline alone, however this was 
only significant in COX-2+7' and COX-2'7' mice at this time (p<0.05). By 7 days 
following instillation of bleomycin, wild type mice significantly upregulated BALF 
PGE2 production compared with instillation of saline alone, p<0.05 and levels were 
maintained at day 14. By day 28 following injury, levels of BALF PGE2 had begun to
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Figure 3.15. Effect of COX-2 genotype on body weight and weight 
change following instillation of saline or bleomycin
Figure 3.15A shows average starting body weight in grams of littermate 
B196 wild type mice compared with heterozygous and homozygous 
COX-2 deficient mice at 6-10 weeks of age, n=25. Weight change 
following IT administration of 0.9% saline is shown in Figure 3.15B and 
bleomycin (lmg/kg) in Figure 3.15C. At least 7-10 animals were used in 
each group in Figures 3.15B and C.
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Figure 3.16. BALF PGE2 levels in WT, COX-2+/ and COX-2-7 mice
Lungs were lavaged with PBS 3, 7, 14 or 28 days following IT 
administration of either bleomycin (1 mg/kg) or saline. PGE2 was 
measured using an EIA. Each bar represents the mean ± SEM of 7-9 
mice. § represents p<0.05 compared with WT saline value at day 7, $ 
represents p<0.05 compared with COX-2+/* saline at day 14, * represents 
p<0.05 compared with respective genotype saline, ** represents p<0.01 
compared with respective genotype saline, f  represents p<0.05 compared 
with WT and COX-2'1' bleomycin at day 7, } represents p<0.05 compared 
with WT and COX-2+/‘ mice bleomycin at day 14 and 28.
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decrease, but were still significantly increased compared with WT mice that received 
saline alone, (Blm: 535 vs Sal: 177pg/ml BALF, p<0.05).
However, COX-27* mice showed compensatory biosynthesis of PGE2 with significant 
upregulation of BALF PGE2 following administration of bleomycin compared with 
saline alone at all timepoints examined, pcO.OOl. BALF PGE2 production increased in a 
time-dependent manner at days 3, 7 and 14 and was maximal at day 14 where there was 
a 21-fold increase in BALF PGE2 compared with saline alone. By day 28 levels had 
decreased compared with day 14, but remained significantly increased compared with 
instillation of saline alone.
At day 3, bleomycin-induced BALF PGE2 levels in COX-27* mice were comparable 
with those of WT and COX-2+/* mice. However, by day 7 BALF PGE2 production was 
significantly greater in COX-27' mice than COX-2+/* mice, p<0.05, with a trend towards 
an increase compared with WT animals. At both 14 and 28 days this trend became 
significant and BALF PGE2 production in COX-27' mice was significantly greater than 
both COX-2+/* and WT animals at these times, p<0.05 in each case.
Mice heterozygous deficient for COX-2 showed no compensatory synthesis of PGE2 . 
Indeed, reduced expression of COX-2 in these animals (see Figure 3.14) resulted in a 
limited induction of PGE2 synthesis in response to bleomycin. BALF PGE2 production 
was significantly increased following bleomycin injury at days 3, 7 and 14 compared 
with saline alone, p<0.05, and peaked at day 14, similar to both WT and COX-27' mice. 
However, PGE2 levels had declined by day 28 following instillation of bleomycin and 
were not significantly increased compared with instillation of saline alone, in contrast to 
both WT and COX-27* animals. Seven days following injury BALF PGE2 was 
significantly lower in COX-2+/' mice than either WT or COX-27* animals exposed to 
bleomycin (p<0.05) with a trend towards decreased levels of PGE2 at both days 14 and 
28.
Together these data suggest a persistent compensatory upregulation of PGE2 in COX-27' 
mice following injury and a reduced capacity to upregulate PGE2 synthesis in mice 
heterozygous for COX-2.
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3.13 Measurement of total lung collagen in COX-2'7' and COX-2+/' mice following 
bleomycin injury
The murine bleomycin model of pulmonary fibrosis is characterised by a significant 
increase in total lung collagen by day 14. By using a relatively low dose (1 mg/kg) of 
bleomycin it was hoped an enhanced fibrotic response to bleomycin-induced lung injury 
would be observed in COX-2 deficient animals compared with wild type controls. The 
fibrotic response to bleomycin was evaluated in two ways, firstly biochemically by 
measuring hydroxyproline content of the lungs using reverse-phase HPLC, and 
secondly histologically using sections stained with the matrix stain MSB.
Figure 3.17 shows that COX-2 does not affect basal collagen production as total lung 
collagen is similar in all three genotypes 14 days following instillation of bleomycin. 
Following bleomycin injury, WT mice show the characteristic increase in lung collagen 
production as previously shown in Figure 3.4. Bleomycin also causes increased 
collagen production in both COX-2+/' and COX-2'7' mice at this time, p<0.05. The 
increase tended to be greater in COX-2+7' mice although this was not significantly 
greater than either WT or COX-2'7' mice.
At the second timepoint examined, basal collagen levels were also unaffected by COX- 
2 genotype (Figure 3.18). Total lung collagen content 28 days following instillation of 
saline was neither different between WT or COX-2 deficient (+7' or '7') mice , nor was it 
different compared with comparable basal levels at day 14 (Figure 3.17).
Again, instillation of bleomycin caused a significant increase in total lung collagen 
content 28 days following injury in all three genotypes compared with instillation of 
saline alone (p<0.01 WT mice, pcO.OOl COX-2+7' mice, p<0.05 COX-2'7* mice, Figure 
3.18). Both WT and COX-2"7' mice showed a trend towards a time-dependent increase 
in lung collagen content at day 28 compared with day 14 (Figure 3.17), although this 
increase did not reach statistical significance. However, COX-2+7' mice showed a highly 
significant time-dependent increase in lung collagen production; by day 28 collagen 
content had increased over 50% compared with day 14, (14 days 2.48mg vs 28 days 
3.77mg, p<0.001). Furthermore, total lung collagen in COX-2+7' mice at day 28 was 
approximately 53% greater than that observed in WT mice and 50% greater than COX- 
2'7' mice, p<0.001 in both cases.
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Figure 3.17. Effect of saline and bleomycin on lung collagen content 
14 days following administration
Saline (0.9%) or bleomycin (lmg/g) were instilled into the lung. After 
14 days the lungs were harvested and hydroxyproline measured using 
HPLC. Each value represents the mean ± SEM for 8-10 animals. * 
indicates p<0.05 compared with genotype saline control.
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Figure 3.18. Effect of saline and bleomycin on lung collagen 
content 28 days following administration.
Saline (0.9%) or bleomycin (1 mg/kg) were instilled into the lung. 
After 28 days the lungs were harvested and hydroxy proline measured 
using HPLC. Each value represents the mean ± SEM for 8-13 animals. 
* indicates p<0.05 & ** indicates p<0.01 compared with genotype 
saline control, f  indicates p<0.001 compared with COX-2+/+ & COX- 
2'/_ blm.
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3.14 Histological analysis of bleomycin induced fibrosis
Histological analysis of lung sections stained using MSB show collagen stained blue 
whilst inflammatory cells appear red. Similarly to measurements of total lung collagen, 
histological analysis 28 days following bleomycin showed greater staining for matrix 
proteins in COX-2+7' mice compared with both WT and COX-2'7' mice. Figure 3.19A-C 
shows all three COX-2 genotypes 28 days following instillation of saline alone. Normal 
lung architecture was retained, with thin alveolar walls and matrix staining limited to 
blood vessels, airways and normal alveolar interstitium. No apparent differences were 
seen between genotypes.
In contrast Figure 3.20A-E shows the lungs 28 days following intratracheal instillation 
of bleomycin. The intensity of the blue stain was markedly increased compared with 
saline treated mice in all genotypes. Both WT and COX-2'7' mice showed a patchy loss 
of alveolar architecture and destruction of the interstitium, accompanied by increased 
matrix deposition in areas where alveolar architecture was disrupted. In COX-2+7' mice, 
bleomycin injury caused an aggressive fibrotic response resulting in widespread 
destruction of lung architecture which was more severe and more extensive than that 
seen in either WT or COX-2'7' mice (Figures 3.20A, B, D).
Higher power shows that affected areas of the lung in COX-2+7' mice were associated 
with intense staining for matrix proteins, and increased cellularity (Figure 3.20C). This 
histological data correlates with biochemical measurements of total lung collagen 
production at day 28 in these animals (Figure 3.18). The lesions in COX-2'7' mice 
contained reduced amounts of matrix staining but an increased mixed inflammatory 
response.
3.15 Effect of COX-2 genotype on inflammatory response to bleomycin
To determine the effect of COX-2 genotype on the inflammatory response, total cell 
numbers were measured, and the relative proportions of inflammatory cells were 
assessed by differential Diff-Quick staining of cytospins from BALF obtained at various 
timepoints following administration of either bleomycin or saline.
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Figure 3.19. Effect of intratracheal instillation of 0.9% saline on 
the lungs of WT, COX-2+/ and COX-27 mice
Low power micrographs of lung sections stained using modified MSB 
from A) WT, B) COX-2+/- and C) COX-2'7- mice 28 days following 
instillation of saline. Original magnification xlOO.
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Figure 3.20. Effect of intratracheal instillation of lmg/kg bleomycin 
on the lungs of WT, COX-2+/ and COX-2 ' mice
Micrographs o f lung sections stained using modified MSB from A) WT,
B) & C) COX-2+/- and D) & E) COX-27' mice 28 days following 
instillation o f bleomycin. Original magnification xlOO (A, B, D) and 
x400 (C & E).
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Total BALF cell numbers from animals instilled with saline were not significantly 
different between genotypes or at any timepoint (Table 3.2) Three days following 
bleomycin instillation total BAL cell numbers tended to be lower than for animals 
instilled with saline but these differences were not statistically significant. Between 7 
and 28 days following bleomycin BAL cell numbers tended to be increased by 30-200% 
although due to variability between animals these differences were not always 
significant (Table 3.2). In WT mice total cell numbers increased following bleomycin 
injury at days 7, 14 and 28 compared with respective saline control animals. BAL cell 
numbers were increased in COX-2+/' mice at days 14 and 28 following injury, and a 
significant increase in total BAL cell numbers was seen in COX-2'7' mice at 28 days 
alone, p<0.05 in all cases. There was no clear difference in BAL total cell numbers 
between genotypes at any timepoint, although the highest cell numbers was observed in 
COX-2'7' animals 28 days following bleomycin, with value three times that of saline 
treated animals.
BALF cell profiles were analysed at 3, 7, 14 and 28 days following injury and did not 
alter significantly between genotypes in response to saline alone. In WT animals 
macrophage numbers increased following bleomycin and became significantly greater 
than saline alone 14 days following injury (Sal 163 ±23.7; Blm 387.5 ±44.9 xlO'3 cells, 
p<0.05, Table 3.2.). Macrophage numbers in COX-2+7' and COX-2'7' animals were 
significantly increased following bleomycin at 28 days (COX-2+/‘ Sal 252 ±70.5; Blm 
485.6 ±60.9; COX-2'7' Sal 169 ±30.2 Blm 410.1 ±69.5, p<0.05 in both cases), however 
no differences in total BAL macrophage number were seen between genotypes at any 
timepoint examined (Table 3.2).
In contrast COX-2 genotype did affect polymorphonuclear leukocyte (PMN) and 
lymphocyte numbers following bleomycin administration. At days 3, 7 and 14 numbers 
of PMNs increased in all genotypes following instillation of bleomycin, peaking at day 
7. Although again, due to variability between animals these differences were not always 
significant (Table 3.2). Significant increases were seen at day 7 in both WT and COX- 
2'7' mice, p<0.05, and at day 14 in COX-2+7' and COX-2'7' mice, p<0.05. By day 28 
numbers of PMNs decreased in WT mice, and were no longer significantly elevated 
over saline alone in both WT and COX-2+7' mice, however numbers of BAL PMNs 
remained elevated in COX-2'7' mice. At 28 days following administration of bleomycin, 
BAL PMN numbers were significantly greater in COX-2'7' mice compared with both
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Day Genotype Treatment Inflammatory cell number (xlO"3)
Total cells Macrophage PMN Lymphocyte
3 WT Saline 238.5 ± 34 .0 237.2 ± 3 .8 1.1 ±0.4 0.4 ±0.2
WT Bleomycin 195.0 ± 31 .6 168.5 ±28.7 24.2 ±19.1 1.7 ± 0 .2*
COX-2+/ Saline 310.6 ± 35 .2 298.9 ±35.3 10.3 ±5.0 1.3 ±0.7
COX-2+/' Bleomycin 229.7 ± 43 .2 188.1 ±30.5 38.6 ±26.2 3.0 ±0.9
COX-2"7' Saline 254.5 ± 32 .9 252.2 ±32.5 1.2 ±0.4 1.0 ±0.4
COX-27 Bleomycin 231.9 ±20 .3 193.3 ±10.2 35.6 ±19 3.3 ±1.3
7 WT Saline 346.0 ±  38.5 335.0 ±39.0 6.0 ±4.0 5.2 ±3.6
WT Bleomycin 459.3 ± 5 9 .2 * 423.0 ±53.7 61.0 ±14.7 * 28.2 ±6.9 *
COX-2+/ Saline 277.4 ±  27.0 270.5 ±26.4 3.3 ±0.7 3.5 ±1.8
COX-2+/" Bleomycin 407.7 ± 53 .0 313.8 ±43.0 70.9 ±34.9 22.3 ±10.3
COX-27" Saline 361.4 ±63 .7 352.8 ±59.1 4.6 ±2.3 4.0 ±2.8
COX-27" Bleomycin 493.2 ±52.5 310.7 ±45.6 86.2 ±22.4* 66.3 ±22.4 *
14 WT Saline 177.9 ±27.7 •163.4 ±23.7 6.5 ±5.4 8.2 ±3.5
WT Bleomycin 430.4 ±  50.9 * 387.5 ±44.9 * 25.8 ±10.0 17.9 ±2.3 *
COX-2+/" Saline 230.0 ±40 .9 242.2 ±51.5 1.5 ±0.3 0.6 ±0.6
COX-2+/" Bleomycin 428.3 ±40.1 * 403.0 ±58.3 11.6 ±2.2* 16.7 ±7.3
COX-27" Saline 207.3 ±33.1 207.3 ±33.1 1.5 ±0.4 0.4 ±0.3
COX-27" Bleomycin 319.9 ±51 .7 327.3 ±55.4 23.0 ±5.8 * 23.6 ±7.4 *
28 WT Saline 207.7 ± 21 .6 202.0 ±21.4 1.7 ±0.9 3.6 ±1.2
WT Bleomycin 357.6 ±  39.6 * 340.7 ±38.0 * 9.3 ±3.3 7.7 ±2.5
COX-2+/" Saline 258.9 ± 71 .6 252.0 ±70.5 4.0 ±1.0 2.6 ±0.8
COX-2+/" Bleomycin 520.5 ±68.1 * 485.6 ±60.9* 27.1 ±13.3 7.7 ±1.9*
COX-27" Saline 174.2 ± 31 .6 169.0 ±30.2 1.8 ±0.7 3.4 ±2.1
COX-2"7" Bleomycin 534.0 ±  84.4 * 410.1 ±69.5 * 73.8 ±26.9 *t 50.7 ±16.2 *t
Table 3.2. Effect of COX-2 genotype on total inflammatory response
Animals were lavaged with PBS at 3, 7 14 and 28 days following IT instillation of 
either saline of bleomycin (lmg/kg). Total cell numbers were determined using a 
haemocytometer and expressed as mean ±SEM total cell count (xlO'3). Cytospin 
preparations were made to obtain differential cell counts and expressed as mean ±SEM 
cell number (xl0‘3). 6-9 animals were used in each group. * indicates p<0.05 compared 
with relative genotype saline, t  indicates p<0.05 compared with WT and COX-2+/' 
bleomycin at 28 days.
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WT and COX-2+/ mice (Table 3.2, WT: 11.1 ±5.6; C0X-2+/’: 27.1 ±13.3; COX-2’'': 
73.8 ±26.9, p<0.05).
Lymphocyte numbers followed a similar pattern (Table 3.2). In all three genotypes 
instillation of bleomycin caused an increase in numbers of BAL lymphocytes at all 
timepoints examined compared with saline alone. Again, due to variation between 
animals these differences were significant in WT mice at days 3, 7 and 14 days, in 
COX-2+/' mice at day 28 alone, and in COX-2'7' mice at days 7, 14 and 28, p<0.05 in all 
cases. By 28 days following bleomycin numbers of BAL lymphocytes were 
significantly greater in COX-2'7' mice compared with both WT and COX-2-+7' animals 
(WT: 7.7 ±2.5; COX-2+7' 7.7 ±1.9; COX-2'7' 50.7 ±16.2, p<0.05 in both cases).
3.16 Heterozygote COX-2 deficient mice as a progressive model of pulmonary 
fibrosis
Pulmonary fibrosis is a progressive process, however the progressive nature of this 
disease is a feature which has been shown to be difficult to reproduce in animal models 
following one injurious stimulus. To investigate if the enhanced fibrotic response 
resulting from decreased expression of COX-2 and reduced PGE2 synthesis can result in 
a perpetuation of a progressive response, animals were left for an extended timecourse 
of 84 days. After this time the fibrotic response was analysed histologically and by the 
measurement of total lung collagen. Additionally, the effect of a longer timecourse on 
COX-2 homozygous deficient mice was examined.
3.16.1. PGE2 production 84 days following injury
At 84 days following the IT administration of either 0.9% saline or bleomycin 
(1 mg/kg), BALF PGE2 levels remained measurable in all groups. However BALF PGE2 
was no longer significantly increased following bleomycin injury compared with 
administration of saline alone in any group. PGE2 synthesis in homozygous COX-2 
deficient mice was no longer increased compared with either WT or COX-2+7' mice. 
Figure 3.21 shows the values in relation to those values at day 28.
3.16.2 Total lung collagen production 84 days following injury
Figure 3.22 represents total lung collagen content at day 84 compared with values
observed at 28 days following either administration of saline or bleomycin (1 mg/kg). At
125
PG
E2 
(p
g/
m
l 
BA
LF
)
1700
1600
1500
1400
700
600
500
400
300
200
100
0
□  28 days 
D  84 days
*
I
T
I
X.
II
I
I
Sal Blm 
WT
Sal Blm 
COX-2+/
Sal Blm 
C O X -2 /
Figure 3.21. BALF PGE2 28 and 84 days following intratracheal 
instillation of saline or bleomycin
Animals were lavaged with PBS at 28 and 84 days following 
instillation of bleomycin (1 mg/kg). BALF PGE2 was measured using a 
commercially available ELA. * indicates p<0.05 compared with saline 
control. 6 - 1 1  animals were used per group.
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Figure 3.22. Total lung collagen 28 and 84 days following 
bleomycin-induced lung injury
Lungs were removed and total lung collagen measured using 
HPLC. Each bar represents the mean ±SEM for 6-12 animals per 
group. * indicates p<0.05; ** p<0.01 compared with genotype 
saline control.
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this timepoint, levels of total lung collagen, either following administration of saline or 
bleomycin, were not significantly different compared with values at day 28 in any 
genotype. This suggests that the fibrotic response was maintained, but not enhanced at 
this time.
3.16.3 Histological assessment o f lung injury 84 days following injury
Histological analysis of lung sections obtained 84 days following administration of 
either saline or bleomycin, shows similar features to those observed at the earlier 
timepoint of 28 days (Figures 3.19 and 3.20). Figure 3.23A-C shows all three COX-2 
genotypes 84 days following instillation of saline alone. Normal lung architecture was 
still apparent, with thin alveolar walls and matrix staining limited to blood vessels, 
airways and normal alveolar interstitium, with no difference between genotypes.
Figure 3.24A-C shows the lungs 84 days following intratracheal instillation of 
bleomycin. Similarly to day 28, the intensity of the blue stain remained markedly 
increased compared with saline treated mice in all genotypes. Again, all three genotypes 
show patchy fibrotic lesions in response to bleomycin, with disruption of alveolar 
architecture, destruction of the interstitium and increased matrix deposition in affected 
areas. Mixed inflammatory cell infiltrates were seen in affected areas of all genotypes. 
The severe fibrotic response seen in COX-2+/' mice at day 28 appeared to be maintained 
at day 84. A greater number of affected areas were seen in COX-2+/‘ mice compared 
with either WT or COX-2'7' animals, typical lesions are shown in (Figures 3.24A, B,
C). This histological data correlates with the biochemical measurements of total lung 
collagen production at day 84 (Figure 3.22).
3.16.4 Inflammatory response at day 84
By day 84 following administration of bleomycin, total cell numbers were not 
significantly different compared with administration of saline alone in WT or COX 7' 
mice, although a significant increase remained in COX-2+7' mice, p<0.05 (Table 3.3). 
Total cell numbers following the administration of saline alone were similar in all 
genotypes at day 84. Furthermore cell number following saline had not changed 
significantly in any genotype throughout the whole of the 84 day timecourse.
Numbers of PMNs were not increased following bleomycin injury in WT mice at day 
84, however increases were still observed in both COX-2+7' and COX-2'7' mice, although
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Figure 3.23. Effect of intratracheal instillation of 0.9% saline on 
the lungs of WT, COX-2+/ and COX-27 mice
Low power micrographs of lung sections stained using modified MSB 
from A) WT, B) COX-2+A and C) COX-27- mice 84 days following 
instillation of saline. Original magnification xlOO.
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Figure 3.24. Effect of intratracheal instillation of 1 mg/kg 
bleomycin on the lungs of WT, COX-2+/‘ and COX-2'/_ mice 
Low power micrographs of lung sections stained using modified 
MSB from A) WT, B) COX-2+A and C) COX-2 '- mice 84 days 
following instillation of bleomycin. Original magnification xlOO.
130
Genotype Treatment Inflammatory cell number (x l0 '3 )
Total cells Macrophage PMN Lymphocyte
WT Saline 184.7 ±18.1 176.1 ±20.4 2.4 ±1.0 8.3 ±2.8
WT Bleomycin 245.7 ±28.8 232.0 ±23.9 1.4 ±0.7 12.3 ±7.0
COX-2+7' Saline 153.9 ±12.0 148.9 ±11.7 1.1 ±3.4 3.9 ±1.4
COX-2+/' Bleomycin 277.3 ±18.0* 256.4 ±25.0 * 3.4 ±1.5 18.7 ±10.4
COX-2'7' Saline 205.5 ±41.7 174.8 ±27.2 1.8 ±1.7 12.4 ±7.2
COX-2'7' Bleomycin 243.4 ±18.4 191.1 ±14.4 6.0 ±1.7*t 46.4 ±14.0 *t
Table 3.3 Inflammatory cell numbers 84 days following IT administration of either 
saline or bleomycin
Animals were lavaged with PBS 84 days following administration of either 0.9% saline 
or 1 mg/kg bleomycin. Total cell numbers were determined using a haemocytometer and 
expressed as mean ±SEM total cell count (xlO 3). Cytospin preparations were made to 
obtain differential cell counts and expressed as mean ±SEM cell number (xlO'3). 7-10 
animals were used in each group. * indicates p<0.05 compared with relative genotype 
saline, t indicates p<0.05 compared with WT bleomycin.
this was only significant in COX-2 7’ animals (Table 3.3, p<0.05). Numbers of BAL 
PMNs in COX-2'7' mice also remained significantly greater than those seen in WT mice, 
similarly to day 28, p<0.05, although not COX-2+7' mice by day 84.
A similar pattern was seen in BAL lymphocyte numbers; only COX-2'7' mice showed 
increased numbers of lymphocytes following instillation of bleomycin compared with 
saline alone at day 84, p<0.05. Again, BAL lymphocyte numbers in COX-2'7' mice were 
significantly greater than those seen in WT mice, but not COX-2+7' mice at this time 
(Table 3.3, WT: 12.3 ±7; COX-2+7': 18.7 ±10.4; COX-2'7': 46.4 ±14, p<0.05 compared 
with WT mice).
3.17 Summary: Effect of COX-2 genotype on the development of bleomycin- 
induced lung fibrosis
It has been shown that both COX-2+7' and COX-2'7' mice have phenotypes distinctly 
different in many aspects from WT control animals. COX-2 deficiency does not affect 
the body weight of these animals, nor does it affect the basal BALF PGE2 production or 
total lung collagen content following instillation of saline alone. However, following 
instillation of bleomycin, differences exist in the response to bleomycin induced lung 
injury, the inflammatory response and the development of fibrosis.
Surprisingly, total absence of functional COX-2 protein (Figure 3.7) in COX-2'7' mice 
did not limit the upregulation of BALF PGE2 synthesis (Figure 3.16) which was 
previously shown to be predominantly COX-2-derived (Figure 3.9). These animals did 
not show a more severe fibrotic response to bleomycin, as hypothesised (Figures 3.17,
3.18 and 3.22). However COX-2'7' mice did show an enhanced inflammatory response 
to bleomycin injury, both at days 28 and 84 (Tables 3.2 and 3.3). Experiments to 
identify potential explanations for this enhanced inflammatory response, together with a 
possible explanation for the compensatory synthesis of PGE2 in these mice will be 
presented in Section 4.
Mice heterozygous for COX-2 showed reduced protein expression in the lung (Figure 
3.7) and following bleomycin challenge, this reduction in COX-2 expression resulted in 
only limited upregulation of BALF PGE2 synthesis (Figure 3.16). With reduced levels 
of the antifibrotic PGE2 present in the lung COX-2+7' mice demonstrate a more severe
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fibrotic response to bleomycin compared with both WT and COX-2'7' animals. Total 
lung collagen accumulation was 53% greater than that seen in WT mice, and 50% 
greater than COX-2*7' mice animals (Figure 3.18). At the longer timepoint of 84 days 
following injury this difference was maintained, although not enhanced (Figure 3.22) 
and therefore COX-2+/" mice do not represent a progressive model of pulmonary fibrosis 
over an 84 day timepoint with only one initial instillation of bleomycin. The enhanced 
fibrotic response seen in COX-2+/* mice was not associated with a more severe 
inflammatory response to bleomycin as the inflammatory response was generally 
unchanged compared with WT mice at each timepoint examined and less severe than 
COX-2'7' mice (Tables 3.2 and 3.3).
Section 4 Compensatory mechanisms in COX-2 homozygous deficient 
mice
The characterisation of the COX-2'7' mouse phenotype in response to bleomycin 
describes a compensatory upregulation in PGE2 synthesis following injury, however this 
phenomena is not observed in the absence of an injury, nor does it occur in mice 
heterozygous for the gene. This unexpected upregulation of BALF PGE2 following 
instillation of bleomycin is accompanied by an enhanced and persistent inflammatory 
response characterised by increased numbers of PMNs and lymphocytes, but this is not 
accompanied by an enhanced fibrotic response to the injury, which is observed in mice 
heterozygous for COX-2. The following section aims to further investigate the 
mechanism and source of the increased PGE2 seen in COX-2'7' mice and to investigate 
possible reasons for the enhanced inflammatory response following injury.
Firstly, western blotting was used to determine if increased PGE2 production can be 
explained either by an increase in substrate availability, via an increase in cytosolic 
phospholipase A2 (CPLA2) production, or alternatively, due to a compensatory 
upregulation of COX-1.
3.18 Expression of CPLA2 in lung tissue following injury
PGE2 production has been shown to peak at approximately day 14, therefore, whole 
lung tissue was removed at this time and powdered under liquid nitrogen. Protein was
extracted by repeat freeze-thaw cycles and electrophoresed through SDS-PAGE gels. 
This was then transferred onto nitrocellulose membranes and probed for CPLA2 using a 
specific antibody. These blots, and those described in section 3.19 were predominancy 
performed by Dr Caroline Wheeler-Jones at the Royal Veterinary College, London. 
Figure 3.25 shows that CPLA2 , the rate limiting enzyme in the release of arachidonic 
acid, is expressed at similar levels in the lungs of both saline treated WT and COX-2'7' 
mice 14 days following IT instillation. However, following bleomycin injury, CPLA2 
was upregulated approximately 1.5-fold in both WT and COX-2 7' lung tissue, but no 
difference was observed between the COX genotypes. Therefore these data suggest that 
the altered production of PGE2 in COX-2'7' mice can not be explained by an increase in 
substrate availability due to increased CPLA2 expression.
3.19 Expression of COX-1 in lung tissue following injury
Since COX-2 deficiency did not effect expression of cPLA2, levels of COX-1 were 
assessed. Again, protein extracted from whole lung tissue removed 14 days following 
administration of either saline or bleomycin, was electrophoresed through SDS-PAGE 
gels and transferred onto nitrocellulose membranes. The membranes were then probed 
for COX-1 using a specific antibody.
Figure 3.26 shows the expression of COX-1 protein in WT and COX-2'7' mice. 
Following the instillation of saline alone, COX-1 expression was similar in the lungs of 
both WT and COX-2'7' mice. However, following intratracheal instillation of bleomycin 
COX-1 protein expression was upregulated approximately 4.5 fold in COX-2'7' mice 
compared with only a 1.5-fold increase in wild type control animals. These data suggest 
that upregulation of PGE2 in the lungs of COX-2'7' mice is, at least in part, mediated via 
a compensatory upregulation in COX-1 production, and not via an increase in CPLA2 
leading to increased arachidonic acid availability.
3.20 Compensatory upregulation of PGE2 in vitro
Both fibroblasts and macrophages are cell types known to produce significant levels of 
PGE2 in the lung and therefore the capacity of these COX-2 deficient cells to synthesise 
PGE2 was investigated.
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Figure 3.25. cPIf^ expression in the lungs of wild type and COX-2'7' 
mice 14 days followings administration of saline or bleomycin 
3.25A shows a representative western blot. Protein extracted from WT 
and COX-2'7* lungs following intratracheal instillation of saline or 
bleomycin was electrophoresed on SDS-PAGE gel and detected 
immunologically using a rabbit anti-mouse monoclonal cPLA2 
antibody. Band densities were quantified as described and Figure 
3.25B shows the fold increase of cPLA2 expression following 
bleomycin over saline control. Blots using 5-7 animals were used per 
group.
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Figure 3.26. COX-1 expression in the lungs of wild type and 
COX-2'/_ mice 14 days followings administration of saline or 
bleomycin
3.26A shows a representative western blot. Protein extracted from 
WT and COX-2'A lungs following intratracheal instillation of saline 
or bleomycin was electrophoresed on SDS-PAGE gel and detected 
immunologically using a goat anti-rabbit polyclonal COX-1 
antibody. Band densities were quantified as described and Figure 
3.26B shows the fold increase of COX-1 expression following 
bleomycin over saline control. 5-8 animals were used per group ** 
indicates p<0.01 compared with WT PGE2
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3.20.1 PGE2  production in COX-2 deficient fibroblasts
Briefly, pulmonary fibroblasts were isolated by explant culture of both WT and COX- 
2'7' lung tissue. Cells were grown to confluence in 12 well plates, quieced for 24 hours 
and then stimulated for 24 hours with TGF-pi (lng/ml). After this time, the cell- 
conditioned media was removed and PGE2 levels were measured as previously 
described.
Figure 3.27 shows that PGE2 production in WT fibroblasts is significantly induced by 
the pro-inflammatory cytokine TGF-pi (p<0.05). Addition of the selective COX-2 
inhibitor NS398 (5p,g/ml) reduced basal PGE2 production by 80% and the TGF-pi- 
stimulated PGE2 production by 90% (p<0.001 in both cases). This suggests PGE2 
production in these cells is mediated predominantly via COX-2. In comparison, COX-2' 
7* fibroblasts produce PGE2 at or below the limit of detection (20pg/ml). This indicating 
a basal production of PGE2 via ‘housekeeping’ levels of COX-1 only, which is not 
inducible by TGF-pi, and is unchanged in the presence of NS398. Therefore fibroblasts 
do not appear to be a source of the increased BALF PGE2 production described in these 
mice.
3.20.2 PGE2  production in COX-2 deficient macrophage/monocytes
Due to the difficulty in isolating sufficient numbers of pulmonary 
macrophage/monocytes an established model routinely used in this laboratory was used 
to isolate peritoneal cells (Bellingan et al., 2002). Briefly, mice were injected with the 
pro-inflammatory mediator thioglycdlate (4%w/v) and after 5 days were lcUUUcL and 
the peritoneum lavaged using PBS. Cells from both WT and COX-2'7' mice were 
isolated and seeded in 96 well plates, allowed to adhere overnight and then washed to 
remove red blood cells and non-adherent inflammatory cells. Fresh media was added, 
and after 24 hours the cell-conditioned media was removed and PGE2 production 
assessed. Macrophages from four different mice per genotype were used in at least 
triplicate wells per experiment. The results are shown in Figure 3.28. PGE2 production 
is measurable in both COX genotype macrophage/monocyte populations. However, 
levels of PGE2 in thioglycolate-stimulated COX-2'7' cells are approximately 2.5-fold 
greater than that measured in stimulated WT cells.
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Figure 3.27. PGE2 production in wild type and COX-27" fibroblasts
Fibroblasts were cultured with either lng/ml TGF-Pj or the selective 
COX-2 inhibitor NS398 (5pg/ml), or both NS398 and TGF-P! for 24 
hours. PGE2 was measured in cell-conditioned media. Each bar represents 
the mean ±SEM for 6  replicate cultures. * indicates p<0.05 compared 
with WT control cells, t  indicates p<0.05 compared with COX-27" TGF- 
p! treated cells. $ indicates p<0.001 compared with WT cells. Data is 
representative of 3 separate experiments.
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Figure 3.28. PGE2 production in wild type and COX-2'/_ 
macrophage/monocytes
Macrophages/monocytes were isolated 5 days after peritoneal injection 
with the inflammatory stimulant thioglycolate. Cells were cultured in 
serum-free conditions for 24 hours and PGE2 measured in the cell- 
conditioned media. Each bar represents the mean ±SEM for a least 6  
replicate wells of 4 separate animals per group. * indicates p<0.05 
compared with WT control cells.
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These data suggest that COX-2'7' macrophages/monocytes possess a compensatory 
mechanism, possibly increased production of COX-1, which results in an upregulation 
of PGE2 production following stimulation.
3.21 Leukotriene C4 expression in COX-2 deficient mice
Leukotrienes (LTs) are alternative metabolites of arachidonic acid, made not via the 
COX pathway, but via 5-lipoxygenase (5-LO). In the absence of COX-2, arachidonic 
acid metabolism may be shunted through the 5-LO pathway to produce increased levels 
of leukotrienes. These eicosanoids are known to be both pro-inflammatory and pro- 
fibrotic (Peters-Golden et al, 2002) and therefore it was important to measure their 
production in COX-2 deficient mice for two reasons: firstly, increased production of 
leukotrienes may contribute to the enhanced inflammatory response to bleomycin seen 
in COX-2 homozygous deficient mice, and secondly, if shunting could also occur in 
mice heterozygous for COX-2 the increased levels of pro-fibrotic leukotrienes may 
contribute to the enhanced fibrotic response to bleomycin observed in these mice.
LTC4 was measured as a representative cysteinyl leukotriene which are the predominant 
class of LT expressed in mice (Moore et al., 2000; Peters-Golden et al, 2002). Animals 
were instilled with either saline or bleomycin (1 mg/kg) and after 7 days lungs were 
lavaged using PBS. After lipid extraction, BALF LTC4 was measured using an EIA. 
Figure 3.29 shows that BALF LTC4 was detectable at baseline following instillation of 
saline alone in all three genotypes. BALF LTC4 was increased in COX-2'7' mice 
compared with WT mice following instillation of saline alone, p<0.05. Following 
instillation of bleomycin, levels of BALF LTC4 did not increase significantly in any 
genotype, and appeared to decrease in COX-2'7' mice although this difference was not 
significant. Together, these data suggests that shunting through the leukotriene pathway 
does not occur in either COX-2'7' or COX-2+7' mice, following bleomycin injury.
3.22 15-epi-Lipoxin A4 expression following inhibition of COX-2 activity
It has been shown that COX-2'7' mice show an enhanced and persistent 
polymorphonuclear (PMN) alveolitis following instillation of bleomycin compared with 
both vehicle treated mice and those treated with the highly selective COX-2 inhibitor, 
NS398. A possible explanation could be that COX-2 has functions other than
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Figure 3.29. BALF LTC4 levels 7 days following bleomycin-induced 
lung injury
Animals were lavaged with PBS 7 days following instillation of either 
saline or bleomycin (1 mg/kg). BALF lipids were first extracted using 
C l 8  Sep-Pak light columns as described, and LTC4 measured using a 
commercially available EIA (Cayman), according to the manufacturers 
instructions. Each value represents the mean ±SEM for 4-6 animals. 
* indicates p<0.05 compared with WT saline.
141
cyclooxygenase activity which are unaffected by NS398, but may aid in resolution of 
inflammation, and are absent in COX-2'7' mice
One potential candidate molecule is 15-epi-lipoxin A4  (15-epi-LXA4), which is a potent 
inhibitor of neutrophil binding, rolling and transmigration through the vascular 
endothelium. 15-epi-LXA4 is generated from arachidonic acid by acetylated COX-2, via 
15-f?-HETE and 5-LO. High concentrations of 15-epi-LXA4 are generated following 
acetylation of COX-2 by aspirin, however, it has been proposed that COX-2 may also 
be acetylated by endogenous acetylases or via non-enzymatic pathways involving 
reactive oxygen species (Chiang et al 1998). In addition, 15-epi-LXA4 can also be 
generated via a COX-2-independent pathway involving cytochrome P450, although the 
degree of involvement of the cytochrome P450 pathway in aspirin-independent 
production of 15-HETE appears to vary between cell types (Claria et al 1996; Titos et al 
1999). NS398 has been shown to reduce but not block 15-i?-HETE production (Serhan 
et al 2000). Furthermore, the extent to which COX-2'7' mice can generate 15-epi-LXA4 
is not known. Therefore to investigate the role of 15-epi-LXA4 in regulating PMN 
infiltration in bleomycin exposed mice, BALF levels were measured from vehicle- 
treated, and NS398-treated WT mice and COX-2'7' mice.
Figure 3.30 shows that 15-epi-LXA4 is present, and measurable in normal mouse lung. 
All three experimental groups produced similar levels of 15-epi-LXA4 following 
administration of saline alone. BALF 15-epi-LXA4 levels following saline alone 
increase slightly at day 14 compared with day 7 in all genotypes, although this 
difference was significant in COX-2'7' mice only, p<0.05.
Following bleomycin challenge production of BALF 15-epi-LXA4 increased at both 7 
and 14 days. Vehicle-treated WT animals significantly induced BALF 15-epi-LXA4 
levels at both 7 and 14 days, p<0.001, as did COX-2'7' mice, p<0.001 day 7, p<0.05 day 
14. WT mice treated with the selective COX-2 inhibitor NS398 showed increased 
BALF 15-epi-LXA4 production at day 7, p<0.05, although this increase was not 
statistically significant at day 14, p=0.07.
Together, these data suggest that production of 15-epi-LXA4 is unaffected by inhibition 
of COX-2, either pharmacologically or by gene deletion. Indeed, BALF 15-epi-LXA4 
levels were significantly higher in bleomycin-treated COX-2'7' mice than either vehicle
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Figure 3.30. Effect of pharmacological inhibition of COX-2 and gene 
deletion on 15-epi-lipoxin A4 levels in BALF 7 and 14 days following 
bleomycin injury
WT mice were treated twice daily with either the selective COX-2 inhibitor 
NS398 (3jug/ml) or vehicle. Both groups of wild type animals and COX-2'7' 
mice were instilled with either saline or bleomycin and after 7 and 14 days 
the lungs were lavaged using PBS. BALF lipids were extracted using C l 8  
Sep-Pak light columns and 15-epi-LXA4 measured using an EIA. Each 
value represents the mean ±SEM for at least 6  animals per group. 
* indicates p<0.05 and ** p<0.001 compared with instillation of saline 
alone, f  indicates p<0.05 compared with both 7 day NS398 and vehicle 
blm, { indicates p<0.05 compared with day 7 COX-2'7' saline.
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or NS398-treated animals at day 7. These data suggest that a reduced capacity to 
synthesise 15-epi-LXA4 does not mediate persistent and enhanced inflammation seen in 
COX-2'7' mice.
3.23 Summary: COX-2 homozygous deficient mice
Although this laboratory has previously shown COX-2'7' mice to exhibit an enhanced 
fibroproliferative response to bleomycin as assessed histologically (Keerthisingam,£>tra>L
2001), this is not mirrored in an increase in total lung collagen production (Figures 3.17 
and 3.18). However, these animals do exhibit an enhanced inflammatory response to 
bleomycin characterised by an increase in PMNs and lymphocytes in the BALF (Tables
3.2 and 3.3). This section has shown that the enhanced inflammatory response is not due 
to shunting through the 5-LO pathway to produce pro-inflammatory leukotrienes, and 
nor is it due to a failure to produce anti-inflammatory 15-epi-LXA4.
However, PGE2 is known to be a pro-inflammatory mediator and COX-2'7' mice do 
show a compensatory upregulation in BALF PGE2 synthesis following bleomycin 
injury (Figure 3.16). This compensatory upregulation of PGE2 is apparent in 
macrophage/monocytes, possibly other cell types, but not fibroblasts derived from 
COX-2'7' mice (Figures 3.27 and 3.28). The increased expression of COX-1 in COX-2'7' 
whole lung tissue suggests that this may be the mechanism by which 
macrophage/monocytes are able to synthesise increased levels of BALF PGE2 in COX- 
2 '7' mice.
1
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A growing body of evidence suggests that PGE2 is an important negative regulator of 
fibroblast function in both the normal and fibrotic lung. It has been shown to be a potent 
inhibitor of fibroblast proliferation (Elias et a l ,1988; Bitterman et al, 1986), collagen 
synthesis (Goldstein and Polgar, 1982; Saltzman et al, 1982), chemotaxis (Kohyama et 
al, 2001), and more recently fibroblast-myofibroblast differentiation (Kolodsick et al, 
2003). Conversely PGE2 has also been shown to promote degradation of newly 
synthesised collagen (Baum et al, 1980; Briila et a., 1995).
PGE2 is also a potent inhibitor of TGF-pi-induced fibroblast proliferation and collagen 
synthesis (McAnulty et al, 1995; 1997) and despite increased levels of pro-fibrotic and 
pro-inflammatory mediators known to increase it’s synthesis, levels of PGE2 in BAL 
fluid from patients with pulmonary fibrosis have been shown to be 50% lower than in 
normal individuals (Borok et al, 1991). Additionally, fibroblasts from the lungs of 
patients with pulmonary fibrosis show decreased synthesis of PGE2 in the presence of 
TGF-Pi, TN F-aor IL-1 (Wilbom et al, 1995; Keerthisingam et al, 2001;Vancheri et 
al, 2000; Marchand-Adam et al, 2003). In vitro, this failure to induce synthesis of 
PGE2 in response to an array of pro-fibrotic mediators has been shown to be associated 
with a decreased capacity to upregulate COX-2 (Wilbom et al, 1995; Keerthisingam et 
al, 2 0 0 1 ), furthermore this leads to a more fibrogenic phenotype in fibrotic lung 
fibroblasts characterised by a loss in the anti-proliferative response to TGF-pi and an 
increase in procollagen production following stimulation with TGF-pi (Keerthisingam 
et a l ,2001). Together these data provide indirect evidence to suggest that dysregulation 
of COX-2 expression and subsequent PGE2 biosynthesis may play a key role in the 
pathogenesis of pulmonary fibrosis.
From this background, the overall aim of this thesis was to show a direct link between 
COX-2 and PGE2 deficiency and the development of pulmonary fibrosis in vivo, using 
the well characterised bleomycin model of lung injury. This was done by inhibiting the 
function of COX-2, and therefore presumably PGE2 synthesis, in two ways; 
pharmacologically using the highly selective COX-2 inhibitor NS398, and genetically 
using COX-2 deficient mice. In support of this hypothesis, a preliminary histological 
investigation of the lungs of homozygous COX-2 deficient mice from this laboratory 
showed an increased fibroproliferative response to bleomycin challenge compared with 
controls (Keerthisingam et a l, 2001).
146
4.1 Breeding strategy and mouse strain
The COX-2 deficient animals used in this study were generated on a C57B1/6SV129 cross 
background (Dinchuk et a l, 1995). Female COX-2'7' mice are infertile due to a failure to 
ovulate and ovarian fibrosis (Morham et al, 1995; Dinchuk et al., 1995), however female 
heterozygotes remain fertile. The original breeding strategy of mating male COX-2'7' 
animals with female COX-2+7' mice aimed to maximise the numbers of COX-2'7' pups 
produced. However, this strategy produced no wild type littermates and therefore the 
COX-2'7' mice were provided with strain-matched C57B1/6SV129 wild type animals 
(B197) by the supplier as an appropriate control.
As previously reported, litters from COX-2'7' animals were less frequent and smaller than 
wild type animals with less COX-2'7' mice available for use than predicted by Mendelian 
inheritance patterns (Morham et al., 1995; Dinchuk et al, 1995). COX-2 deficiency may 
have resulted in reduced conception as both COX-2 and PGE2 have been shown to be 
important in sperm formation and sperm-oocyte fusion (Marshbum et al, 1989; Joyce et 
al, 1987). Furthermore, survival to the time of weaning and completion of genotyping 
was reduced in COX-2'7' animals, presumably due to renal failure as previously reported 
(Dinchuk et al, 1995; Morham et al., 1995).
To increase the numbers of available animals, heterozygous breeding pairs were used 
which additionally produced wild type littermate mice (B196). Both B197 and B196 mice 
represent valid wild type controls for studies using COX-2 deficient mice, and both strains 
have been used in previous publications (Keerthisingam et al., 2001; Zeldin et al., 2001). 
However, it was important to assess any phenotypic variation between the strains in 
response to bleomycin injury. No significant difference was seen between the strains in 
either body weight, or change in body weight following instillation of bleomycin, and 
total lung collagen production did not alter between strains. Although BALF PGE2 levels 
were significantly higher in B196 mice compared with B197, both basally and following 
bleomycin injury, the 6.5-7-fold increase was similar in both strains (see Figures 3.3 and 
3.4). Despite these similarities, the results for the two strains of WT mice were kept 
separate in all experiments and not combined.
Both B197 and B196 (including COX-2'7' and COX-2+/ ) strains of mice are on a mixed 
C57B1/6SV129 background. Due to the difficulties in breeding described, back-crossing
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onto an inbred strain of mouse was not considered feasible. However, variable segregation 
of litters towards either a C57B1/6 or SV129 parentage has the potential to increase 
phenotypic variability in response to bleomycin instillation. Mouse strain is known to 
affect the fibrotic response to bleomycin, for example, C57B1/6 mice exhibit the 
characteristic fibrotic response to bleomycin whereas BALBc mice do not (Schrier et al, 
1983; Ortiz et al., 1999). However, bleomycin has been shown to lead to a similar 
inflammatory response and collagen production in both C57B1/6 and SV129J mice at 14 
days (Ortiz et al., 1999) and C57B1/6SV129 have previously been shown to respond in a 
similar manner to pure SV129J mice (Munger et al., 1999). Furthermore, global analysis 
of gene expression in C57B1/6 and SV129 mice has demonstrated a 67% homology in 
their response to bleomycin with an 80% homology in inflammatory response genes and a 
75% homology in matrix remodelling genes (Kaminski et al., 2000). Therefore variable 
segregation should not be a significant source of error.
4.2 Effect of bleomycin on PGE2 production
PGE2 is the major eicosanoid product of fibroblasts in the lung (Levine and Alam, 1979; 
Korn et al., 1983; Shindo et al, 1988; Brock et al., 1999) and has previously been shown 
to be increased in lung homogenate (Giri and Witt, 1985) and serum (Chandler and Giri, 
1983) following bleomycin injury. This thesis has shown that administration of bleomycin 
also causes an upregulation of PGE2 in the BALF of WT mice (Figures 3.3, 3.4 and 3.9). 
This increase is time-dependent; levels are significantly increased compared with saline 
alone after 3 days and continue to increase at days 7 and 14. By day 28 levels have 
decreased from the maximum, but remain raised compared with administration of saline 
alone (Figure 3.9). The increased synthesis of BALF PGE2 for at least 28 days differs 
from levels of PGE2 measured in serum. Following bleomycin, PGE2 levels in serum peak 
earlier at day 4, but have returned to baseline levels by day 21 (Chandler and Giri 1983). 
This difference may reflect the local tissue generation of PGE2 by different cell 
populations. It is possible that cells of the acute inflammatory response are responsible for 
much of the early PGE2 generation measured both in BALF and serum, whereas resident 
lung cells such as fibroblasts and epithelial cells synthesise the later PGE2 measured 
locally in BALF which is not detectable systemically in serum. This upregulation of 
BALF PGE2 synthesis for at least 28 days is also significantly longer than that reported in
o^it
BALF following intratracheal instillation of the transition metal V2O5 (Bonner et al.,
A
2002). In this study PGE2 levels peaked at day 1 but returned to baseline by 3 days
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following injury (see Table 4.1). This may reflect the severity of injury and indeed the 
authors of this paper comment on a less severe injury response in mice compared to 
previous studies in rats.
4.3 Role of COX-2 in BALF PGE2 production
4.3.1 Effect of pharmacological inhibition of COX-2 using NS398 on BALF PGE2  
production
NS398 is one of the most selective COX-2 inhibitors (Futaki et al, 1993; Futaki et 
al., 1994; Warner et al, 1999) and has previously been shown to be highly selective for 
COX-2 and to significantly inhibit inflammation-induced PGE2 production in vivo at 
doses as low as l-1.5mg/kg (Masferrer et al, 1994; Paya et al., 1997; Futaki et al., 1997), 
without affecting constitutive PG synthesis in the stomach (Masferrer et al., 1994). At 1 
and lOmg/kg NS398 has previously been shown not to inhibit COX-1 activity in mouse 
granuloma tissue (Gilroy et al, 1998), and at doses of up to 30mg/kg body weight it has 
been shown not to inhibit COX-1 activity either systemically or in the stomach of mice 
(Wallace et a l, 1998). Thus a dose of 3mg/kg administered orally twice daily was used to 
maximise effects whilst maintaining selectivity. Therefore, any inhibitory effects on PGE2 
production in the lung by NS398 at the dose of 3mg/kg body weight used in this study are 
likely to have been mediated via COX-2.
Twice daily administration of NS398 almost completely inhibited BALF PGE2 for at least 
14 days following bleomycin-induced lung injury (Figure 3.9A & 3.9B). These data, 
together with western analysis of COX-1 and COX-2 levels in the lung following 
administration of either saline or bleomycin (Figure 3.7), supports the suggestion that 
PGE2 synthesis following bleomycin injury administration is predominately COX-2 
derived.
However, at day 28, 3mg/kg NS398 was insufficient to significantly inhibit BALF PGE2 
synthesis (Figure 3.9C). This may be due to several reasons, for example the 
development of tolerance to the inhibitor due to increased metabolism of NS398 with 
time, or positive feedback following inhibition of PGE2 as both PGE2 and NS398 have 
been shown to induce COX-2 (Pilbeam et al, 1993; Lu et al, 1995). In light of the data in 
COX-2'7' mice (see Figure 3.16, 3.26 and section 4.3.2), compensatory upregulation of 
the remaining COX isoform(s) following pharmacological inhibition may also be a
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possible explanation. To date, there have been no studies to suggest that NS398 can 
increase COX-1 activity, however previous studies using NS398 have not examined 
prolonged administration in mice. This explanation does appear unlikely however as 
western analysis has shown no increase in COX-1 expression in lung tissue at day 28 
following treatment with NS398 (data not shown, personal communication Caroline 
Wheeler-Jones). Any possible role for COX-3 in PGE2 synthesis in the lung would require 
further investigation but tools do not currently exist commercially to specifically examine 
its expression. However, it appears unlikely to be a major contributing factor to PGE2 
levels since expression of COX-3 in the lung, and many other tissues, has been shown to 
be minimal when compared with that in the brain (Chandrasekharan et al, 2002), 
although it is currently unknown if expression of COX-3 in the lung may alter with injury.
A recent publication may suggest an alternative explanation. Gao and colleagues describe 
an alternative non-enzymatic pathway for formation of bioactive PGD2 and PGE2 
independent of cyclooxygenase, and therefore unaffected by administration of NS398 
(Gao et al., 2003). Prostaglandin-like compounds termed isoprostanes (IsoP) have 
previously been shown to form in humans from the free radical-catalysed peroxidation of 
AA independent of COX (Morrow et al, 1990a). Analogous to PGs, IsoPs contain E/D- 
type prostane rings which are similar to COX-derived PGs (Morrow et al., 1999). Whilst 
the structures of these compounds are similar, IsoPs are formed from endoperoxides in 
which the majority contain side chains cis to the prostane ring (O’Connor et al., 1984; 
Morrow et al., 1999; Morrow et al., 1990b) whereas the PG intermediate PGH2 formed by 
COX contains side chains in the trans configuration relative to the prostane ring. A major 
IsoP is 15-E2t-IsoP (8 -isoPGE2), but unlike PGE2 is unstable and epimerises to PGE2 by 
undergoing reversible rearrangement of the side chains that are initially cis, to the more 
stable trans configuration.
Using gas chromatography (GC) and mass spectrometry (MS) Goo shows that compounds 
with a retention time and molecular weight identical to COX-derived PGD2 and PGE2 , 
(enantiomers, termed ent-VGEjfD?) are formed both in vitro and in vivo via the IsoP 
pathway. At baseline, levels of ent-PGE2 were low, however following oxidative injury 
with carbon tetrachloride ( C C I 4 )  levels of both ent-VGD2  and ent-VGEi increased 
significantly in rats and represent up to 15% of the PGD2 present and 3% of PGE2 present. 
Furthermore, Gao and colleagues showed that liver tissue obtained from 19 day old COX- 
deficient (COX-r/7COX-2'/‘) mouse pups harvested in utero was capable of synthesising
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ent-PGD2 and ent-PGE2 , an observation which may also be significant to this thesis (see 
section 4.3.2). Two further observations are made in this publication which may be of 
relevance; firstly in an unpublished observation Gao states that unlike PGE2 , ent-PGE2 is 
a poor substrate for 15-PGDH (see section 1.13) suggesting that the metabolism of ent- 
PGE2 is significantly different from PGE2. Secondly, the paper raises the issue that the 
degree of suppression of PG production by NSAIDs varies depending on the eicosanoid 
measured. For example, high dose of non-steroidals such as 1.5g of aspirin to normal 
human volunteers is associated with a 90% reduction in thromboxane formation, greater 
than 80% reduction in PGI2 but a no greater than 60% decrease in PGE2 (Bippi and 
Frolich 1990; Rane et al., 1978; FitzGerald et al., 1983). Reasons for this discrepancy are 
unknown but in light of the findings that ent-PGE2 can be formed in a non-COX 
mechanism, Gcu& postulates that in certain settings PGE2 could be produced from IsoP 
intermediates in the presence of NSAIDs.
Although in the Gaj? study ent-PGE2 may represent only 3% of the total PGE2 
synthesised, these observations may impact on this thesis in several ways: (a) bleomycin 
is known to cause oxidative stress (Kappus, 1987) which may be analogous to C C I 4  
injury; (b) the specific ELA used to measure BALF PGE2 levels throughout this thesis 
would be unable to differentiate between PGE2 and ent-PGE2 and therefore levels of both 
compounds are included in all measurements; (c) it is predicted that generation of PGE2 
via IsoPs would not be inhibited by NS398 used in this thesis; (d) if indeed ent-PGE2 
breakdown by 15-PDGH is reduced, levels may accumulate over time. By day 28 
following administration of bleomycin and treatment with NS398, PGE2 production is no 
longer inhibited compared with vehicle alone and these levels may represent increased 
quantities of ent-PGE2 at this time. However, to examine this hypothesis BALF samples 
throughout the 28 day timecourse would need to be analysed for ent-PGE2 using GC/MS 
as described which is not feasible for this thesis.
4.3.2 COX-2'1' mice and BALF PGE2 production
COX-2'7' mice are incapable of upregulating COX-2 protein following bleomycin injury 
(Figure 3.14), and it was therefore hypothesised that these mice would be unable to 
upregulate synthesis of PGE2 . However, it has been shown that following administration 
of bleomycin this is not the case. Basal levels of BALF PGE2 following instillation of 
saline alone were low and did not differ between genotypes (Figure 3.16), however, 
contradictory to the hypothesis, at all timepoints studied BALF PGE2 was significantly
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increased in COX-27' mice compared with saline alone (Figure 3.16). Indeed, at 14 and 
28 days following injury, PGE2 was significantly increased compared with bleomycin- 
exposed wild type animals. This significant upregulation of PGE2 synthesis seems 
initially contrary to previously reported studies in the lungs of COX-27' mice which are 
summarised in Table 4.1. Studies by both Bonner and Zeldin showed reduced expression 
of PGE2 compared with wild type animals following exposure to V2O5 and 
lipopolysaccharide (LPS) respectively (Bonner et al,. 2002; Zeldin et al., 2001), and 
Gavett et al., reported unchanged levels of PGE2 synthesis in COX-27' mice using a 
model of induced asthma following ovalbumin challenge, although there appeared to be a 
trend towards increased PGE2 production following challenge in both WT and COX-27' 
mice (Gavett et al., 1999). Additionally, in the colon, Morteau and colleagues showed 
that COX-2 deficiency prevents the increase of PGE2 from tissue seen in wild type mice 
in a model of colitis induced by dextran sodium sulphate (DSS; Morteau et al., 2000).
Stimulus
used
Time
following
exposure
BALF PGE2 WT mice 
(pg/ml)
BALF PGE2 COX-2 ' mice 
(pg/ml)
Basal Challenged Basal Challenged
LPS (Zeldin) Immediately N/A 128 ± 1 0 N/A 58 ± 8
Ovalbumin
(Gavett)
24 hours 206 ±42 383 ±55 201 ±38 *300 ±84
V2O5
(Bonner)-....
24 hours *500 ±125 *100 ±145 *200 ±25 *345 ±155
V2O5
(Bonner)
15 days *460 ±105 *500 ±140 *290 ±25 *285 ±60
Bleomycin 14 days 233 ±65 1202 ±431 144 ±50 2975 ±518
Bleomycin 28 days 177 ±70 535 ±167 336 ±151 1489 ±163
Table 4.1 BALF PGE2  levels following injury. * Approximate values only, exact figure
not published. N/A not assessed
The data presented in this thesis have shown that instillation of a relatively low dose of 
bleomycin causes a more severe injury than either LPS, ovalbumin challenge or V2O5 , 
indeed BALF PGE2 levels in wild type mice 28 days following bleomycin are higher than 
that collected at early timepoints following LPS and ovalbumin challenge, and are 
comparable with PGE2 levels 3-15 days following instillation of V2O5 (see Table 4.1). 
Therefore previous studies may not have reached an injury threshold whereby 
compensatory mechanisms are initiated in COX-27' mice. As shown in Table 4.1, Gavett 
and co-workers, showed a trend towards increased BALF PGE2 synthesis in COX-27' 
mice 24 hours following the last ovalbumin challenge (Gavett et a i, 1999). Although this
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50% increase does not reach statistical significance, these data indicate that the remaining 
COX isoform(s) is(are) capable of synthesising PGE2 . Ovalbumin challenge may not 
have a reached a threshold whereby compensatory mechanisms are able to synthesise 
significant amounts of PGE2 . This idea is supported by the observation that we saw no 
basal upregulation of PGE2 following instillation of saline alone in COX-2'7' mice 
(Figure 3.16). Furthermore the compensatory response may be time dependent and 24 
hours following the final ovalbumin challenge may not be sufficient to initiate 
compensatory mechanisms. This is supported by the observation that compared with WT 
animals, COX-2'7' mice show no increased synthesis of PGE2 until day 7 following 
administration of bleomycin.
In addition to timing and severity of challenge, a third difference between this study and 
those discussed above (Gavett et al, 1999; Morteau et al., 2000 and Zeldin et al., 2001; 
Bonner et al., 2002) is the COX-2'7* animals used. The previous studies used COX-2'7' 
mice descended from those generated by disruption of exon 8  of the COX-2 gene (termed 
COX-2ex87ex8) by Morham and colleagues (Morham et al., 1995). However, the mice used 
in this study are descended from those generated by Dinchuk and co-workers (Dinchuk, 
et al., 1995) by the targeted disruption of exon 1 of the COX-2 gene (COX-2exl/exl). 
Phenotypic variations between strains of knockout mice generated via disruption of 
different exons have previously been reported and may be of relevance in this study. For 
example, the phenotype of mice generated by the disruption of exon 8  of the TGF-p 
signalling protein Smad 3 (Smad3ex87ex8; Yang et al., 1999) show quite distinct, and in 
part contradictory phenotypes compared with those generated by targeted disruption of 
exon 2 (Smad3ex27ex2; Zhu et al., 1998). Smad3ex27ex2 mice developed metastatic colorectal 
cancer by the time they were 4-6 months old and Zhu and colleagues made no evaluation 
of immune function. In comparison, Smad3ex87ex8 knockouts were virtually tumour free 
but show impaired mucosal immunity and diminished T cell responsiveness to TGF-p. 
Although not previously reported, it is possible that this phenomenon may, in part, 
explain differences in response to bleomycin challenge seen in the COX-2ex 17exl mice 
compared with other models using COX-2ex87ex8 deficient mice. Data examining body 
weight and change in weight following instillation of bleomycin further supports this 
suggestion. This thesis has shown that COX-2 genotype has no significant effect on either 
parameter, however the effect of COX-2 deficiency and body weight has been 
investigated on one previous occasion. Fain and colleagues reported that COX-2+/" mice 
(generated via disruption of exon 8 ) develop obesity compared to WT and COX-2"7' mice
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(Fain et al., 2001), however, this is not observed in the COX+7' mice used in this study, 
where COX-2 genotype had no effect on body weight or weight change following injury 
(Figure 3.15). However, whilst compensatory upregulation of PGE2 synthesis has not 
been previously described in studies using COX-2ex87ex8 animals in vivo, fibroblasts 
derived from these mice have been shown to produced increased levels of PGE2 both 
basally and following stimulation (Kirtikara et al., 1998). This study will be described in 
greater detail in the next section.
4.3.2.1 Mechanism for upregulation ofPGE 2 synthesis
Through the use of the selective COX-2 inhibitor NS398, it has been shown that the 
majority of BALF PGE2 generated by wildtype mice following bleomycin challenge is 
COX-2 derived (Figure 3.9). However, it is apparent that COX-2'7' mice are capable of 
using a compensatory mechanism to generate significant levels of PGE2 following 
injury in the absence of COX-2. The possibility of a further COX isoform or splice 
variant, in addition to the described COX-3, which would be inducible, but inhibited by 
selective COX-2 inhibitors has been discussed (Willoughby et al., 2000), although there 
is no clear evidence to support its existence.
An alternative explanation may be the generation of ent-PGE2 (see section 4.3.1) in 
COX-2'7' mice. However the levels of BALF PGE2 synthesised by COX-2'7' mice at day 
14 are 10-fold greater than the levels described at day 28 in B 197 mice (Figure 3.9 and 
3.16) and it appears unlikely that the 3% of total PGE2 represented by enf-PGE2 could 
account for the large increases seen in COX-2'7' compared with WT animals at this time. 
Furthermore, there is no reason to suggest that COX-2"7' mice would make increased 
levels of ent-PGE2 compared with WT animals. Therefore, it is more likely that the 
compensatory upregulation of PGE2 described in COX-2'7' mice originates from either 
increased substrate availability feeding through the COX-1 (and/or COX-3) pathway 
caused by increased levels of CPLA2 , the rate-limiting enzyme for the release of free 
arachidonic acid, or alternatively increased expression of COX-1/3 in the lungs of these 
mice. Again, COX-3-derived PGE2 is unlikely to make a substantial contribution to 
overall levels in the lungs of COX-2'7' mice following bleomycin due to its low 
expression in the lung (Chandrasekharan et al., 2002, see section 4.3.1), although it is 
currently unknown if COX-3 expression may be induced by injury.
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Upregulation of PGE2 synthesis in cells obtained from COX-2 deficient mice has 
previously been described. Kirtikara et. al. showed increased basal and IL-lp- 
stimulated release of PGE2 in COX-2ex8/ex8 deficient lung fibroblasts, with increased 
basal protein expression of both COX-1 and cPLA2 in these cells. Following IL-lp 
treatment, COX-1 protein expression was not subsequently increased, whereas 
expression of cPLA2 was further increased, mediating an additional rise in PGE2 
(Kirtikara et a l , 1998). From these data it was hypothesised that differences in COX-1, 
and specifically cPLA2, expression may occur in the lungs of WT and COX-2'7' mice, 
both basally and following bleomycin-induced injury. But no differences were observed 
in basal expression of either cPLA2 or COX-1 in the lungs of either WT or COX-2'7' 
mice following instillation of saline. Following bleomycin-treatment a 1.5-fold increase 
in cPLA2 protein expression was observed, but did not differ between genotype (Figure 
3.25). However, following injury the 4.5-fold increase in COX-1 protein expression in 
lung tissue from COX-2'7' mice was significantly greater than the 1.5 increase in WT 
animals (Figure 3,26). Therefore it is likely that in contrast to COX-2ex87ex8 deficient 
fibroblasts, the increased synthesis of PGE2 seen in the lungs of COX-2 deficient mice 
following bleomycin injury was mediated, at least in part, via the increased expression 
of COX-1, and not by increased cPLA2 activity. This observation raises further 
questions which this thesis has begun to address; firstly, what is(are) the cellular 
source(s) of increased COX-1-mediated PGE2 production? And secondly, are increased 
source-cell numbers responsible for increased PGE2 synthesis, or does COX-1 
expression increase in these cells?
4.3.2.2 Cellular source o f compensatory increase o f  BALF PGE2
To investigate the mechanism of compensatory upregulation of PGE2, populations of 
fibroblasts and macrophages were isolated. Both cell types are known to generate 
substantial amounts PGE2 in the lung and are present in increased numbers in 
pulmonary fibrosis. Additionally, as previously discussed, COX-2ex87ex8 deficient 
fibroblasts have been shown to upregulate PGE2 synthesis compared with WT and 
COX-1 deficient cells (Kirtikara et al., 1998).
Basal levels of PGE2 in wild type fibroblasts were significantly increased following 
stimulation with TGF-pi and reduced from control values by 80% in the presence of the 
selective COX-2 inhibitor NS398. Selective inhibition of COX-2 also reduced TGF-pi- 
stimulated PGE2 production by 90% (Figure 3.27). This suggests that WT cells
predominantly synthesise PGE2 via COX-2, supporting the in vivo observations using 
NS398, and can be further induced by the addition of TGF-pi. In comparison, COX- 
2 exi/exi deficient fibroblasts in this study produced significantly less PGE2 basally than 
wild type cells, showed no induction of PGE2 synthesis following stimulation by TGF- 
pi and PGE2 synthesis was unaffected by NS398. (Figure 3.27). This corresponds with 
data generated by Dinchuk and co workers who showed that COX-2ex 1/exl deficient 
primary embryonic fibroblasts produced over 1 0 -fold less PGE2 than wild type cells 8  
hours following stimulation with serum (Dinchuk et al., 1995). These differences in 
PGE2 production seen in COX-2exl/exl fibroblasts further supports the suggestion that 
the two lineage s of COX-2 deficient mice are phenotypically different. However, these 
differences may also be due to the nature of cells involved; these experiments were 
conducted using primary cells, whereas the data described by Kirtikara and colleagues 
was obtained from transformed cells (Kirtikara et al., 1998).
Similarly to COX-2'7' fibroblasts, a recent publication has shown that following 
stimulation with either LPS or EL-1, COX-2 deficient alveolar epithelial cells (AECs) 
are unable to upregulate PGE2 synthesis compared with WT cells (Lama et al, 2002). 
These data suggest that AECs are therefore unlikely to be a cellular source of 
compensatory upregulation of PGE2 biosynthesis in vivo.
In comparison with fibroblasts and AECs, stimulated COX-2'7' peritoneal 
macrophages/monocytes showed significantly increased production of PGE2 compared 
with wild type cells (Figure 3.28). Together these in vitro data suggest that th£ 
increased synthesis of PGE2 seen in COX-2'7' mice is likely to be via 
macrophage/monocytes, but not fibroblasts or AECs, and the data in whole lting tissue 
suggests this is due to compensatory expression of COX-1 in these cells. This 
hypothesis is supported by two observations; ( 1 ) the increased synthesis of PGE2 is 
unlikely to be generated by increased numbers of macrophages synthesising 
‘housekeeping’ levels of PGE2 via homeostatic levels of COX-1 in COX-2"7' mice as 
total macrophage number does not differ between the two genotypes; (2 ) a recent study 
has indeed described compensatory expression of COX-1 mRNA in peritoneal 
macrophages from COX-2 deficient mice (Zhang et al., 2002). This study did not 
examine protein expression of COX-1 nor PGE2 synthesis from these cells, nor COX-1 
mRNA expression in COX-2'7' AECs or fibroblasts. However, it provides more 
compelling evidence that the increased synthesis of PGE2 in COX-2'7' mice is COX-1
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derived and generated by macrophages. This cell type-specific response may be due to 
regulation by different transcription factors in cell populations, or altered signalling 
pathways between cell types.
A criticism of this work may be that the macrophage/monocyte populations were 
obtained from mice challenged with thioglycolate, whereas the fibroblasts used were 
isolated from unchallenged animals. Thioglycolate challenge may have been sufficient 
to initiate compensatory upregulation of PGE2 synthesis in macrophages/monocytes that 
had not occurred in fibroblasts whilst in situ. However, it is of note that stimulation with 
TGF-pi for 24 hours was not sufficient to induce COX-1-derived PGE2 synthesis in 
COX-2 7' fibroblasts. Furthermore, PGE2 production in other inflammatory cells types 
from COX-2'7' mice has not been examined, namely PMNs and lymphocytes, both of 
which are present in increased numbers in BALF from COX-2'7' mice compared with 
WT animals, and are known to produce PGE2 (Morley et al., 1979).
4.3.3 COX-2*1' mice and BALF PGE2 production
By using mice heterozygous for COX-2, compensation between COX isoforms as 
observed in COX-2'7' mice appears to have been avoided. Primary embryonic fibroblasts 
cultured from COX-2+7' mice have previously been shown to produce intermediary 
levels of both COX-2 mRNA and PGE2 compared with WT and COX-2'7' cells 
(Dinchuk et al., 1995) In addition, this thesis has shown intermediate levels of COX-2 
protein expression in COX-2+7' mice following bleomycin administration (see Figure 
3.14). COX-2+7' mice show only a limited induction of BALF PGE2 synthesis following 
bleomycin injury, which is significantly lower that WT mice at day 7. Levels peak at 
day 14 but by day 28 COX-2+7' mice produced only basal levels of PGE2 with no 
significant increase following bleomycin compared with saline alone. In comparison, 
BALF PGE2 remains significantly increased in both wild type and COX-2'7' animals. 
Interestingly, these observations are consistent with data in patients with pulmonary 
fibrosis where expression of COX-2 is reduced (Wilbom et al., 1995; Keerthisingam et 
al., 2000) and levels of BALF PGE2 are 50% lower than non-fibrotic controls (Borok et 
al., 1990). This suggests that mice heterozygous for COX-2 provide a good model of 
patients with pulmonary fibrosis in this respect.
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4.4 Role of COX-2 and the inflammatory response to bleomycin
The role of COX-2 in the inflammatory response to bleomycin-induced lung injury is by 
no means clear-cut. Pharmacological inhibition of COX-2 using NS398 did not alter the 
inflammatory response to bleomycin in either BALF total cell numbers, or cell profiles. 
In contrast, genetic disruption of COX-2 in COX-2'7' mice resulted in an enhanced 
inflammatory response to bleomycin compared with WT, COX-2+/‘ and NS398-treated 
WT animals. By 28 days following injury PMN and lymphocyte numbers in WT, COX- 
2+/* and NS398-treated WT mice had decreased to baseline values as inflammation 
resolved (see Table 3.2). In contrast, BALF PMN and lymphocyte numbers were still 
elevated in COX-2'7' mice, and significantly increased compared with all other 
genotypes/treatment groups. By 84 days following injury, both BALF PMN and 
lymphocyte numbers in COX-2'7' mice remained elevated compared with saline controls, 
and were also significantly increased compared with WT mice (see Table 3.3). 
Furthermore, at this timepoint, numbers of BALF PMNs and lymphocytes appeared to be 
related to COX-2 deficiency as an intermediate response was seen in COX-2+7' mice. 
Although both BALF PMN and lymphocyte numbers were not increased following 
bleomycin injury in COX-2+7' mice, cell numbers were non-significantly increased 
compared with WT animals. This observation appears to be COX-2, but not PGE2- 
dependent as BALF PGE2 levels were similar in all three COX-2 genotypes at this time.
This persistent lymphocytosis and neutrophilia suggests that COX-2 is important in the 
development and/or resolution of inflammation. However, the inflammatory response of 
COX-2'7' mice to different models of injury has not been consistent. In addition to this 
study, several other groups have demonstrated evidence of enhanced inflammation in 
COX-2'7' mice: enhanced pulmonary eosinophilia and lymphocytosis in ovalbumin- 
induced asthma (Gavett et al., 1999 and Carey et al., 2003); persistent chronic 
inflammation in a carrageenin-induced paw injury (Wallace et al., 1998); enhanced 
colonic inflammation in DSS-induced bovJj injury (Morteau et al., 2000); and an 
increased inflammatory score in response to intratracheal instillation of V20s (Bonner et 
al., 2002). However two studies have demonstrated no difference at early timepoints 
following injury (Zeldin et al, 2001; Dinchuk et al., 1995), and a further two studies 
have demonstrated reduced inflammation, firstly in collagen-induced arthritis (Myers et 
al, 2000), and more recently in a sepsis model, COX-2'7' mice were shown to be resistant 
to endotoxemia induced by LPS instillation (Ejima et al., 2003). This inconsistency in the
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inflammatory response may relate to the varying insults administered and to the timepoint 
assessed, for example, the inflammatory response 1 hour following carrageenin-induced 
paw injury does not differ between COX-2'7' and WT mice, after 5hours COX-2'7' animals 
show a decreased inflammatory response (Dinchuk et al., 1995; Wallace et al., 1998) but 
after 1 week COX-2'7' mice show a persistent inflammation which had resolved in WT 
mice (Wallace etal ,  1998).
4.4.1 Mechanism for enhanced inflammation in COX-2'/m mice 
The mechanism for increased and persistent inflammation following bleomycin 
instillation is therefore unclear. One potential explanation may be the abundance of pro- 
inflammatory leukotrienes via shunting of AA through the lipoxygenase (5-LO) pathway. 
In patients with aspirin-intolerant asthma shunting of AA through the 5-LO pathway has 
been considered a mechanism of increased inflammation following the inhibition of COX 
(Babu and Salvi, 2000). Therefore LTC4 was measured as a representative cysteinyl 
leukotriene which are the predominant class of LT expressed in mice (Moore et al, 2000; 
Peters-Golden et al, 2002). But levels of BALF LTC4 were low in COX-2'7' mice 
(Figure 3.29) and unaltered compared with WT animals. Therefore it is unlikely that 
increased production of pro-inflammatory LT are responsible for the enhanced 
inflammation observed. This is further supported by the observation that Gavett and 
colleagues showed no increase in LTB4 production in COX-2'7' mice following 
ovalbumin challenge (Gavett et al, 1999).
An alternative explanation may be the absence of anti-inflammatory eicosanoids due to 
COX-2 deletion. COX-2 has been shown to play an important role in the resolution of 
inflammation by generating anti-inflammatory cyclopentanone prostaglandins 
(15deoxyA1214PGJ2, Gilroy et al, 1999) via PGD2. Therefore a failure to synthesise 15- 
deoxyA12' 14PGJ2 may explain why COX-2 '7' mice are unable to resolve their 
inflammatory response to bleomycin injury. However, NS398 has also been shown to 
inhibit 15-deoxyA1214PGJ2 synthesis and exacerbate inflammation (Gilroy et al., 1999). 
Although this thesis has shown administration of NS398 unable to inhibit bleomycin- 
induced PGE2 production by 28 days, and therefore presumably production of 15- 
deoxyA12' 14PGJ2, treatment with NS398 did not exacerbate the inflammatory response at 
either 14 or 28 days, and therefore it appears unlikely that differential synthesis of 15- 
deoxyA12"14PGJ2 can explain the persistent inflammation seen in COX-2'7' mice.
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It is possible that COX-2 has actions unrelated to the cyclooxygenase activity of the 
COX-2 molecule which are unaffected by NS398 but may aid in resolution of 
inflammation, and are absent in COX-2"7' mice. A potential candidate molecule is 15-epi- 
LXA4  (see Section 3.21, Figure 3.30). Briefly, 15-epi-LXA4 is a potent inhibitor of 
neutrophil binding, rolling and transmigration through the vascular endothelium. It is 
predominantly generated in transcellular biosynthesis of AA by acetylated COX-2 via 15- 
^-HETE and 5-LO, however it has been proposed that COX-2 may also be acetylated by 
endogenous acetylases or via non-enzymatic pathways involving reactive oxygen species 
(Chiang et al, 1998). NS398 has been shown not to block 15-/?-HETE generation^ 
(Serhan et al, 2000) and therefore 15-epi-LXA4 was measured to investigate if an 
absence in its synthesis may explain the failure to resolve the bleomycin-induced 
neutrophilia observed in COX-2"7' mice. All three experimental groups produced similar 
levels of 15-epi-LXA4  following administration of saline alone which suggests that basal 
production is not COX-2-mediated. Following bleomycin, production of 15-epi-LXA4 
was significantly induced but unaffected by inhibition of COX-2, either 
pharmacologically or by gene deletion. Again, this suggests a COX-2-independednt 
mechanism, potentially though cytochrome P450-mediated generation of 15-/?-HETE, 
although this has previously been described to vary between cell types (Claria et a l, 
1996; Titos et al, 1999). At 7 days following injury 15-epi-LXA4 levels are significantly 
greater in COX-2"7" mice compared with both vehicle and NS398-treated animals. This 
may be explained by increased numbers of inflammatory cells present in COX-2"7' mice 
leading to increased transcellular synthesis of 15-epi-LXA4. Therefore a reduced capacity 
to synthesis 15-epi-LXA4 does not mediate persistent and enhanced inflammation in 
COX-2'7' mice.
However, the most likely explanation for the increased inflammation observed in COX- 
2"7" mice, at least at day 28, is as a result of the high levels of BALF PGE2 which is a 
known neutrophil chemoattractant. Therefore the enhanced and persistent inflammation 
may not be a direct consequence of an absence of COX-2 either promoting or limiting 
resolution of inflammation, but the compensatory expression of COX-1 resulting in high 
levels of pro-inflammatory PGE2 which is still significantly increased 28 days following 
instillation of bleomycin. However, previous studies using COX-2'7" mice have failed to 
demonstrate a consistent link between the severity of inflammation and prostaglandin 
levels following injury (section 4.4 Gavett et al, 1999; Wallace et al, 1998; Morteau et 
al, 2000; Bonner et al, 2002; Zeldin et al, 2001; Dinchuk et al, 1995; Myers et al,
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2000; Ejima et al, 2003) and two of these studies both describe an increased lung 
inflammatory response following V2O5 and LPS instillation in the presence of low levels 
of PGE2 (see Table 4.1, Bonner et al, 2002; Zeldin et a l, 2000). This inconsistency was 
also evident at day 84 following instillation of bleomycin where BALF PMN and 
lymphocyte numbers in COX-2'7' mice remain elevated compared with WT animals, 
despite similar levels of BALF PGE2 . Studies at timepoints intermediate to days 28 and 
84 may provide additional information regarding the timecourse of PGE2 upregulation in 
the lungs of COX-2'7' mice and the link between high levels of BALF PGE2 and enhanced 
inflammation, however it appears as though COX-2 may have, as yet undetermined, 
prostaglandin-independent effects which contribute to the inflammatory response.
The data in this thesis also questions the association between inflammation and the 
development of fibrosis following bleomycin-induced lung injury. As described, COX- 
2 '7' mice show an enhanced inflammatory response yet no increased production of lung 
collagen compared with WT animals. However, mice heterozygous for COX-2 show a 
comparable inflammatory response to WT mice yet develop a severe fibrotic response 
(see Figure 3.18, Table 3.2 and Section 4.5.3). Numerous studies report an association 
between a reduced leukocyte recruitment into the lung and protection against the 
fibrotic effects of bleomycin compared with WT animals (Peters-Golden et al, 2002, 
Howell et al, 2001; Nagase et al, 2002). However the converse is not true with COX- 
2 +7' mice and may provide evidence to support recent suggestions that development of 
inflammation and fibrosis are not interdependent (see Section 1.3.2; Selman and Pardo, 
2002; Gauldie, 2002a; Gauldie et a l , 2002b).
4.5 Role of COX-2 in development of pulmonary fibrosis
The role of COX-2 in the development of pulmonary fibrosis was assessed 
histologically at day 28 and 84 and biochemically by measuring total lung collagen at 
days 14, 28 and 84.
4.5.1 Effect ofNS398 treatment on the development o f pulmonary fibrosis 
Both histological assessment and measurement of total lung collagen show that 
pharmacological inhibition of COX-2 using NS398 has no affect on the development of 
pulmonary fibrosis following instillation of bleomycin. At 14 days when administration 
of NS398 almost completely inhibits PGE2 production (Figure 3.9, section 4.3.1), the
161
mean increase in lung collagen following bleomycin is not significantly increased in 
NS398-treated animals compared with vehicle-treated mice. In comparison, total lung 
collagen is significantly increased compared with saline alone in vehicle treated mice. 
By 28 days following injury, bleomycin causes a significant upregulation in total lung 
collagen in both vehicle and NS398-treated animals however there is no difference 
between treatment groups at this time.
Other studies using NSAIDs have shown that inhibition of COX ameliorated lung 
fibrosis following instillation of bleomycin (see Section 1.6.2, Thrall et al., 1979; Mall 
et al., 1991; Chandler and Young, 1989) and together, these results appears to contradict 
the hypothesis that PGE2 is an anti-fibrotic mediator and its reduced expression can 
potentiate bleomycin-induced lung injury. However, the mechanism of either protection, 
or in this case, an unaltered response, may be due to the anti-inflammatory properties of 
COX inhibitors and the timescale over which they were administered. In all of the 
above studies NSAIDs were administered prior to instillation of bleomycin and 
throughout the timecourse, however when indomethacin was administered in only the 
fibrotic stage of the bleomycin model after day 1 0 , an enhanced fibrotic response to 
bleomycin was observed (Moore et al., 2000). This suggests that inhibition of COX 
during the initial phase of bleomycin injury could have reduced the proinflammatory 
effects of COX-2 which may have inhibited the development of fibrosis in these 
animals. In retrospect, it may have been better in this study to have delayed 
administration of NS398 to day 10.
4.5.2 COX-2'1' mice and the development of pulmonary fibrosis 
In a previous histological study COX-2'7' mice have been shown to have an increased 
fibroproliferative response to bleomycin challenge compared with WT controls 
(Keerthisingam et al., 2001). Using reverse-phase HPLC both wild type and COX-2'7' 
mice showed significantly increased total lung collagen typical of the model, but no 
difference was observed between genotypes, suggesting that ablation of COX-2 does 
not lead to enhanced collagen deposition (Figure 3.17). Whilst the biochemical data 
may seem to contradict the previous histological findings at day 14, it is of note that a 
fibroproliferative response to bleomycin was discussed which was a measure of both 
matrix protein staining and inflammation. Therefore the enhanced fibroproliferative 
response seen histologically may represent predominantly the enhanced inflammatory 
response at this timepoint (Keerthisingam et al., 2001). The enhanced inflammatory
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response in these animals may also explain the unaltered fibrotic response in COX-2'7' 
mice which is contrary to the original hypothesis. Increased numbers of neutrophils 
would result in increased generation of proteases and oxygen radicals promoting ECM 
degradation (Everts et al, 1996) and studies using silica, coal dust or cigarette smoke 
have all demonstrated neutrophil-mediated tissue breakdown in the lung (Dhami et al, 
2000; Zay et al, 1999). Increased numbers of lymphocytes could also affect fibroblast 
collagen production through the secretion of anti-fibrotic mediators such as INF-y (Giri 
et a l, 1986). However, since PGE2 is known to inhibit fibroblast collagen production, 
proliferation and fibroblast-myofibroblast transition, it is likely that high levels of 
BALF PGE2 observed in COX-2'7' mice are primarily responsible for limiting the 
fibrotic response in these animals (Figure 3.16, section 4.3.2). Dietary induction of 
PGEi (the E series prostaglandin derived from dihomo-y-linoleic acid) synthesis has 
been shown to limit bleomycin-induced lung collagen deposition (Ziboh et al, 1997) 
and high levels of BALF PGE2 may promote collagen degradation in COX-2'7' mice 
since PGEi has been shown to promote collagen degradation (Baum et a l, 1980). 
Therefore, increased levels of BALF PGE2 may further alter the balance between 
collagen synthesis and breakdown in COX-2'7' mice.
By extending the timecourse to 84 days it was hoped that the compensatory 
upregulation of PGE2 in COX-2'7' mice may have subsided, and therefore a more severe 
fibrotic response to bleomycin may have developed. BALF PGE2 levels did decrease to 
basal levels by day 84 and total inflammatory cell numbers were unchanged compared 
with both WT and COX-2+7' mice. However, low PGE2 was not sufficient to cause any 
further increase in the fibrotic response at this time; total lung collagen remained 
unchanged compared with levels seen at 28 days in COX-2'7' mice and were not 
different from WT controls. PMN numbers were no longer significantly increased in 
COX-2'7' mice at this time, however lymphocyte numbers remained elevated following 
bleomycin and may have remained a source of anti-fibrotic IFN-y.
The inhibitory effects on other COX-2-derived prostanoids following either 
administration of NS398, or COX-2 gene deletion should also be considered. Decreased 
levels of other COX-2-derived prostanoids may play a role in the fibrotic and/or 
inflammatory response to bleomycin as intratracheal instillation of bleomycin has been 
shown to induce synthesis of 6 -keto-PGFia (stable metabolite of PGI2), thromboxane 
(TX)B2 (stable metabolite of TXA2) and PGF20C in addition to PGE2 in hamsters
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(Chandler and Giri, 1983; Giri and Witt, 1985). TXA2 has been shown to increase 
proliferation, and DNA and RNA synthesis in several cell types, including fibroblasts 
(Murota et al, 1977; Mene et al., 1990), and conversely, prostacyclin (PGI2) decreases 
smooth muscle cell proliferation and collagen synthesis (Sinzinger et al., 1997; 
Gallagher et al., 1998). Many studies using COX-2'7' mice have not evaluated the effect 
of gene deletion on the formation of prostanoids other than PGE2 , however Bonner and 
colleagues measured levels of the pro-inflammatory PGD2 following V2O5 challenge in 
both WT and COX-2'7' mice. Similar levels were reported in both genotypes suggesting 
that differences in PGD2 production did not significantly contribute to the altered 
inflammatory and fibrotic responses reported in the lungs of COX-2'7* mice (Bonner et 
al, 2002). A recent study has also examined the role of PGI2 in ovalbumin-induced 
airway remodelling using IP gene-deficient mice. This study found that disruption of the 
IP gene enhanced the fibrogenic .response to repeated allergen challenge by increasing 
levels of active TGF-pi in the BALF, and levels of hydroxyproline in the lung (Nagao et 
al., 2003). However, assuming that NS398 treatment and COX-2 gene deletion resulted 
in a deficiency in PGI2 in this study, neither NS398-treated WT animals or COX-2'7' 
mice showed a similar enhanced fibrotic response to bleomycin.
In summary, the measurement of other COX-2-derived prostanoids following inhibition 
of COX-2 function, either genetically or pharmacologically, may be considered in the 
future, however PGE2 remains the dominant prostanoid in the lung, and of lung 
fibroblasts (Levine and Alam, 1979; Korn et al., 1983; Shindon et al., 1988; Brock et 
al, 1999).
4.5.3 COX-2+l~ mice and the development o f pulmonary fibrosis 
With only limited induction of PGE2 , COX-2+7' mice demonstrate a more severe and 
more extensive fibrosis at day 28 than either Wild type or COX-2'7', both histologically 
and biochemically (Figures 3.20B, and 3.18). Although COX-2+7' mice show a trend 
towards increased collagen 14 days following bleomycin total lung collagen, this is not 
significantly increased compared with either wild type or COX-2'7' animals at this time 
indicating that this phenotypic response is time dependent and may be associated with 
peak levels of PGE2 at day 14.
A criticism of the bleomycin model is that it is not a progressive model. It was hoped 
that the fibrotic phenotype observed in COX-2+7' mice may have lead to a progressive
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model of fibrosis unseen in other mice. Animals were instilled with either saline or 
bleomycin and after 84 days the fibrotic response was assessed (also see section 4.5.2). 
However, the fibrotic response of COX-2+/' mice was maintained but not enhanced at 84 
days, whilst a trend was seen towards increased collagen in the lungs of COX-2+/' mice 
compared with WT and COX-2 7' animals, it was no longer significant. Therefore COX- 
2+/' mice do not represent a progressive model of bleomycin-induced lung injury. This 
may have been due to the low dose of bleomycin used in this study, or the single injury. 
An alternative model may involve more than one instillation of bleomycin over the 3 
month period which may better reflect patients with pulmonary fibrosis.
Despite the data at 84 days, data at day 28 demonstrates that a limited induction of 
PGE2 in mice heterozygous for COX-2 results in an enhanced fibrotic response to 
bleomycin-induced lung injury, and represents a good model of patients with pulmonary 
fibrosis in these respects.
4.5.3.1 Mechanism o f enhanced response in COX-2+/' mice
As previously mentioned (section 4.4.1) COX-2+/' mice show a ‘normal’ inflammatory 
response to bleomycin injury yet develop a more severe fibrotic response (section 
4.5.3). Therefore it is unlikely that the inflammatory response itself can have triggered 
the extraordinary fibrotic response. PGE2 is an anti-fibrotic molecule known to inhibit 
fibroblast proliferation, collagen production and differentiation and these data suggests 
that in mice heterozygous for COX-2, limited induction of PGE2 is an important 
mechanism in the progression of fibrotic disease. Indeed, a reduction in levels of PGE2 
has previously been linked to a pro-fibrotic phenotype. Moore and colleagues reported 
that mice deficient in granulocyte-macrophage colony-stimulating factor (GM-CSF) 
show enhanced fibrosis following bleomycin which correlates with reduced levels of 
PGE2 in both alveolar macrophages and whole lung homogenates from these animals 
(Moore et a l , 2000). In addition, as previously described (section 4.5.1) this study 
showed that administration of the COX inhibitor indomethacin to wild type animals 10- 
21 days following bleomycin enhanced the fibrotic response (Moore et al., 2000). 
Furthermore, 5LO'7' mice deficient in LT biosynthesis are protected from bleomycin- 
induced lung fibrosis (Peters-Golden et al., 2002). One mechanism of protection is by 
increased synthesis of BALF PGE2 produced via ‘shunting’ through the COX pathway. 
With reduced levels of COX-2 in mice heterozygous for the gene it is possible that AA 
may be preferentially metabolised through the 5-LO pathway to produce pro-fibrotic
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leukotrienes and this may, in part, account for their enhanced fibrotic response. 
However, this was found not to be the case in COX-2+/~ mice, where LTC4 levels are 
low (see Figure 3.29) indicating no shunting of AA metabolism through the 5-LO 
pathway.
Although these data have shown PGE2 deficiency to be an important mechanism in an 
enhanced response to bleomycin-induced fibrosis, it may not be the only mechanism 
involved in the increased collagen production in COX-2+/‘ mice. A complex interaction 
between both stimulatory and inhibitory mediators is known to contribute to the 
regulation of fibroblast proliferation and collagen synthesis. This is a tightly regulated 
process and a reduction in the levels of the inhibitory mediator PGE2 seen in COX-2+/' 
mice may alter the balance towards stimulatory mediators such as TGF-p, TNF-a, IL-1, 
PDGF, IGF-1, or thrombin. It is possible that one or a combination of stimulatory
mediators may be increased in the lungs of COX-2+/' mice which in turn may stimulate
increased fibroblast proliferation and collagen production in the lung following 
bleomycin injury. Future work could be aimed at measuring pro-fibrotic mediators in 
BALF from these animals, for example TGF-pi.
4.6 Summary and future work
The key findings of this thesis are:
The production of PGE2 in BALF following administration of bleomycin is 
predominately COX-2-derived.
The reduced expression of COX-2 in COX-2+/' mice results in limited induction of 
PGE2 following bleomycin induced lung injury and subsequently a more severe fibrotic 
response to injury than WT animals. In these respects COX-2+/’ mice represent a good 
model of patients with pulmonary fibrosis where levels of COX-2 and PGE2 have 
shown to be decreased, rather than absent in BALF and cells derived from the lungs of 
patients with pulmonary fibrosis (Borok et al., 1991; Ozaki et al., 1987; Wilbom et al., 
1995; Keerthisingam et al., 2001; Vancheri et al, 2000; 1: Marchand-Adam et al,
2003).
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Pharmacological inhibition of COX-2 function using the highly selective inhibitor 
NS398 inhibits BALF PGE2 production for at least 14 days following bleomycin- 
1 induced lung injury. However by 28 days PGE2 production is no longer significantly
1
reduced and reasons for this are complex and currently unclear. At either 14 or 28 days 
following injury the fibrotic response is unaltered in mice treated with NS398 and this 
may reflect the dosing strategy for the drug. In retrospect, limiting the inhibition of 
COX-2 to the fibrotic phase alone, i.e. between days 10-28 after injury, may have been 
preferable.
The complete absence of COX-2 in COX-2'7' mice results in a severe and persistent 
inflammatory response to bleomycin injury characterised by an increase in BALF PMN 
and lymphocyte numbers. PGE2 production is significantly upregulated in BALF 
macrophage/monocytes and this thesis suggests this is via compensatory synthesis of 
the remaining isoform COX-1. The enhanced inflammatory response may be a direct 
result of increased COX-1-derived PGE2 production in the lung. COX-2'7' mice show an 
unaltered fibrotic response to bleomycin injury compared with WT mice and it is 
suggested that the enhanced inflammatory response and increased BALF PGE2 levels 
limit the fibrotic response in these mice. Together with the data using COX-2+/* mice, 
this supports the suggestion that increasing or decreasing levels of PGE2 in the lung 
modulates the fibrotic response to bleomycin as predicted; the decreased synthesis of 
PGE2 in COX-2+7' mice resulted in an enhanced fibrotic response, whereas increased 
PGE2 in COX-2'7' mice limited the fibrotic response in these animals.
Together these data have demonstrated not only the importance of using all available 
tools to determine the role of specific molecules in a disease model, but also the caution 
which should accompany the use of knockout mice where compensation must be an 
important consideration.
4.6.1 Future work
From these data future studies could:
Examine PGE2 production in neutrophils and/or lymphocytes derived from COX-2'7' 
mice to investigate their contribution to compensatory upregulation of PGE2 synthesis. 
Additionally, PGE2 production in COX-2'7' fibroblasts derived from mice challenged 
with bleomycin could be examined to investigate if compensatory upregulation of PGE2
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synthesis was dependent on challenge in situ. Following this, COX-1 protein levels 
should be examined in all COX-2 deficient cell types which show compensatory 
upregulation of PGE2 synthesis. This would provide direct evidence to show that the 
increased COX-1 expression observed in COX-2'1' lung tissue was causal for the 
increased PGE2 production in COX-2'7' cells in vitro.
Measure other prostanoids which may play a role in the development of bleomycin- 
induced lung injury which would be inhibited either following administration of NS398 
or absent in COX-2'7' mice.
Use conditional COX-2 knockout mice. In both NS398-treated WT and COX-2'7' mice 
the functional absence of COX- 2  was not sufficient to prevent upregulation of PGE2 
synthesis in the lung. Indeed, COX-2'7" mice showed increased PGE2 synthesis which 
this thesis suggests to be via compensatory expression of COX-1. Therefore the use of 
conditional COX-2'7' mice may avoid the compensatory effects observed in COX-2*7* 
mice. If compensation was avoided, these animals could also be used to investigate if 
the enhanced inflammatory response observed in COX-2'7" mice was a direct result of 
the absence of the gene, or as suggested, purely a consequence of the compensatory 
upregulation of PGE2 synthesis. Conditional COX-2'7" mice may also represent a better 
model than COX-2+7' mice to investigate the specific roles of COX-2 and PGE2 in the 
development of lung injury and fibrosis.
4.6.2 Therapeutic implications
Data in this thesis using COX-2+7" mice has shown for the first time that reduced 
expression of COX-2 and therefore PGE2 biosynthesis results in a more severe fibrotic 
response to bleomycin-induced pulmonary fibrosia
Therefore augmenting levels of PGE2 in patients with pulmonary fibrosis may 
represent a novel treatment for the disease althovAftk OureJs
i h t  b e , d iff ic u lt  cfuiL f o  U a jl  • However, Borok and colleagues
increased levels of PGEi in the lower respiratory tract by aerosol administration but this 
was very short-lived and levels declined to basal levels by 3 hours following 
administration (Borok et al., 1991).
In addition to the problem of instability, the systemic side effects make long term 
administration of PGE2 impractical, however an alternative suggestion is to overexpress
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COX-2 (and therefore upregulate PGE2 synthesis) by pulmonary gene transfer. This 
could be done using the LID vector, a non viral gene delivery system, which has been 
shown to have high transfection efficiency and minimal toxicity in vivo (Jenkins et al., 
2000; Jenkins et al, 2003). Preliminary data has shown that using the LID vector 
sufficient COX-2 gene can be delivered to the lungs of mice in order to generate large 
quantities of PGE2 (Jenkins, 2002; Jenkins et al, 2002) and therefore COX-2 gene 
therapy may represent a potential therapy for the treatment of pulmonary fibrosis in the 
future.
Alternatively, rather than upregulating COX-2, or PGE2, a selective PGE2 receptor 
agonist may represent a potential therapeutic target. Section 1.15 describes how many 
of the cellular actions of PGE2 in the lung are mediated via the EP2 and EP4 receptors. 
Until recently, selective EP2/4 receptors were not long lasting enough to be used in 
vivo, however a recent publication has described CP-533,536, a highly selective EP2 
receptor which when directly injected into bone induced bone healing in rat and canine 
models of bone fractures (Paralkar et al, 2003). Whilst direct injection into the lung is 
not a feasible option, future work by the pharmaceutical industry may identify a similar 
molecule which could be successfully used in the lung.
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